Printout

29 November 2025 12:25

Government eProcurement System

Welcome : a.naveen.gmc@gmail.com
Last login : 28-Nov-2025 09:48 AM

Server Time
29-Nov-2025 12:24:26

Home Logout

eProcurement System Government of India

TENDER MANAGEMENT

- **Master Management**
  - Org Hierarchy Master
  - View Internal Documents
- **User Management**
  - Debar User
  - My Organisation Hierarchy
  - My Accounts
- **Tender Management**
  - Create Tender / Tender List
  - Publish Tender
  - Published Tenders
  - Seek Clarifications
  - Pre-bid Meeting
  - Downloaded Tenders
  - Tender Status
  - Archived Tenders
  - Archived Clarification
  - Stage 2 Create Tender / Tender List
  - NDA Documents History
  - NDA Documents
  - Stage 2 Publish Tender
  - Stage 2 Published Tender
  - Sanction / Bill Generation
  - Validate GeMARPTS ID
- **Corrigendum**
  - Create Corrigendum
  - Publish Corrigendum
  - Published Corrigendum
- **Bid Opening**
  - Tenders to be Opened
- **Bid Evaluation**
  - Technical Evaluation
  - Financial Evaluation
  - Short fall Documents
  - Confirmatory Document
  - AOC/Empanelment
  - Short Fall Documents History
  - Confirmatory Documents History
- **Auction Management**
  - Tender cum Auction
  - Publish Auction
  - Published Auction
  - Create Auction Corrigendum
  - Publish Auction Corrigendum
  - Published Auction Corrigendum
  - Freeze Auction
  - View Live Auction

View More Details

Tender Details

Organisation Chain	All india Institute of Medical Sciences Bilaspur||Administration unit - AIIMS Bilaspur		
Tender Reference Number	AIIMS/BLS/G/24-25/363/E-Ten-18		
Tender ID	2025_AMSBL_886796_1	Withdrawal Allowed	Yes
Tender Type	Open Tender	Form of contract	Item Rate
Tender Category	Goods	No. of Covers	2
General Technical Evaluation Allowed	No	ItemWise Technical Evaluation Allowed	No
Payment Mode	Offline	Is Multi Currency Allowed For BOQ	No
Is Multi Currency Allowed For Fee	No	Allow Two Stage Bidding	No

Payment Instruments

Offline

S.No	Instrument Type
1	Demand Draft
2	FDR
3	Bankers Cheque
4	Bank Guarantee

Cover Details, No. Of Covers - 2

Cover No	Cover	Document Type	Description
1	Fee/PreQual /Technical	.pdf	Tender Document
2	Finance	.xls	BOQ Sheet

Tender Fee Details, [Total Fee in ₹ * - 0.00]

Tender Fee in ₹	0.00		
Fee Payable To	Nil	Fee Payable At	Nil
Tender Fee Exemption Allowed	No		

EMD Fee Details

EMD Amount in ₹	2,00,000	EMD Exemption Allowed	Yes
EMD Fee Type	fixed	EMD Percentage	NA
EMD Payable To	MISCELLANEOUS FUND, AIIMS BILASPUR	EMD Payable At	AIIMS BILASPUR HP

Work Item Details

Title	RATE CONTRACT SUPPLY OF DRUGS (INJECTIONS, PATCH, RESPULES, VACCINE, MDI, SUPPOSITORY, SACHET, IV FLUIDS, ANTISEPTIC, DISINFECTANT AND CONTROLLED SUBSTANCES/NARCOTICS DRUGS ETC.				
Work Description	RATE CONTRACT SUPPLY OF DRUGS (INJECTIONS, PATCH, RESPULES, VACCINE, MDI, SUPPOSITORY, SACHET, IV FLUIDS, ANTISEPTIC, DISINFECTANT AND CONTROLLED SUBSTANCES/NARCOTICS DRUGS ETC.				
Pre Qualification Details	AS PER TENDER DOCUMENT				
Independent External Monitor/Remarks	NA				
Show Tender Value in Public Domain	Yes				
Tender Value in ₹	35,28,60,000				
Product Category	Consumables (Hospital / Lab)	Sub category	NA		
Contract Type	Rate Contract	Bid Validity(Days)	270	Period Of Work(Days)	730
Location	AIIMS BILASPUR	Pincode	174037	Pre Bid Meeting Place	AIIMS BILASPUR
Pre Bid Meeting Address	Admin block, AIIMS Bilaspur	Pre Bid Meeting Date	03-Dec-2025 03:00 PM	Bid Opening Place	AIIMS BILASPUR HP
Should Allow NDA Tender	No	Allow Preferential Bidder	No		

Critical Dates

Publish Date	29-Nov-2025 12:24 PM	Bid Opening Date	31-Dec-2025 03:00 PM

- View Auction History

Bid Management

- Bid History

Survey Management

- FeedBack

Document Download / Sale Start Date	29-Nov-2025 06:00 PM	Document Download / Sale End Date	30-Dec-2025 03:00 PM
Clarification Start Date	29-Nov-2025 06:30 PM	Clarification End Date	02-Dec-2025 10:00 AM
Bid Submission Start Date	09-Dec-2025 09:00 AM	Bid Submission End Date	30-Dec-2025 03:00 PM

Tender Documents

NIT Document

S.No	Document Name	Description	Document Size (in KB)
1	Tendernotice_1.pdf	NIT	216.35

Download as zip file

Work Item Documents

S.No	Document Type	Document Name	Description	Document Size (in KB)
1	BOQ	BOQ_932122.xls	BOQ Sheet	701.00
2	Tender Documents	Tender18.pdf	Tender document	1229.78

Bid Openers List

S.No.	Bid Opener Login Id	Bid Opener Name	Certificate Name	Serial No
1.	a.naveen.gmc@gmail.com	AVULA NAVEEN	Avula Naveen	5a d2 a4 79
2.	dr.anurag.biochem@aiimsbilaspur.edu.in	ANURAG SANKHYAN	Anurag Sankhyan	5b 00 c9 dc
3.	ee.electrical@aiimsbilaspur.edu.in	Sikander Singh	SIKANDER SINGH	18 31 de 5
4.	ao.accounts@aiimsbilaspur.edu.in	Ajay Kumar	AJAY KUMAR SHARMA	17 f4 12 0

GeMARPTS Details

GeMARPTS ID	1IP76XS2B8YD
Description	Successfully
Report Initiated On	22-Nov-2025
Valid Until	22-Dec-2025

Tender Properties

Auto Tendering Process allowed	No	Show Technical bid status	Yes
Show Finance bid status	Yes	Stage to disclose Bid Details in Public Domain	Technical Bid Opening
BoQ Comparative Chart model	Normal	BoQ Compartive chart decimal places	2
BoQ Comparative Chart Rank Type	L	Form Based BoQ	No

TIA Undertaking

S.No	Undertaking to Order	Tender complying with Order	Reason for non compliance of Order
1	PPP-MII Order 2017	Agree	
2	MSEs Order 2012	Agree	

Tender Inviting Authority

Name	FACULY INCHARGE PROCUREMENT
Address	FACULY INCHARGE PROCUREMENT, AIIMS BILASPUR HP

View Modification details

Tender Creator Details

Created By	ANURAG SANKHYAN
Designation	Assistant Professor
Created Date	22-Nov-2025 03:55 PM

Version:1.09.23 16-Oct-2025

ALL INDIA INSTITUTE OF MEDICAL SCIENCES,
BILASPUR, HIMACHAL PRADESH-174001, INDIA

PROCUREMENT SECTION
TENDER ENQUIRY DOCUMENT
(TWO BID SYSTEM FOR SUPPLY OF DRUGS (INJECTIONS, PATCH, RESPULES, VACCINE, MDI, SUPPOSITORY, SACHET, IV FLUIDS, ANTISEPTIC, DISINFECTANT AND CONTROLLED SUBSTANCES/NARCOTICS DRUGS ETC.)

(This document consisting of **63** Pages)

Advertised Tender Enquiry No.:	**AIIMS/BLS/(G)/25-26/E-Tender/18**
Rate Contract items:	**RATE CONTRACT SUPPLY OF DRUGS (INJECTIONS, PATCH, RESPULES, VACCINE, MDI, SUPPOSITORY, SACHET, IV FLUIDS, ANTISEPTIC, DISINFECTANT AND CONTROLLED SUBSTANCES/NARCOTICS DRUGS ETC.**
Period of Rate Contract:	**Initially for a period of Two years, which can be further extended another one year on mutual consent basis.**

The tenders are to be submitted by the manufacturers/sole importer only. Tenders quoted by suppliers on behalf of manufacturers will not be entertained even if they are authorized by the manufacturers.

The EMD/Bid Security shall be deposited through Bank Guarantee/Demand Draft/FDR drawn in favour of the **Miscellaneous Fund, AIIMS Bilaspur Himachal Pradesh (A/No 41512727609 IFSC: SBIN0063972).** The original Earnest Money/Bid Security must be delivered to the Faculty In-Charge (Procurement), Hospital D -Block, AIIMS, Bilaspur, Himachal-174001

Evaluation Criteria for following Selecting following Items:

Adalimumab	Cisplatin	Degarelix	Gemcitabine	Mitomycin	Trastuzumab
Bevacizumab	Cyclophosphamide	Denosumab	Idarubicin	Oxaliplatin	
Carboplatin	Cytarabine(Cytosine Arabinoside)	Docetaxel	Ifosfamide with Mesna	Paclitaxel	
Carfilzomib	Dacarbazine	Doxorubicin	Irinotecan	Pemetrexed	
Cetuximab	Thiotepa	Epirubicin	Methotrexate	Rituximab	

Bidders shall to quote for **all strengths** of the above-mentioned item (Due to dose mixing issue). For example, in the case of **Injection Rituximab**, the bidder must quote for **both strengths (100 mg and 500 mg)**. The **evaluation and selection** will be carried out based on the **total value of all strengths** calculated as:
(Estimated Quantity mentioned in the Tender × Quoted Rate by bidder) for all strength.
Firms not quoting for both/all the strengths will not be considered

The price should be quoted for the **Accounting Unit (UOM)** indicated in the e-tender document.

The 'hard copy' of technical bid along with **EMD instrument** shall be placed in one sealed envelope super-scribed "**Proposal with EMD/Exempted (Tick on Appropriate) for Tender for entering into a rate contract for SUPPLY OF DRUGS (INJECTIONS, PATCH, RESPULES, VACCINE, MDI, SUPPOSITORY, SACHET, IV FLUIDS, ANTISEPTIC, DISINFECTANT AND CONTROLLED SUBSTANCES/NARCOTICS DRUGS ETC in All India Institute of Medical Sciences, Bilaspur H.P**." to be sent following address:

F.I. Procurement
Procurement Section
AIIMS Bilaspur, HP 174037

Email: stores.aiimsbilaspur@gmail.com
URL: - **https://www.aiimsbilaspur.edu.in/**

SECTION-I

ALL INDIA INSTITUTE OF MEDICAL SCIENCES BILASPUR, HIMCHAL PRADESH-174001

NOTICE INVITING TENDERS (NIT)

Advertised Tender Enquiry No: AIIMS/BLS/(G)/25-26/E-Tender/18

On behalf of Executive Director, AIIMS, Bilaspur, Himachal Pradesh -174001, online bids are invited in two bid system (Techno-Commercial Bid and Financial Bid) from eligible and qualified firms/manufacturers for supply of following Goods for conclusion of Rate Contract for a period of **02 Years and may be extendable** for further **one year**: -

Schedule Name	Details	No. of Items	Estimated Amount	Amount of Bid Security/EMD (INR)	Average Annual Turnover in Last 3 Years (FY 2022-23 to 2024-25)
Schedule 1(1.001 to 1.801)	**SUPPLY OF DRUGS (INJECTIONS, PATCH, RESPULES, VACCINE, MDI, SUPPOSITORY, SACHET, IV FLUIDS, ANTISEPTIC, DISINFECTANT AND CONTROLLED SUBSTANCES/NARCOTICS DRUGS ETC.**	801	**₹35,28,60,014/-**	2,00,000/-	35 Crores

CRITICAL DATE SHEET

Published Date & Time	As mentioned in CPP Portal
Bid Document Download/Sale Start Date	As mentioned in CPP Portal
Seek Clarification Start Date	As mentioned in CPP Portal
Seek Clarification End Date	As mentioned in CPP Portal
Pre-Bid Meeting Date	As mentioned in CPP Portal
Pre-Bid Meeting Venue	AIIMS Bilaspur H.P.
Bid Submission Start Date & Time	As mentioned in CPP Portal
Bid Submission End Date & Time	As mentioned in CPP Portal
Bid Opening Date & Time	As mentioned in CPP Portal

Instructions:

1. Bids shall be submitted online only at CPPP website: https://eprocure.gov.in/eprocure/app
2. The Bidder shall download the Tender Enquiry Document directly from the websites https://eprocure.gov.in/eprocure/app & AIIMS Bilaspur websites **https://www.aiimsbilaspur.edu.in/** and shall not tamper/modify it including downloaded Price Bid template in any manner. In case if the same is found to be tempered/modified in any manner, Tender/Bid will be summarily rejected and EMD would be forfeited.
3. The complete bidding process is online. Bidders should be possession of valid Digital Signature Certificate (DSC) of class III for online submission of bids. Prior to bidding DSC need to be registered on the website mentioned above.
4. Bidders are advised to follow the instructions provided in the "Instructions for Online Bid Submission" in GIB of Tender Enquiry Document.
5. Bidders are advised to visit this website regularly to keep themselves updated, for any changes / modifications in the Tender Enquiry Document.
6. Intending bidder are advised to visit CPPP website https://eprocure.gov.in/eprocure/app regularly till closing date of submission of bid, for any corrigendum.
7. The documents to be submitted in their bid may be scanned with 100 dpi with black and white option which helps in fast uploading.
8. The EMD/Bid Security shall be deposited through Bank Guarantee/Demand Draft/FDR drawn **in favour of the Miscellaneous Fund, AIIMS Bilaspur Himachal Pradesh (A/No 41512727609 IFSC: SBIN0063972).** The original Earnest Money/Bid Security must be delivered to the **Faculty In-Charge (Procurement), Hospital E -Block, AIIMS, Bilaspur, Himachal-174001** till bid opening date and time as mentioned in "Critical Date Sheet" failing which the bid shall be summarily rejected.
9. The tender received after due date or without the earnest money or without samples wherever required shall not be considered.
10. The Estimated Quantities will vary, either increase or decrease and the decision of the Executive Director/Medical Superintendent AIIMS, which shall be final and binding to all parties.
11. The Bidder is expected to examine all instructions, forms, terms and specifications in the bidding document. The bid should be precise, complete and in the prescribed format as per the requirement of the bid document. **The bid should not be conditional**. Failure to furnish all information required by the bidding document or submission of a bid not responsive to the bidding

documents in all respect will be at the Bidder's risk and may result in rejection of the bid.

12. The Bidder shall bear all costs associated with the preparation and submission of its bid and AIIMS, Bilaspur will in no case be held responsible or liable for these costs, regardless of the conduct or outcome of the bidding process.
13. The EMD / Bid Security shall be deposited through Bank Guarantee / Demand Draft / FDR drawn in favor of the Miscellaneous Account AIIMS Bilaspur. The original Earnest Money / Bid Security must be submitted to Faculty In charge (Procurement), Procurement Section, Ground Floor, E Block, AIIMS, Bilaspur H.P. 174037 till "Bid Submission End Date & Time" as mentioned in "Critical Date Sheet/CPP Portal" failing which the bid shall be summarily rejected.
14. Pre-bid queries can be made before pre-bid meeting through e-mail Procure_drug@gmail.com up to the time mentioned.
15. Micro and Small Enterprises and Small-Scale Industries are exempted for EMD as per AIIMS, Bilaspur (HP) purchase guidelines.

E-Tendering Portal:

https://eprocure.gov.in/eprocure/app

For any technical related queries please call the Helpdesk.The 24 x 7 Help Desk Number +91 0120-4200462, +91 0120-4001002, +91 0120-4001005.

E-Mail : support-eproc[at]nic[dot]in,

SECTION - II
GENERAL INSTRUCTIONS TO BIDDERS (GIB)

A. PREAMBLE

1. Definitions and Abbreviations

1.1 The following definitions and abbreviations, which have been used in these documents shall have the meanings as indicated below:

1.2. **Definitions**:

i) "Purchaser" means the organization i.e. AIIMS/Hospital/Department/Sections purchasing goods as incorporated in the Tender Enquiry Document.
ii) "Bid" means Quotation / Tender received from a Firm / Tenderer / Bidder.
iii) "Bidder" means Tenderer/ the Individual or Firm submitting Bids / Quotation / Tender
iv) "Supplier" means the individual or the firm supplying the goods as incorporated in the Rate Contract/Purchase Order.
v) "Goods" means all articles, material, commodity, livestock, furniture, fixtures, raw material, spares, instruments, machinery, equipment, vehicles, medicines, assemblies, sub-assemblies, accessories, intangible products like software, technology transfer, licenses, patents or other intellectual properties purchased or otherwise acquired for the use of Government but excludes books, publications, periodicals, etc. for a library. The term 'goods' also includes works and services which are incidental or consequential to the supply of such goods, such as, transportation, insurance, installation, commissioning, training and maintenance.
vi) "Services" means services allied and incidental to the supply of goods, such as transportation, installation, commissioning, provision of technical assistance, training, after sales service, maintenance service and other such obligations of the supplier covered under the Rate Contract.
vii) "Bid Security" (BS) means Earnest Money Deposit / monetary or financial guarantee to be furnished by a bidder along with its tender.
viii) "Contract" means Rate Contract/Purchase Order which means the written agreement entered into between the purchaser and the supplier, together with all the documents mentioned therein and including all attachments, annexure etc. therein.
ix) "Performance Security" means monetary or financial guarantee to be furnished by the successful bidder for due performance of the Rate Contract/Purchase Order placed on it. Performance Security is also known as Security Deposit.
x) "Consignee" means the Center/Hospital/Department/Sections /person to whom the goods are required to be delivered as specified in the Purchase Order.
xi) "Specification" also called Technical Specifications means the document/standard that prescribes the requirement with which goods has to conform.
xii) "Inspection" means activities such as measuring, examining, testing, gauging one or more characteristics of the product and comparing the same with the specified requirement mentioned in the Rate Contract/Purchase Order to determine conformity.
xiii) "Day" means calendar day.

1.3 Abbreviations:

i) "ATE" means Advertised Tender Enquiry
ii) "NIT" means Notice Inviting Tenders.
iii) "GIB" means General Instructions to Bidders
iv) "SIB" means Special Instructions to Bidders
v) "GCC" means General Conditions of Contract
vi) "SCC" means Special Conditions of Contract
vii) "DP" means Delivery Period
viii) "BG" means Bank Guarantee
ix) "GST" means Goods & Service Tax
x) "RC" means Rate Contract

4. Introduction

4.1 All India Institute of Medical Sciences, Bilaspur is being established under the Pradhan Mantri Swasthya Suraksha Yojana (PMSSY) of Govt. of India. The Institute is to be established over a span of about 247-acre (99.96 hectare) land on National Highway – 205 (Shimla-Kangra), in the village Kothipura of District Bilaspur, Himachal Pradesh. AIIMS- Bilaspur .The Hon'ble Prime Minister of India, Shri Narendra Modi inaugurated on 05 October 2022 and has been made functional with full strength of 750 bedded hospital equipped with all modern facilities. The All India Institute of Medical Sciences (AIIMS) Bilaspur is catering Drugs/Medicines/I.V. Fluids to the Indoor Patients. The list of IV Fluids, Antiseptic & Disinfectant to indoor patients required by AIIMS, is enclosed herewith for your information/reference. The Purchaser has issued these Tender Documents for purchase of goods as mentioned in Section – VI – "Schedule of Requirements"/Annexure –'A', which also indicates, interalia, the required delivery schedule, terms and place of delivery.

4.2 This section (Section II - "General Instructions to Bidders") provides the relevant information as well as instructions to assist the prospective bidders in preparation and submission of bids. It also includes the mode and procedure to be adopted by the bidder for receipt and opening as well as scrutiny and evaluation of bids and subsequent placement of Rate Contract/Purchase Order.

4.3 The bidder shall also read the Special Instructions to Bidders (SIB) related to this purchase, as contained in Section III of these documents and follow the same accordingly. Whenever there is a conflict between the GIB and the SIB, the provisions contained in the SIB shall prevail over those in the GIB.

4.4 Before formulating the bid and submitting the same to the purchaser, the bidder should read and examine all the terms, conditions, instructions, etc. contained in the Tender Document. Failure to provide and/or comply with the required information, instructions etc. incorporated in these Tender Documents may result in rejection of its Bid.

4.5 The rates quoted, approved and accepted by the Executive Director, AIIMS shall be valid for **two years** from the date of signing of the agreement deed **(extendable up-to one year on mutual agreement, if required)**.

5. Availability of Funds

5.1 Expenditure to be incurred for the proposed purchase will be met from the funds available with the purchaser/consignee.

6. Language of Bid

6.1 The bid submitted by the bidder and all subsequent correspondence and documents relating to the bid exchanged between the bidder and the purchaser, shall be written in the English language. However, the language of any printed literature furnished by the bidder in connection with its bid may be written in any other language provided the same is accompanied by an English translation and, for purposes of interpretation of the bid, the English translation shall prevail**.**

7. Bid Expense

7.1 The bidder shall bear all costs and expenditure incurred and/or to be incurred by it in connection with its bid including preparation, uploading of its bid and for subsequent processing the same. The purchaser will, in no case be responsible or liable for any such cost, expenditure etc. regardless of the conduct or outcome of the Tender process.

B. TENDER ENQUIRY DOCUMENT

8. Content of Tender Enquiry Document

8.1 In addition to Section I – "Notice Inviting Tender" (NIT), the Tender Enquiry Document includes:

i)	Section II	–	General Instructions to Bidders (GIB)
ii)	Section III	–	Special Instructions to Bidders (SIB)
iii)	Section IV	–	General Conditions of Contract (GCC)
iv)	Section V	–	Special Conditions of Contract (SCC)
v)	Section VI	–	Schedule of Requirements
vi)	Section VII	–	Specifications
vii)	Section VIII	–	Qualification Criteria
viii)	Section IX	–	Tender Acceptance Form
ix)	Section X	–	Price Schedules (BoQs)
x)	Section XI	–	Bank Guarantee Form for Bid Security
xi)	Section XII	–	Bank Guarantee Form for Performance Security
xii)	Section XIII	–	Rate Contract Forms
xiii)	Section XIV	–	Performa of Consignee Receipt Certificate
xiv)	Section XV	–	Performa of Final Consignee Acceptance Certificate
xv)	Section XVI	-	List of items quoted
xvi)	Section XVII	-	Performa to be filled by the tenderer
xvii)	Section XVIII	-	Manufacturing & Marketing Certificate
xviii)	Section XIX	-	Production Capacity Assessment Certificate
xix)	Section XX	-	Certificate of Price Justification
xx)	Section XXI	-	Certificate of Local Content
xxi)	Section XXII	-	Compliance certificate of GFR-144 (xi).
xxii)	Section XXIII	-	Checklist

8.2 The relevant details of the required goods, the terms, conditions and procedure for Tender, bid

evaluation, placement of Rate Contract/Purchase Order, the applicable contract terms and, also, the standard formats to be used for this purpose are incorporated in the above-mentioned documents. The interested bidders are expected to examine all such details etc to proceed further.

9. Corrigendum to Tender Enquiry Document

At any time prior to the deadline for submission of bids, the purchaser may, for any reason deemed fit by it, modify the Tender Enquiry Document by issuing suitable Corrigendum to it

9.1 Corrigendum will be notified through https://eprocure.gov.in/ eprocure/app only.

9.2 In order to provide reasonable time to the prospective bidders to take necessary action in preparing their bids as per the amendment, the purchaser may, at its discretion extend the deadline appropriately for the submission of bids and other allied time frames, which are linked with that deadline.

10. Clarification of Tender Enquiry Document & Pre- Bid Meeting

10.1 A bidder requiring any clarification or elucidation on any issue of the Tender Enquiry Document may take up the same with the purchaser through CPP Portal only. The purchaser will respond through CPP Portal to such request provided the same is uploaded within the time schedule mentioned in "Critical Date Sheet".

10.2 All the Prospective bidders are requested to attend Pre-Bid Meeting at venue & on date as mentioned in Critical Date Sheet to have a clear understanding on schedule of requirements, specifications and on terms & conditions of the tender. After due deliberation, changes if any may be incorporated in the tender document and will be uploaded on our official website as "Corrigendum". Therefore, bidders may submit their bid accordingly as per changes if any incorporated after Pre-Bid Meeting. No press advertisement will be made for corrigendum(s).

C. PREPARATION OF BIDS

11. Documents Comprising the Bid

11.1 The **Two Bid System**, i.e. "Techno – Commercial Bid" and "Price Bid" prepared by the bidder shall comprise the following:

A) Techno – Commercial Bid (Un-priced Bid)

i) Scanned copy of "EMD/Bid Security" furnished in accordance with GIB alternatively, documentary evidence as per GIT for claiming exemption from payment of EMD/Bid security to be uploaded. THE EMD/BID SECURITY DEPOSITED AGAINST OTHER TENDERS CANNOT BE ADJUSTED OR CONSIDERED FOR THIS TENDER. NO INTEREST IS PAYABLE ON EMD/BID SECURITY. EMD/Bid Security of the approved firms, who fulfills pre- qualification requirements, would be retained till the firm is registered at AIIMS for the supply of Drugs/Medicines items.

FIRM WHICH HAD BEEN DECLARED ELIGIBLE ON THE BASIS OF PATENT/NICHE MOLECULE SHALL NOT BE EXEMPT UNDER THIS CLAUSE AND SHALL HAVE TO SUBMIT ALL DOCUMENTS AS PER THE REQUIREMENT OF THIS TENDER

ii) Scanned copy of the "List of Items Quoted" as per Section–X of the Tender Enquiry Document**.** ***(Only technical details such as specifications, make, and model shall be submitted with the Technical Bid of quoted items. If financial information, rates submitted in the Technical Bid will lead to summary rejection of the bid.)***

iii) Scanned copy of "Tender Acceptance Form" as per **Section IX** to be uploaded.

iv) Scanned Copy of GST Registration Certificate.

v) Scanned copy of non-backlisting/ non-debarred Certificate on non-judicial stamp paper of Rs. 10.

vi) Scanned copy of turnover should be duly authenticated by a Chartered Accountant for the last three years (FY 2022-23 to 2024-25) should be enclosed.

vii) Participating Firms will have to submit audited financial statement (Profit & Loss Statement and Balance Sheet) verified by registered Chartered Accountant for last three preceding financial years (i.e. 2022-23, 2023-24 and 2024-25) in support of the annual turnover.

viii) Scanned copy of Documentary evidence, as necessary in terms of clauses of GIB establishing that the bidder is eligible to submit the bid and, also, qualified to perform the Rate Contract if its bid is accepted to be uploaded.

ix) Scanned copy of **Power of Attorney** in favor of signatory of Tender/Bid to be uploaded.

x) Scanned copy of Documents and relevant details to establish in accordance with GIB that the goods to be supplied by the bidder conform to the requirement of the Tender Enquiry Document to be uploaded.

xi) Scanned copy of Documents confirming to Sole Proprietorship/ Partnership/Private Limited Firm in the country of origin as the case may be to be uploaded.

xii) Self-certification regarding local content as per **Section XXI.**

xiii) Restrictions under Rule 144 (xi) of the GFRs 2017 as per order no. F.No.6/18/2019 PPD dated 23rd July, 2020 regarding land Border sharing issued by Department of Expenditure, Public Procurement Division will be applicable. Relevant documents regarding this order to be uploaded as per section **Section-XXII (Performa).**

xiv) The Scanned Copies of following documents, wherever applicable may be uploaded under "Other Important Documents".

xv) Scanned Copy of undertakings and Other Documents Manufacturing & Market Standing /Experience Certificate, Copy of WHO-GMP certificate/Valid Schedule 'M' Certificate, valid manufacturing license, Performance Certificate, Production-Capacity assessment Certificate, Non-Conviction Certificate etc. as per TED.

Note:
It is the responsibility of bidder to go through the Tender Enquiry Document to ensure uploading all required documents in addition to above, if any

B) **Price Bid:**

Price Schedule(s) as per BoQ format filled up with all the details including Make, Model etc. of the goods offered to be uploaded.

i) **Schedule of price bid in the form of BOQ_XXXX .xls:**

The below mentioned (Section X) price bid format is provided as BoQ_XXXX.xls along with this Tender Enquiry Document at https://eprocure.gov.in/eprocure/app. Bidders are advised to download this BoQ_XXXX.xls as it is and quote their offer/rates in the permitted column and upload the same in the commercial bid. Bidder shall not tamper/modify downloaded price bid template in any manner. In case if the same is found to be tempered/modified in any manner, tender will be completely rejected and tenderer is liable to be banned from doing business with AIIMS Bilaspur.

ii) **Additional information and instruction on GST:**

If the bidder desires to ask for GST, the same must be specifically indicated in the financial bid. Any other taxes or duties to be paid extra must be included by the bidder in the unit cost. In the absence of any such stipulation the price will be taken inclusive of such taxes and no claim for the same will be entertained later. The rate of GST quoted in the tender shall be taken for price comparison. However, the rate of GST quoted in the tender or the actual rate of GST applicable, whichever is lower shall be payable by the purchaser. The supplier can charge a higher GST than quoted in the tender only if the rate of GST was revised by the government after the tender closing date. Bidders are advised to be particularly careful infilling the GST rate in the financial bid as no upward revision of GST shall be allowed unless the rate is revised by the government after bid submission date. If seller derives any benefits due to reduction/change of tax rates by the Govt., same shall be passed on to the buyer.

iii) The Bidder shall indicate in the Price Schedule provided in BoQ all the specified components of prices shown therein including the unit prices on Free Delivery at Site basis, applicable GST, HSN Code, it proposes to supply against the requirement. The Bidders shall indicate MRP in the relevant column against each item of BoQ. The details about make & model, if applicable, may also be indicated. All the columns shown in the Price Schedule should be filled up as required.

iv) Tenders should be submitted only for the drugs etc., asked for. Substitutes/Equivalents should not be offered. In case the drug asked for is not available and if rate for any of the item not quoted the column should be left blank.

v) Free offers by the bidder shall not be accepted. Bidders desiring to offer free goods/items may reduce their rates suitably while quoting.

vi) Prices quoted should be inclusive of all charges like packing, forwarding, Insurance, duties and education cess etc., However the breakup of GST have to be shown separately.

vii) Rates should be according to unit (UOM) asked for. Specification & packing size of each product should be as per details given in the tender.

viii) In no case the quoted rates should be more than MRP at the time of submission of quotation. If subsequently during the currency of Rate Contract there is decreased in MRP, the bidder shall inform the purchaser promptly along with revised reduced rates on pro-rata basis. In case, if bidder quotes more than MRP and/or does not inform purchaser about reduction in MRP, it will be viewed seriously and appropriate administrative action will be taken including de-barring the firm.

ix) There is more than one schedule in the "Schedule of Requirements," the bidder may submit its bid for any one or more schedules. However, for the drugs listed below **monoclonal antibodies**, **the bidder must quote for all available strengths mentioned in the tender under that particular schedule,** covering the complete requirement of goods as specified. For example, in the case of Injection Rituximab, the bidder shall quote for both 100 mg and 500 mg strengths. The evaluation and selection will be carried out based on the total value of all strengths, calculated as: **(Estimated**

Quantity mentioned in the Tender × Quoted Rate by the Bidder) for all strengths combined. If a bidder fails to quote for all strengths of the following items, their rates will not be considered for following items**:**

Adalimumab	Cisplatin	Degarelix	Gemcitabine	Mitomycin	Trastuzumab
Bevacizumab	Cyclophosphamide	Denosumab	Idarubicin	Oxaliplatin	
Carboplatin	Cytarabine(Cytosine Arabinoside)	Docetaxel	Ifosfamide with Mesna	Paclitaxel	
Carfilzomib	Dacarbazine	Doxorubicin	Irinotecan	Pemetrexed	
Cetuximab	Thiotepa	Epirubicin	Methotrexate	Rituximab	

x) In case of controlled drugs by the Government (Under DPCO), the quotation must be sent subject to the controlled rates and other conditions and supplier will be paid at the controlled price or rates offered by the supplier whichever is less. Controlled drugs must be clearly mentioned as such in the bidders' quotations.

11.2 The authorized signatory of the bidder must digitally sign the bid. Individuals digitally signing the bid or other documents connected with a Rate Contract must specify whether he signs as:

i) A 'Sole Proprietor' of the firm or constituted attorney of such Sole Proprietor.

ii) In case of partnership firm, he must have authority to quote & to refer to arbitration dispute concerning the business of the partnership either by virtue of the partnership agreement or a power of attorney;

iii) Constituted attorney of the firm if it is a company.

Note:

1) In case of (ii) above, a copy of the partnership agreement duly registered with "Registrar of Firm's" or general power of attorney, in either, case, attested by a Notary Public should be uploaded, or affidavit on stamped paper of all the partners admitting execution of the partnership agreement or the general power of attorney should be uploaded.

2) In case of the partnership firms, where no authority to refer disputes concerning the business of the partnership has been conferred on any partner, the bid and all other related documents must be signed by every partner of the firm and uploaded.

3) Person digitally signing the Tender Acceptance Form or any documents forming part of the contract on behalf of another shall be deemed to warrantee that he has authority to bind such other persons and if, on enquiry, it appears that the persons so signing had no authority to do so, the purchaser may, without prejudice to other civil and criminal remedies, liable for rejection of bid or cancel of contract and hold the signatory liable for all cost and damages.

11.3 A bid, which does not fulfill any of the above requirements and/or gives evasive information/reply against any such requirement, shall be liable to be ignored and rejected.

11.4 Bid sent by fax/email shall be ignored.

12. Bid Currencies

12.1 The bidder supplying indigenous goods or already imported goods shall quote only in Indian Rupees (INR).

12.2 Bids, where prices are quoted in any other way shall be treated as non -responsive and rejected.

13. Firm Price

13.1 Prices quoted by the bidder shall remain firm and fixed during the currency of the Rate Contract and not subject to variation on any account. Purchase Orders will be placed by Centers/Hospital/Departments/Store Sections against this Rate Contract till the currency period of Rate Contract.

13.2 Statuary variation in GST will be applicable.

14. Alternative Models/Brands/Quality

14.1 Alternative Models/Brands/Quality are not permitted. The Bidders are required to quote Models/Brands/Quality of best quality meeting tender specifications. Wherever, a bidder quotes alternative Models/ Brands/ Quality, there bid will not be considered for that item.

15. Documents Establishing Bidder's Eligibility and Qualifications

15.1 The bidder shall furnish, as part of its bid, relevant details and documents establishing its eligibility to quote and its qualifications to perform the Rate

Contract if its bid is accepted. The "Qualification Criteria" have been given in Section VIII.

15.2 Quotations shall be strictly according to the required specifications, and in the case of formulations, detailed formula along with the connected literature, Drug licenses etc. should be furnished. The

name of the manufacturer and the brand name should also be stated.

16. Documents establishing good's Conformity to Tender Enquiry Document.

16.1 The bidder shall upload in its bid the required as well as the relevant documents like technical data, literature, drawings etc. to establish that the goods offered in the bid fully conform to the goods specified by the purchaser in the Tender Enquiry Document. For this purpose, the bidder shall also upload a clause-by- clause commentary on the technical specifications and other technical details incorporated by the purchaser in the Tender Enquiry Document to establish technical responsiveness of the goods offered in its bid.

16.2 In case there is any variation and/or deviation between the goods prescribed by the purchaser and that offered by the bidder, the bidder shall list out the same in a chart form without ambiguity and provide the same along with its bid.

16.3 If a bidder furnishes wrong and/or misguiding data, statement(s) etc. about technical acceptability of the goods offered by it, its bid will be liable to be ignored and rejected in addition to other remedies available to the purchaser in this regard.

17. Bid Security (BS) /EMD

17.1 Pursuant to the bidder shall furnish along with its bid, Bid Security for amount as shown in the Notice Inviting Tenders (NIT).

17.2 The original Earnest Money/Bid Security must be delivered to address as given in NIT till bid opening date and time as mentioned in "Critical Date Sheet" failing which the bid shall be summarily rejected. The scanned copy of original Bid Security/EMD may be uploaded along with the bid.

17.3 The bidders who are currently registered with MSME for the goods as per Tender document specification shall be eligible for exemption from Bid Security as defined in MSE Procurement Policy issued by the department of MSME. In case the bidder falls in this category, the bidder shall upload relevant certificate of registration for the subject goods issued by department of MSME.

17.4 The Bid Security shall be denominated in Indian Rupees. The Bid Security shall be furnished in one of the following forms:

i) Account Payee Demand Draft/ Banker's cheque
ii) Fixed Deposit Receipt
iii) Bank Guarantee

17.5 The demand draft or banker's cheque shall be drawn on any commercial bank in India, in favour of as indicated in the NIT payable at Bilaspur. In case of Bank Guarantee, the same is to be provided from any commercial bank in India or country of the bidder as per the format specified under Section XI in these documents.

17.6 The Bid Security shall be valid for a period of forty-five (45) days beyond the validity period of the bid. As validity period of Bid is 270 days, the Bid Security shall be valid for 315 days from Techno – Commercial Bid opening date.

17.7 The Bid Security of successful bidder will be returned without any interest, after receipt of performance security from that bidder.

17.8 Bid Security is required to protect the purchaser's right against the risk of the Bidder's conduct, which would warrant the forfeiture of the Bid Security. Bid Security of a bidder will be forfeited, if the bidder withdraws or amends its bids or impairs or derogates from the bid in any respect within the period of validity of its bid or if it comes to the notice that the information/documents furnished in its bid is incorrect, false, misleading or forged without prejudice to other rights of the purchaser. The Bid Security of the successful bidder will be forfeited without prejudice to other rights of Purchaser if it fails to furnish the required performance security within the specified period.

18. Bid Validity

18.1 The bid shall remain valid for acceptance for a period of 270 days (Two hundred and Seventy days) after the date of bid opening prescribed in the Tender Document. Any bid valid for a shorter period shall be treated as unresponsive and rejected.

18.2 In exceptional cases, the bidder may be requested by the purchaser to extend the validity of their bids up to a specified period. Such request(s) and responses thereto shall be conveyed by mail/fax/email.

The bidders, who agree to extend the bid validity, are to extend the same without any change or modification of their original bid and they are also to extend the validity period of the Bid Security accordingly. A bidder, who may not agree to extend its bid validity after the expiry of the original validity period, their bid will not be considered further and the Bid Security furnished by them shall be returned.

18.3 In case the day up to which the bids are to remain valid falls on/ subsequently declared a holiday or closed day for the purchaser, the bid validity shall automatically be extended up to the next working day.

19. Instructions for Online Bid Submission and Registration on CPP Portal:

19.1 The bidders shall submit their online bids as per the instruction given for online bid process. The bidders are required to submit soft copies of their bids electronically on the CPP Portal, using valid Digital Signature Certificates. The instructions given below are meant to assist the bidders in registering on the CPP Portal, prepare their bids in accordance with the requirements and submitting their bids online on the CPP Portal. More information useful for submitting online bids on the CPP Portal may be obtained at: https://eprocure.gov.in/eprocure/app.

19.2 Registration on CPP Portal:

i) Bidders are required to enroll on the e-Procurement module of the Central Public Procurement Portal (URL: https://eprocure.gov.in/ eprocure/app)by clicking on the link "Online bidder Enrolment" on the CPP Portal which is free of charge.

ii) As part of the enrolment process, the bidders will be required to choose a unique username and assign a password for their accounts.

iii) Bidders are advised to register their valid email address and mobile numbers as part of the registration process. These would be used for any communication from the CPP Portal.

iv) Upon enrolment, the bidders will be required to register their valid Digital Signature Certificate (Class II or Class III Certificates with signing key usage) issued by any Certifying Authority recognized by CCA India (e.g. Sify/nCode /eMudhra etc.), with their profile.

v) Only one valid DSC should be registered by a bidder. Please note that the bidders are responsible to ensure that they do not lend their DSC's to others which may lead to misuse.

vi) Bidder then logs in to the site through the secured log-in by entering their user ID / password and the password of the DSC / e-Token.

19.3 Searching for Tender Enquiry Document on CPP Portal:

i) There is various search options built in the CPP Portal, to facilitate bidders to search active tenders by several parameters. These parameters could include Tender ID, Organization Name, Location, Date, Value, etc. There is also an option of advanced search for tenders, wherein the bidders may combine a number of search parameters such as Organization Name, Form of Contract, Location, Date, Other keywords etc. to search for a tender published on the CPP Portal.

ii) Once the bidders have selected the tenders they are interested in, they may download the required documents / tender schedules. These tenders can be moved to the respective 'My Tenders' folder. This would enable the CPP Portal to intimate the bidders through SMS / e-mail in case there is any corrigendum issued to the tender document.

iii) The bidder should make a note of the unique Tender ID assigned to each tender; in case they want to obtain any clarification / help from the Helpdesk.

19.4 Preparation of Bids for uploading on CPP Portal

i) Bidder should take into account any corrigendum published on the tender document before submitting their bids.

ii) Please go through the tender advertisement and the Tender Enquiry Document carefully to understand the documents required to be submitted as part of the bid. Please note the number of covers in which the bid documents have to be submitted, the number of documents - including the names and content of each of the document that need to be submitted. Any deviations from these may lead to rejection of the bid.

iii) Bidder, in advance, should get ready the documents/BoQ to be uploaded as indicated in the Tender Enquiry Document and generally, they can be in PDF / XLS / RAR / DWF/JPG formats. Scanned documents to be uploaded may be scanned with 100 dpi with black and white option which helps in reducing size of the scanned document and resulting in fast uploading. It is the responsibility of the bidder to ensure that uploaded scanned documents are legible.

iv) To avoid the time and effort required in uploading the same set of standard documents which are required to be submitted as a part of every bid, a provision of uploading such standard documents has been provided to the bidders. Bidders can use "My Space" or ''Other Important Documents'' area available to them to upload such documents. These documents may be directly submitted from the "My Space" area while submitting a bid, and need not be uploaded again and again. This will lead to a reduction in the time required for bid submission process.

20. Submission of Bids for uploading on CPP Portal

20.1 Bidder should log into the site well in advance for bid submission so that they can upload the bid in time i.e. on or before the bid submission time. Bidder will be responsible for any delay due to other issues.

20.2 The bidder has to digitally sign and upload the required bid documents one by one as indicated in the Tender Enquiry document.

20.3 Bidder has to select the payment option as "offline" to pay the Bid Security/ EMD as applicable and enter details of the instrument.

20.4 Bidder should prepare the Bid Security/EMD as per the instructions specified in the Tender Enquiry Document. The original should be posted/couriered/given in person to the concerned official, latest by the last date of bid submission or as specified in the Tender Enquiry Document. The details of the DD/any other accepted instrument, physically sent, should tally with the details available in the scanned copy and the data entered during bid submission time. Otherwise, the uploaded bid will be rejected.

20.5 Bidders are requested to note that they should necessarily submit their financial bids in the format provided and no other format is acceptable. If the price bid has been given as a standard BoQ format with the tender document, then the same is to be downloaded and to be filled by all the bidders. Bidders are required to download the BoQ file, open it and complete the white coloured (unprotected) cells with their respective financial quotes and other details (such as name of the bidder). No other cells should be changed. Once the details have been completed, the bidder should save it and submit it online, without changing the filename. If the BoQ file is found to be modified by the bidder, the bid will be rejected.

20.6 The server time (which is displayed on the bidders' dashboard) will be considered as the standard time for referencing the deadlines for submission of the bids by the bidders, opening of bids etc. The bidders should follow this time during bid submission.

20.7 All the documents being submitted by the bidders would be encrypted using PKI encryption techniques to ensure the secrecy of the data. The data entered cannot be viewed by unauthorized persons until the time of bid opening. The confidentiality of the bids is maintained using the secured Socket Layer 128 bit encryption technology. Data storage encryption of sensitive fields is done. Any bid document that is uploaded to the server is subjected to symmetric encryption using a system generated symmetric key. Further this key is subjected to asymmetric encryption using buyers/bid openers' public keys. Overall, the uploaded tender documents become readable only after the tender opening by the authorized bid openers.

20.8 The uploaded Tender/Bid shall become readable only after the tender opening by the authorized bid openers.

20.9 Upon the successful and timely submission of bids (i.e. after Clicking "Freeze Bid Submission" in the portal), the portal will give a successful bid submission message & a bid summary will be displayed with the bid no. and the date & time of submission of the bid with all other relevant details.

20.10 The bid summary has to be printed and kept as an acknowledgement of the submission of the bid. This acknowledgement may be used as an entry pass for any bid opening meetings.

20.11 Assistance to Bidders for uploading CPP Portal:

i) Any queries relating to the Tender Enquiry Document and the terms and conditions contained therein should be addressed to the Tender Inviting Authority for a tender or the relevant contact person indicated in the NIT.

ii) Any queries relating to the process of online bid submission or queries relating to CPP Portal in general may be directed to the 24x7 CPP Portal Helpdesk

E. BID OPENING

21. Opening of Bids

21.1 E- Bids will be opened after due time and date and the bidders may check the status etc. on CPP Portal.

21.2 No change/alteration on plea of clerical or typographical error in rates or other terms in the tender will be permitted under any circumstances.

21.3 Withdrawal of the complete tender can be allowed but, in such cases, the earnest money shall be forfeited in full.

21.4 Partial withdrawal (in respect of one or more items quoted) will not be allowed under any circumstances.

F. SCRUTINY AND EVALUATION OF BIDS

22. Basic Principle

22.1 Bids will be evaluated on the basis of the terms & conditions already incorporated in the Tender Enquiry Document, based on which bids have been received and the terms, conditions etc. mentioned by the bidders in their bids. No new condition will be brought in while scrutinizing and evaluating the bids.

23. Scrutiny of Bids

23.1 The Purchaser will examine the Bids to determine whether they are complete, whether any computational errors have been made, whether required Bid Securities have been furnished, whether the documents have been properly signed stamped and whether the Bids are generally in order.

23.2 The Purchaser's determination of a Bid's responsiveness is to be based on the contents of the Bid itself without recourse to extrinsic evidence.

23.3 The Bids will be scrutinized to determine whether they are complete and meet the essential and important requirements, conditions etc. as prescribed in the Tender Enquiry Document.

23.4 **PHARMACOPOEIAL SPECIFICATION**:
Pharmacopoeia' specifications i.e. IP/BP/USP should be clearly mentioned against each drug/constituent of the drug quoted as per the provisions of Drug and Cosmetics Act, 1945.

23.5 In the absence of submission of the following, a bid shall be declared non- responsive during the evaluation and will be ignored;

i) Tender Acceptance Form as per Section IX (signed & stamped) not uploaded.
ii) Bid validity is shorter than the required period.
iii) Required Bid Security (Amount, validity etc.)/exemption documents have not been uploaded as per stipulated provisions.
iv) Bidder has not agreed to give the required Performance Security of required amount in an acceptable form for due performance of the contract.
v) Bidder has not agreed to other essential condition(s) specially incorporated in the Tender document like terms of payment, liquidated damages clause, shelf-life clause, warranty clause, dispute resolution mechanism, and applicable law.
vi) Poor/unsatisfactory past performance.
vii) Bidders who stand de-registered/banned/blacklisted by any Central Govt. / State Govt. Ministries/AIIMS, Bilaspur HP.
viii) Bidder has not agreed to currency of Rate Contract period.
ix) Bidder has not agreed for the delivery terms and delivery period.
x) Non-submission of Certificate of Local Content as per Section-XXI
xi) Non-submission of GFR 144 (xi) compliance
xii) Tender validity is shorter than the required period
xiii) Required EMD or its exemption documents have not been provided
xiv) Bidder has not agreed to give the required performance security of required amount in an acceptable form.
xv) Poor/unsatisfactory past performance.
xvi) Bidder is not eligible as per average turnover requirement mentioned.
xvii) Bidder is not eligible as per tender conditions
xviii) Bidder has not quoted for the entire quantity as specified in the List of Requirements/ BOQ for the quoted.
xix) Non-submission of Average Turnover Certificate for specified Financial Year.
xx) Non-submission of audited financial statement (Profit & Loss Statement and Balance Sheet) verified by registered Chartered Accountant for last three preceding financial years (i.e. 2022-23, 2023-24 and 2024-25) in support of the annual turnover.
xxi) Other Document as mentioned in Tender Documents.

23.6 INSPECTIONOF FIRM'S PREMISES:
The Director or his nominee reserves the right for inspection of the pharmaceutical firms participating in the tenders, by officers appointed by the Director. They can carry out inspection for assessing the capacity/capability/eligibility of the firm to make supplies on the basis of rate- contract and to ensure that good manufacturing practices are being followed by the manufacturer. The decision of the Director shall be final in this regard.

24. Minor Infirmity/Irregularity/Non-Conformity

24.1 If during the evaluation, the purchaser finds any minor informality and/or irregularity and/or non-conformity in a bid, the purchaser will convey its observation on such 'minor' issues, which has not price

implication, to the bidders by registered/speed post/ e-mail/fax etc. asking the bidder to respond by a specified date. If the bidder does not reply by the specified date or gives evasive reply without clarifying the point at issue in clear terms, that bid will be liable to be ignored.

25. Qualification Criteria

25.1 Bids of the bidder, who have not uploaded required documents or do not meet the required Qualification Criteria prescribed in Section VIII, will be treated as non - responsive and will not be considered further.

26. Item-wise Evaluation

26.1 In case the Schedule of Requirements contains multiple items, the responsive bids will be evaluated and compared separately for each item except as mentioned under Clause 11(B) (ix) above for certain special drugs for which the lowest bidder will be determined by the method stated therein.

27. Comparison of Bids

26.1. The comparison of the responsive Bids shall be carried out on Free Delivery at consignee site basis.

28. Purchase Preference for Evaluation

28.1 The Purchaser reserves the right to give the price preference to small-scale sectors etc. and purchase preference to central public sector undertakings as per the instruction in vogue while evaluating, comparing and ranking the responsive Bids.

29. Bidder's capability to perform the Rate Contract

29.1 The purchaser, through the above process of bid scrutiny and bid evaluation will determine to its satisfaction whether the bidder, whose bid has been determined as the lowest evaluated responsive bid is eligible, qualified and capable in all respects to perform the Rate Contract satisfactorily.

29.2 The above-mentioned determination will, inter alia, take into account the bidder satisfying all the requirements of the purchaser as incorporated in the Tender Enquiry Document. Such determination will be based upon scrutiny and examination of all relevant data and details submitted by the bidder in its bid as well as such other allied information as deemed appropriate by the purchaser.

30. Contacting the Purchaser

30.1 From the time of submission of bid to the time of awarding the Rate Contract, if a bidder needs to contact the purchaser for any reason relating to NIT/Tender Enquiry Document and / or its bid, it should do so only through CPP portal.

30.2 In case a bidder attempts to influence the purchaser in the purchaser's decision on scrutiny, comparison & evaluation of bids and awarding the contract, the bid

of the bidder shall be liable for rejection in addition to appropriate administrative actions being taken against that bidder, as deemed fit by the purchaser.

G. AWARD OF RATE CONTRACT

31. Purchaser's Right to accept any bid and to reject any or all bids.

31.1 The purchaser reserves the right to accept in part or in full any bid or reject any or more bid(s) without assigning any reason or to cancel the Tender process and reject all bids at any time prior to award of Rate Contract, without incurring any liability, whatsoever to the affected bidder(s).

32. Award Criteria

32.1 Subject to the above, the Rate Contract will be awarded to the lowest evaluated responsive bidder decided by the purchaser. In cases where advance samples have been called in "Special Instructions to Bidders" in Section III,

32.2 The contract for supply of Drugs, Disinfectant Fluids etc. Items to Department/Store Section, AIIMS, Bilaspur (HP), shall be awarded to the lowest responsive bidder (basic rate + GST) for each item (i.e. L1 for each item) **except as mentioned under Clause 11(B) (ix)** above for certain special drugs for which the lowest bidder will be determined by the method stated therein.

32.3 The annual estimate is given only as an indication. The actual quantity procured may increase or decrease. No assurance is given that the quantity stated will actually be procured.

33. Purchase Orders to be placed during currency of Rate Contract

33.1 Purchase Orders will be placed from time to time by the Centers/Hospitals/Department/ Store Sections of AIIMS during the currency of Rate Contract, as per actual requirement, in which the exact quantities required on each occasion together with the date of delivery shall be specified in the purchase order.

34. Notification of Award

34.1 Before expiry of the bid validity period, the purchaser will notify the successful bidder (s) in writing, by

registered / speed post or by fax/ email (to be confirmed by registered / speed post) that its bid for Goods, which have been selected by the purchaser, has been accepted, also briefly indicating there in the essential details like description, specification and quantity of the goods and corresponding prices accepted. The successful bidder must furnish to the purchaser the required Performance Security within Twenty-One days from the date of dispatch of this notification, failing which the Bid Security will be forfeited and the award will be cancelled. Relevant details about the Performance Security have been provided in clause 3 of GCC under Section IV.

34.2 The Notification of Award shall constitute the conclusion of the Rate Contract.

35. Issue of Rate Contract

35.1 Promptly after notification of award, the Purchaser will mail the Rate Contract form (as per Section XIII or Draft Detailed Rate Contract, format to be provided post-award) duly completed and signed, in duplicate, to the successful bidder by registered / speed post.

35.2 Within twenty-one days from the date of the Rate Contract, the successful bidder shall return the original copy of the Rate Contract, duly signed and dated, to the Purchaser/ by registered / speed post/courier.

36. Non-receipt of Performance Security by the Purchaser

36.1 Failure of the successful bidder in providing Performance Security and / or returning Rate Contract copy duly signed in terms of GIB clauses above shall make the bidder liable for forfeiture of its Bid Security and, also, for further actions by the Purchaser it as per the clause 12-Termination of default of GCC under Section IV.

37. Return of Bid Security/EMD

37.1 The Bid Security/EMD of the successful bidder and the unsuccessful bidder will be returned to them without any interest.

38. Publication of Bid Result

38.1 The name and address of the successful bidder(s) receiving the Rate Contract(s) will be mentioned in the CPP Portal.

H. CORRUPT OR FRADULENT PRACTICES

39. Corrupt or Fraudulent Practices

39.1 It is required by all concerned namely the Bidder /Suppliers/ Purchaser/Consignee/End User etc. to observe the highest standard of ethics during the procurement and execution of such Rate Contract/Purchase Orders. In pursuance of this policy, the Purchaser: -

a) defines, for the purposes of this provision, the terms set forth below as follows:

   i) "Corrupt practice" means the offering, giving, receiving or soliciting of anything of value to influence the action of a public official in the procurement process or in Rate Contract/Purchase Orders execution; and

   ii) "Fraudulent practice" means a misrepresentation of facts in order to influence a procurement process or the execution of a Rate Contract/Purchase Orders to the detriment of the Purchaser, and includes collusive practice among bidders (prior to or after Bid submission) designed to establish Bid prices at artificial non-competitive levels and to deprive the Purchaser of the benefits of free and open competition;

b) Will reject a proposal for award if it determines that the Bidder recommended for award has engaged in corrupt or fraudulent practices in competing for the Rate Contract/Purchase Orders in question;

c) Will declare a firm ineligible, either indefinitely or for a stated period of time, to be awarded a Rate Contract/Purchase Orders by the purchaser if it at any time determines that the firm has engaged in corrupt or fraudulent practices in competing for, or in executing the Rate Contract/Purchase Orders.

SECTION – III
SPECIAL INSTRUCTIONS TO BIDDERS (SIB)

The following Special Instructions to Bidders will apply for this purchase. These special instructions will modify/substitute/supplement the corresponding General Instructions to Bidders (GIB) incorporated in Section II. The corresponding GIB clause numbers have also been indicated in the text below:

In case of any conflict between the provision in the GIB and that in the SIB, the provision contained in the SIB shall prevail.

Sl. No.	GIB Clause No.	Topic	SIB Provision
1.	1 - 40		No Change

1. If asked, the bidder will submit the samples for each item in original packing, duly labeled (Printed) and sealed having date of manufacturing, date of Expiry, manufactured by with batch No. within 4 days. If the bidder fails to submit the sample within given time, the bid will be summarily rejected and no correspondence will be entertained in this regard.
2. Samples for Intravenous Fluids and Disinfectant Items along with the carton boxes are to be submitted to the Store Section, Block D, AIIMS, Bilaspur (HP) -174001 on weekdays (Monday to Friday) between 2 P.M and 4 P.M. The messenger may request for a receipt from the person accepting the samples.
3. Samples for disinfectant items are to be clearly labeled outside indicating the name and address of the company. A list of all the items for which samples have been sent should be enclosed in the sample package. Companies not submitting samples along with the carton boxes will not be considered and no reminder will be sent.

SECTION - IV

GENERAL CONDITIONS OF CONTRACT (GCC)

1. Application

1.1 The General Conditions of Contract incorporated in this section shall be applicable for this purchase to the extent the same are not superseded by the Special Conditions of Contract prescribed under Section V, Schedule of Requirements under Section VI and Technical Specification under Section VII/Annexure-A of this document.

2. Patent Rights

2.1 The supplier shall, at all times, indemnify and keep indemnified the purchaser, free of cost, against all claims which may arise in respect of goods to be provided by the supplier under the Rate Contract/Purchase Orders for infringement of any intellectual property rights or any other right protected by patent, registration of designs or trademarks. In the event of any such claim in respect of alleged breach of patent, registered designs, trademarks etc. being made against the purchaser, the purchaser shall notify the supplier of the same and the supplier shall, at his own expenses take care of the same for settlement without any liability to the purchaser.

3. Performance Security

3.1 Within Twenty-One (21) days from date of the issue of Notification of Award by the Purchaser, the supplier shall furnish Performance Security to the Purchaser for an amount equal to Five percent (5 %) of the 2 years Estimated Quantity of the items for which Rate Contract is being awarded, valid up to currency of Rate Contract plus Warranty Period (if applicable) ninety (90) days. The Performance Security would be minimum Rs. 5,000.00 (Rupees Five thousand only).

3.2 The quantity of the consumables mentioned in the tender is adhoc/approximate/not final and can be increased or decreased depending upon the actual requirement, if requirement of items increased in future, additional amount of Performance Bank Guarantee is to be submitted by Second Party @ 5 % of the value of additional amount of supply order.

3.3 The Performance Security shall be denominated in Indian Rupees in any of the following forms:

i) Account Payee Demand Draft

ii) Fixed Deposit Receipt drawn from any Scheduled bank in India

iii) Bank Guarantee issued by a Scheduled bank in India, in the prescribed form as provided in Section XII of this document

3.4 In the event of any failure /default of the supplier with or without any quantifiable loss to the government, the amount of the Performance Security is liable to be forfeited equivalent to the amount of Supply Order. The needful will be done to cover any failure/default of the supplier with or without any quantifiable loss to the Government.

3.5 In the event of any extension of currency of Rate Contract, the supplier shall, within fifteen (15) days of issue of the amendment, furnish the corresponding amendment to the Performance Security (as necessary), rendering the same valid in all respects in terms of the Rate Contract, as amended.

3.6 Subject to above, the Purchaser will release the Performance Security without any interest to the supplier on completion of the supplier's all contractual obligations including the warranty obligations (if applicable).

4. Technical Specifications

4.1 The Goods to be provided by the supplier under this Rate Contract shall conform to the 'Technical Specification' under Sections VII of this document.

5. Inspection, Testing and Quality Control

5.1 The purchaser has contractual right to inspect, test and, if necessary, reject the goods to confirm their conformity to the Rate Contract specifications and other quality control details incorporated in the Rate Contract.

5.2 If during such inspections and tests the contracted goods fail to conform to the required specifications and standards, the purchaser may reject them and the supplier shall either replace the rejected goods or make all alterations necessary to meet the specifications and standards, as required, free of cost to the purchaser and re-submit the same to the purchaser for conducting the inspections and tests again. No payment shall be made for rejected material and the bidder shall be responsible for removing/withdrawn the same at their own cost. If the bidder fails to replace the goods within the stipulated time, the Institute reserves the right to destroy the said items. The cost incurred towards destruction shall be recovered from the bidder. If items are not replaced within 15 days, risk purchase will be done from alternative sources and extra cost will be charged from the Supplier.

5.3 Regular and random testing of drugs will be under taken by AIIMS Bilaspur from any NABL accredited /Govt. approved laboratories at the time of supply and at any time during the shelf life or whenever any defect is noticed. The Executive Director AIIMS Bilaspur HP shall be at liberty to undertake regular and random testing of the drugs supplied by the pharmaceutical firm/ bidder at regular interval to

maintain and ensure the quality of drugs.

5.4 The report of the NABL accredited/Govt. approved laboratory shall be accepted by the pharmaceutical firm. In case the same is disputed by the pharmaceutical firm, the report of the approved Central Drug Testing Laboratory as approved by CDSCO (Appellate Authority) only will be accepted as final. However, the same should be submitted within three months, from the date of communication of the disputed test report to the pharmaceutical firm. For this, the pharmaceutical firm should approach the concerned Drug Control Authorities for getting the drugs tested, as per procedure.

5.5 If any drug sample fails the test or is found to be of substandard quality, action as below will be initiated:

(a) If any drugs supplied against this Rate Contract are found to be not of standard quality as per specifications on analysis and/or on inspection by Competent Authority, the pharmaceutical firm will be liable to replace the entire quantity within 15 days otherwise extra cost under risk purchase will be charged from the company.

(b) In case any items supplied are found to be substandard or inferior, the bidder shall be responsible for removing/withdrawn the same at their own cost. If the bidder fails to replace the goods within the stipulated time, the Institute reserves the right to destroy the said items. The cost incurred towards destruction, along with the value of the destroyed items (if already paid), shall be recovered from the bidder. The Institute shall not be liable to make any payment for substandard or inferior items.

(c) If the product is found to be not of standard quality, the cost of testing done by the Institute will be recovered from the supplier.

(d) If the firm fails to replace substandard drugs or if inferior quality supplies are reported on three occasions, the firm may be debarred (for three years for all items under the rate contract/subsequent tenders) and the EMD/Performance Security shall be forfeited.

(e) A copy of the test report will be sent to the DCGI for necessary action at their end.

5.6 Goods accepted by the purchaser/consignee in inspection in terms of the Rate Contract/Purchase Orders shall in no way dilute purchaser's/consignee's right to reject the same later, if found deficient in terms of the warranty clause, if applicable.

Quality Control

I. The stores offered should comply with the provisions of the Drugs and Cosmetics Act, 1940 and the Rules made there under as and Drug Price Control order.

II. While quoting against items with ISI Mark, it should be ensured that ISI code number is indicated on quotation and at the time of making the supplies, the pharmaceutical firm should ensure that the items supplied has ISI Mark as well as Code Number, as is the statutory requirement of the Bureau of Indian Standards. The attested copy of the valid ISI Marking license issued by Bureau of Indian Standards should be enclosed along with the quotation.

6. Terms of Delivery

6.1 Goods shall be delivered by the supplier on "Free Delivery at Site" basis and delivered as per Delivery Period specified in the Purchase Order placed against Rate Contract. Please note that the time shall be the essence of the contract.

6.2 The goods are to be supplied by F.O.R. destination and all the transit loss/expenses whatsoever, will be borne by the supplier/firm.

7. Warranty

7.1 The supplier warrants comprehensively that the goods supplied under the Rate Contract is new, unused and incorporate all recent improvements in design and materials unless prescribed otherwise by the purchaser in the Rate Contract. The supplier further warrants that the goods supplied under the Rate Contract/Purchase Orders shall have no defect arising from design, materials or workmanship or from any act or omission of the supplier that may develop under normal use of the supplied goods under the conditions prevailing in India.

7.2 The warranty period (if applicable as stated in Schedule of Requirement in Section-VI or Technical Specification in Section- VII) shall include all spares, labor and preventive maintenance from the date of completion of the satisfactory installation and acceptance till warranty period.

8. Prices

8.1 Prices quoted by the bidder shall remain firm and fixed during the currency of the Rate Contract and not subject to variation on any account. Purchase Orders will be placed by Centers/Hospital/Departments/Store Sections against this Rate Contract till the currency period of Rate Contract.

8.2 Statuary variation in GST will be applicable during currency of the contract, during the original Delivery Period of Purchase Order after

submitting supporting documents (Government notifications) issued by concern department.

8.3 **Rate Revision:** Successful bidders shall not be entitled to any rate- revision of price for any reason except Govt. levies which become applicable after finalization of rate contract along with adequate documentary proof thereof.

9. Payment Terms

9.1 100% payment would be made on receipt of goods in good condition and acceptance, upon the submission of the following documents:

i) Original copies of supplier's invoice showing Rate Contract/Purchase Orders number, goods description, quantity, packing list, unit price and total amount;

ii) "Consignee Receipt Certificate" as per Section XIV of Tender document in original

iii) "Final Consignee Acceptance Certificate" as per Section XV of goods to be issued by the End User subject to recoveries, if any, either on account of non-rectification of defects/deficiencies not attended by the Supplier or otherwise.

9.2 Any dues or payments that have arisen to the Institution from the supplier for which no specific time-limit has been laid down in the terms & conditions, shall be payable by the supplier within such time limit as may be prescribed in the various letters/orders addressed to the contractors. On failure to do so the supplier shall be liable to be debarred for not paying dues or payment etc. to the hospital for a period as decided by the Director or his nominee.

9.3 Conditions of advance payments or payment against delivery shall not be accepted.

10. Delivery

10.1 The supplier shall deliver the goods under the Rate Contract within the time schedule specified by the Purchaser Order as per in the Schedule of Requirements and as incorporated in the Rate Contract. The time for and the date of delivery of the goods stipulated in the Purchase Order shall be deemed to be of the essence of the contract and the delivery must be completed no later than the date (s) as specified in the Purchase Order.

10.2 Supply orders placed against the contract, on or just before last date of the tenure of contract will have to be accepted /honored by the supplier.

10.3 **No guarantee can be given as to the minimum quantity which will be demanded against this contract, but the supplier will supply such quantity as may be ordered by the Stores Officer during the tenure of the contract.**

10.4 Subject to the provision under Force Majeure clause of GCC, any unexcused delay by the supplier in maintaining its contractual obligations towards delivery of goods shall render the supplier liable to any or all of the following sanctions:

i) Imposition of liquidated damages,

ii) Forfeiture of its Performance Security and

iii) Termination of the Rate Contract/Purchase Orders for default.

10.5 If at any time during the currency of the Rate Contract, the supplier encounters conditions hindering timely delivery of the goods, the supplier shall promptly inform the Purchaser in writing but not later than 10 days from the date of issue of the Purchase Order about the same and its likely duration and make a request to the Purchaser for extension of the delivery schedule accordingly. In case no communication is received within 10 days from the date of issue of Purchase Order, it will be presumed that supplier has accepted the Purchase Order in all regards. On receiving the supplier's communication, the Purchaser shall examine the situation as soon as possible and, at its discretion, may agree to extend the delivery schedule, with or without liquidated damages for completion of supplier's contractual obligations by issuing an amendment to the Purchase Order.

10.6 When the period of delivery is extended due to unexcused delay by the supplier, the amendment letter extending the delivery period shall, inter alia contain the following conditions:

i) The Purchaser shall recover from the supplier, under the provisions of the Force Majeure clause of the General Conditions of Contract, Liquidated Damages on the goods, which the Supplier has failed to deliver within the delivery period stipulated in the Purchase Order.

ii) That no increase in price on account of any ground, whatsoever, including any stipulation in the Rate Contract for increase in price on any other ground and, also including statutory increase in or fresh imposition of GST levied in respect of the goods specified in the Purchase Order, which takes place after the date of delivery stipulated in the Purchase Order shall be admissible on such of the said goods as are delivered and performed after the date of the delivery stipulated in the Purchase Order.

iii) But nevertheless, the Purchaser shall be entitled to the benefit of any decrease in price on account of reduction in GST which takes place after the expiry of the date of delivery stipulated in the Purchase Order.

10.7 The supplier shall not dispatch the goods after expiry of the delivery period. The supplier is required to apply to the Purchaser for extension of delivery period and obtain the same before dispatch. In case the supplier dispatches the goods without obtaining an extension, it would be doing so at its own risk and no claim for payment for such supply and / or any other expense related to such supply shall lie against the purchaser.

10.8 Passing of Property

(i) The property in the goods shall not pass to the purchaser unless and until the goods have been delivered to the consignee in accordance with the contract.

(ii) Where there is a contract for sale of specific goods and the supplier is bound to do something to the goods for the purpose of putting them into a deliverable state the property does not pass until such thing is done.

(iii) Unless otherwise agreed, the goods remain at the supplier's risk until the property therein is transferred to the purchaser.

10.9 The delivery period should not exceed 45 (Forty Five) days for all supplies but in emergency the delivery period may be reduced up to 15 days and firm is bound to supply the items within DOD (Date of delivery) period. Bidders are hereby directed to quote the rates of only those drugs/medicines for which they can ensure supply within 45 days of issue of supply-order along with Test Report either on Form 39 from Govt. approved analytical testing laboratory or from in house Test Lab (approved by NABL (National Accreditation Board for Testing and Calibration Laboratories or GLP (Good Lab Practice) accredited Lab. without which the supply will not be accepted. It will be the responsibility of the vendor to provide the certificate of NABL/GLP accredited of the laboratory from which the test report is given. In case the total value of supply order of drugs is less than Rs.-10,000/- in house Lab Test Report will be accepted. However, AIIMS reserves the right to get the supplies tested again from a Govt. /NABL accredited laboratory. In case of failure to either supply the goods within DOD (Date of delivery) period or if goods are not accompanied with lab. test report, they may be debarred, after three defaults, from participating in the next tender for a period of three years and their EMD/ Bid Security/Performance Security Money may be forfeited and risk purchase clause will be invoked. However, in case of imported drugs, In house Test Report of the manufacturing Company will be accepted.

10.10 Supply time: Timing 2.00 P.M to 4.00 P.M (from Monday to Friday) &
11.00 A.M to 12.00 Noon (on Saturday).

10.11 Before making the supply, approved rate contract holder should ensure that all labels of cartons, ampoules, vials, bottles, jars, tubes etc. should be embossed, imprinted, stamped with letters, other requirements like "AIIMS SUPPLY NOT FOR SALE" stamp with permanent ink on each item/strip up to primary level. The supply Challan should be accompanied by test report from NABL accredited lab/Govt. Approved Lab. While delivering the supplies, the firm will ensure that quantities are as per challan, quality of material is as per Rate contract specifications etc. All the items which are stamped with "AIIMS SUPPLY NOT FOR SALE" mark, including rejected stores, cannot be sold to the public by the bidder.

10.12 The supplier shall arrange to effect free replacement of any quantity which may deteriorate in potency, strength approaching expiry or expired etc. before the date of expiry marked on the labels.

10.13 If the supplied item is not utilized before expiry date the supplier should undertake to replace with fresh stock of items as and when required.

10.14 MARKING: Each packing shall be marked with nomenclature of the drug and shall be labeled in accordance with the requirement of the Drugs and Cosmetics Act, 1940 and the rules made there under.

10.15 First supply of the item should accompany with manufacturing license/import license mentioning the name of the item supplied.

10.16 The order will be awarded to the successful bidder for the supply of drugs for the specified period and the bidder shall supply on receipt of supply orders from the Faculty Incharge(P) or another designated official. A scanned copy of supply order will be sent to the e mail of the manufacturer and supplier The bidders are requested to give their & distributor correct postal address, Contact No. and valid e mail-id. Further they are requested to check the email regularly.

10.17 If part supply is ordered the supplier must execute the mentioned part supply at once. Split part supply is not accepted.

10.18 **PACKING:**

1) Tendering firms must quote for the packing specified against each item in the schedule annexed to the rate-enquiry, as any other packing may not be accepted.
2) Where no pack is specified, bidders may quote for standard pack which is available in the market.
3) Loose supplies / damaged packing / tampered or damaged labeled supplies shall not be accepted under any circumstances.
4) Rates should be quoted for strip packing only except where mentioned.
5) Supplies to be made in the box of Standard packing. However tablets/capsules in loose pack (tin/bottle) shall not be accepted.
6) Liquid orals to be supplied only in glass / plastic bottles conforming to IP/BP/USP/Drugs & Cosmetics Act, 1940.
7) Large volume parenteral to be quoted and supplied only in glass/plastic bottles / poly packs conforming to I.P. /BP/USP/ Drug & Cosmetic Act, 1940.
8) It should be ensured that only first use packaging material of uniform size including bottles and vials, is used for making supplies on the basis of rate-contract.
9) All primary packing containers should be strictly conforming to the specification included in the relevant pharmacopoeia.
10) Packing should be able to prevent damage or deterioration during transit.
11) All containers i.e. bottles, cartons, tubes etc. are required to be secure with pilferage-proof seals to ensure genuineness of the products packed and the correctness of the contents. MRP should not be written/embossed/should be defaced with indelible ink on any labels otherwise it will disqualified for that supply.

10.19 The supply offered should comply with the provisions of the Drugs and Cosmetics Act, 1940 and the

Rules made there under as amended up to date and Drug Price Control order.

10.20 In case of I.V. fluids unless otherwise indicated should be manufactured using Form Fill Seal (FFS) technology. The bottles should be well packed in sturdy boxes to withstand stacking and transport. If packing is not satisfactory and the cardboard boxes are flimsy, the supply will be rejected.

10.21 Proper maintenance of the cold chain during transit is essential for drugs that require storage in cold room. Packages received without proper cool packs and whose temperature is not within stipulated range will be rejected.

10.22 In case of supply of IV-fluids should be in truck having fixed metallic roof to avoid damage during transit.

10.23 As far as possible supply should be made from single or minimum number of batches. Separate batches should be packed separately.

10.24 Packing slip containing full details about the contents like Quantity, Batch number, Manufacturing Date, and Expiry date should be pasted on every parcel.

10.25 The company should ensure that the size of the letter font in the strips of the tablets, capsules and in the vials and ampoules should be clearly visible and readable to enable the Pharmacists/Doctors/Patients to identify the drugs without difficulty. Failing which the drugs will be rejected.

10.26 The supply has to accompany with MATERIAL SAFETY DATA SHEET (MSDS) containing information on physical and chemical properties of the material, potential hazards and exposure control measures, how to work safely with these materials, information on usages, storage, handling and emergency procedures relate to the hazards of the materials, If applicable.

10.27 The strip and the package should clearly state the name of the manufacturer who has participated in the tender. Supply in loose packing is not acceptable.

10.28 Special drugs wherever strip packing is not available will be accepted, if provided in plastic/glass bottles.

11. Liquidated Damages

11.1 PENALTY FOR NON-SUPPLY/LATE SUPPLY

i) Subject to Force Majeure clause of the General Conditions of Contract, if the supplier fails to deliver any or all of the goods within the time frame(s) incorporated in the Purchase Order, the Purchaser shall, without prejudice to other rights and remedies available to the Purchaser under the Rate Contract, deduct from the Purchase Order, as liquidated damages, a sum equivalent to 0.5% per week of delay or part thereof on delayed supply of goods, until actual delivery or performance subject to a maximum of 10% of the Purchase Order price. Once the maximum is reached Purchaser may consider termination of the Purchase Order as per GCC.

ii) If supplier fails to execute the supply order three times during the period of rate contract, it shall be debarred for the next three years with effect from the last failure and forfeiting of Performance Security for that drug

11.2 In case of default institute will have the right to procure the ordered item from open market /another party at their own risk and expenses under risk purchase clause. Non-execution of supply order - For the reasons of failure to supply partially or completely within DOD period, if the Purchaser has to buy the items from the RC 2 (L- 2), RC 3 (L- 3) or approved local vendor firm, the rate difference in cost will be recovered from RC holder i.e L1 /Billing Agency as appointed by the Rate Contract Holder. In case if L-2 firm is not available in panel, Procurement cell has to buy the item from locally approved vender and the difference of cost will be recovered from RC holder/Billing agency payments. The difference of amount will be deducted from the forthcoming bills of the supplier pertaining to any product. Repeated failure (Three times) to supply in part or in full may amount to termination of rate contract for the product (s) and forfeiture of Performance Security, **which may also lead to debarring of the firm for subsequent tenders (up to 3 years).** Reasons of failure to supply the material will be communicated by the firm to the Institute timely.

11.3 The approved rate contract holders should supply all their ordered items within DOD period as per supply order terms and these terms should be strictly adhered to. **In case they fail to supply the item within DOD period, the reminder letter would not be issued in any circumstances and penalty will be imposed.** The item would be arranged either through local purchase or from open

market under Risk Purchase Clause without any information in this regard. The difference amount shall be recovered from the pending dues of the firm.

11.4 It is hereby also informed that in case any administrative action (imposing of liquidated damages, warning letter, risk purchase, short supply etc.) is taken by the AIIMS during the rate contract period against any approved vendor, it would be reflected during finalization of the next rate contract as "Past performance" of that firm.

11.5 The Director or his nominee reserves the right to invite at his sole discretion, separate quotations to effect purchase outside this contract in the event of any urgent demand arising in hospital, where no stock is held or otherwise.

12. Termination for Default

12.1 The Purchaser without prejudice to any other contractual rights and remedies available to it the Purchaser, may, by written notice of default sent to the supplier, terminate the Rate Contract and/or Purchase Order in whole or in part, if the supplier fails to deliver any or all of the goods or fails to perform any other contractual obligation(s) within the time period specified in the Purchase Order, or within any extension thereof granted by the Purchaser.

12.2 The Performance Security in such cases will be forfeited equivalent to the amount of Purchase Order.

12.3 Unless otherwise instructed by the Purchaser, the supplier shall continue to perform the Rate Contract/Purchase Orders to the extent not terminated.

13. Termination for Insolvency

13.1 If the supplier becomes bankrupt or otherwise insolvent, the purchaser reserves the right to terminate the Rate Contract/Purchase Orders at any time, by serving written notice to the supplier without any compensation, whatsoever, to the supplier, subject to further condition that such termination will not prejudice or affect the rights and remedies which have accrued and / or will accrue thereafter to the Purchaser.

14. Force Majeure

14.1 Notwithstanding the provisions contained in above clauses of GCC, the supplier shall not be liable for imposition of any such sanction so long the delay and/or failure of the supplier in fulfilling its obligations under the Rate Contract/Purchase Orders is the result of an event of Force Majeure.

14.2 For purposes of this clause, Force Majeure means an event beyond the control of the supplier and not involving the supplier's fault or negligence and which is not foreseeable and not brought about at the instance of the party claiming to be affected by such event and which has caused the non – performance or delay in performance. Such events may include, but are not restricted to, wars or revolutions, hostility, acts of public enemy, civil commotion, sabotage, fires, floods, explosions, epidemics, quarantine restrictions, strikes excluding by its employees, lockouts excluding by its management and freight embargoes.

14.3 If a Force Majeure situation arises, the supplier shall promptly notify the Purchaser in writing of such conditions and the cause thereof within twenty one days of occurrence of such event. Unless otherwise directed by the Purchaser in writing, the supplier shall continue to perform its obligations under the Rate Contract/Purchase Orders as far as reasonably practical, and shall seek all reasonable alternative means for performance not prevented by the Force Majeure event.

14.4 If the performance in whole or in part or any obligation under this Rate Contract/Purchase Orders is prevented or delayed by any reason of Force Majeure for a period exceeding sixty days, either party may at its option terminate the Rate Contract/Purchase Orders without any financial repercussion on either side.

14.5 In case due to a Force Majeure event the Purchaser is unable to fulfill its contractual commitment and responsibility, the Purchaser will notify the supplier accordingly and subsequent actions taken on similar lines described in above sub-paragraphs.

15. Termination for Convenience

15.1 The Purchaser reserves the right to terminate the Rate Contract, in whole or in part for its Purchaser's convenience, by serving written notice on the supplier of 30 days at any time during the currency of the Rate Contract.

15.2 The Supplier reserves the right to terminate the Rate Contract, in whole or in part for its Purchaser's convenience, by serving written notice by the supplier of 90 days at any time during the currency of the Rate Contract.

16. Resolution of Disputes

16.1 If dispute or difference of any kind shall arise between the Purchaser/Consignee and the supplier in connection with or relating to the Rate Contract/Purchase Orders, the parties shall make every effort to resolve the same amicably by mutual consultations.

16.2 If the parties fail to resolve their dispute or difference by such mutual consultation within twenty-one days of its occurrence, then, unless otherwise provided in the SCC, either the Purchaser/Consignee or the supplier may give notice to the other party of its intention to commence arbitration, as hereinafter provided the applicable arbitration procedure will be as per the Arbitration and Conciliation Act, 1996 of India.

16.3 In the case of a dispute or difference arising between the Purchaser and a domestic Supplier relating to any matter arising out of or connected with the Rate Contract/Purchase Orders, such dispute or difference shall be referred to the sole arbitration to be appointed by the Director, AIIMS. The award of the arbitrator shall be final and binding on the parties to the Rate Contract/Purchase Orders subject to the provision that the Arbitrator shall give reasoned award in case the value of claim in reference exceeds Rupees One lakhs (Rs. 1,00,000/-)

16.4 Venue of Arbitration: The venue of arbitration shall be the place from where the Rate Contract/Purchase Orders has been issued, i.e., Bilaspur, H.P.

16.5 Jurisdiction of the court will be from the place where the Tender Document has been issued, i.e., Bilaspur HP, India.

16.6 Applicable Law: The Rate Contract/Purchase Orders shall be governed by and interpreted in accordance with the laws of India for the time being in force.

17 Withholding and Lien in respect of sums claimed

17.1 Whenever any claim for payment arises under the Rate Contract/Purchase Orders against the supplier the purchaser shall be entitled to withhold and also have a lien to retain such sum from the security deposit or sum of money arising out of under any other Rate Contract/Purchase Orders made by the supplier with the purchaser, pending finalization or adjudication of any such claim.

17.2 It is an agreed term of the Rate Contract/Purchase Orders that the sum of money so withheld or retained under the lien referred to above, by the purchaser, will be kept withheld or retained till the claim arising about of or under the Rate Contract/Purchase Orders is determined by the Arbitrator or by the competent court as the case may be and the supplier will have no claim for interest or damages whatsoever on any account in respect of such withholding or retention.

17 BLACKLISTING

17.1 If the bidder fails to supply two or more times within the stipulated period of 45 days (55 days for narcotic drugs) during the tender period, the performance security of the bidder is liable to be forfeited to the institution, in addition to the recovery of penalty involved for the above purchase.

17.2 Further, the bidder will also be liable to be blacklisted for 3 years to trade with this institute. Details of bidders blacklisted by the institute will be put up in the institute website. The same will be informed to similar government procurement agencies.

17.3 Any violation of tender norms may lead to blacklisting of the bidder by the Institute initially for one year and followed by 3 years.

SECTION – V
SPECIAL CONDITIONS OF CONTRACT (SCC)

The following Special Conditions of Contract (SCC) will apply for this purchase. The corresponding clauses of General Conditions of Contract (GCC) relating to the SCC stipulations have also been incorporated below.

These Special Conditions will modify/substitute/supplement the corresponding (GCC) clauses.

Whenever there is any conflict between the provision in the GCC and that in the SCC, the provision contained in the SCC shall prevail.

The warranty conditions, Shelf life, if applicable, will be as mentioned in the Schedule of Requirement as per section VI of the Tender Enquiry Document.

1. **The quantity shown in the tender can be <u>increased or decreased</u> to any extent depending upon the actual requirement.**

SECTION – VI SCHEDULE OF REQUIREMENTS

As per "Annexure A"- List of Drugs/Molecules

1. Delivery Period:

1.1 The Delivery Period is maximum 45 days from date of issue of Purchase Order against the Rate Contract. In case of exigency, a shorter Delivery Period can be given and if, it is not acceptable to Supplier, it may be intimated to the Purchase Officer within seven days from the date of issue of the Purchase Order, otherwise it will be assumed that the Purchase Order has been accepted. The date of delivery will be the date by when it is to be delivered at consignee site. If the Supply is unable to supply the items purchase order will be awarded to next lowest bidder willing to supply or from the open market, at the risk and cost to the bidder.

1.2 The purchaser will not pay separately for transit insurance and the contractor will be responsible for delivery of items covered by the supply- order in good condition at the specified destination and for this purpose, freight, insurance, octroi etc., if any will have to be borne by the supplier. The consignee will, as soon as possible, but not later than 07 days of the date of arrival of stores at destination, notify the supplier/ bidder, of any loss or damage to the stores that may have occurred in the transit.

2. Shelf-Life:

a) For Drugs having shelf life of Two years or less: As on the date of delivery, Drugs should not be older than one fourth (1/4) of its shelf life from the date of manufacture.

b) For Drugs having shelf life more than Two years: As on the date of delivery, Drugs should not be older than one sixth (1/6) of its shelf life from the date of manufacture.

c) For all those drugs, which are required to be stored under controlled temperature / cold chain, have to be supplied under controlled temperature/cold chain.

d) If the supplied item is not utilized before expiry date the supplier should undertake to replace with fresh stock of items as and when required.

e) The supplier shall arrange to effect free replacement of any quantity which may deteriorate in potency, strength approaching expiry or expired etc. before the date of expiry marked on the labels.

However, the consignee may relax these criteria in case of exigencies with reasons duly recorded and shall be responsible for use of those stores within its given shelf life, with a suitable undertaking from the supplier, the terms of which shall be decided by the consignee as per the requirement of the stores and usage pattern. The Consignee should ensure that there should not be any loss to the Corporation.

3. The supply offered should comply with the provisions of the Drugs and Cosmetics Act, 1940 and the Rules made there under as amended up to date and Drug Price Control order.

While making quotations against re-packing and chemical items, it must be ensured that ISI code number is indicated on quotation and at the time of making the supplies, the firm should ensure that the item supplied has ISI mark as well as code number, as is the statutory requirement of the Bureau of Indian Standards. The attested copy of the valid ISI marking license issued by Bureau of Indian Standards should be enclosed along with quotation.

For delayed delivery, liquidated damages will get applied as per GCC.

SECTION – VII
SPECIFICATION
As per "Annexure A"- List of Drugs/Molecules

Section – VIII Qualification Criteria

1. The tenders are to be submitted by the **manufacturers*/sole importer** only. Tenders quoted by suppliers on behalf of manufacturers will not be entertained even if they are authorized by the manufacturers. However, manufacturers can give authority letter to the supplier / distributor / stockiest for the purpose of making supplies, raising bills, collecting payment etc. after selection in the tender/before submission of the tender. In such cases, the manufacturer has to accept responsibility for any lapse on the part of the distributor/supplier and an undertaking to this effect from the manufacturer will have to be submitted. Failure to submit such an undertaking will lead to rejection of authorization and manufacturer will have to supply drugs directly. This authorization should be valid for the entire duration of the contract. No change in the authorized supplier/distributor will be allowed during the rate contract period. An extraordinary situation it may be permitted after the approval from the competent authority. Sub authorization further to any other agent for delivery of the goods or for raising bills/collecting payment etc. will not be accepted.

*__Products Manufactured by OEM through third party/loan license will be considered. But only OEM (marketer) will participate in the tender.__

2. Scanned copy of **Manufacturing & Market standing/ experience certificate** of minimum **"Three Years"** of the molecule quoted by them duly certified by Central/ State Drug Controller in the Performa Section- XVIII. The certificate should have been issued recently i.e. not more than one year old from the date of the opening of the tender.
3. WHO GMP/GMP Certificate Scanned Copy of Valid WHO-GMP certificate/ Valid Schedule 'M' certificate issued by Centre/ State Drug Controller and should not have been issued more than five years old.
4. In case of imported drugs (i.e. not manufactured in India), **COPP (Certificate of Pharmaceutical Products)/ import license** and copy of the import registration of that particular molecule quoted in the tender indicating the list of products should be submitted as per WHO norms and '3-years' Marketing experience certificate issued by the Drug Controller.
5. Scanned copy of **valid manufacturing license** issued by Centre/State Drug Controller indicating the list of products should be submitted**.** Public Sector Undertakings with at least "3-years" market standing having manufacturing license issued by Centre/ State Drug Controller.
6. If applicable, scanned copy of **valid narcotic license** issued by Central/State Excise Commissioner should be submitted by the bidder.
7. In case of newly introduced drugs/molecules, the manufacturer can be eligible provided the firm submits a certificate from the DCGI, in this regard. In such cases, the firm has to submit an MMC of the molecule concerned from the date of issue of Certificate by the DCGI of the new drug to that firm. In such case MMC of 03 years is not cleared/ completed, it will be relaxed accordingly. Also, in case of imported Drug/Formulations Form-45 (Permission Certificate) issued by DCGI will also be accepted.

   In case of the newly off-patent molecules wherein MMC of 03 years is not cleared/ completed, it will be relaxed in accordance with the time from which the molecule has been declared off-patent.
   In case, renewal of MMC is pending, the application for renewal will be read in continuation with the last MMC provided there is no break between the two. However, the renewed MMC will have to be provided by the firm before completion of technical evaluation; failing which the bid will summarily be rejected.

8. Firms which have **US-FDA** approval for export/selling of specified drugs in USA, may submit copies of approval documents from FDA in support of their claim.

9. Manufacturing firm should upload the scanned copy of performance certificate of 02 years for supply of drugs/medicines/iv fluids within last 05 financial years i.e. **2020-21, 2021-22, 2022-23, 2023-24 and 2024-25** from any Govt. Hospital/PSUs./reputed hospital/Institutions/International buyer on the purchaser letter head where the bidders is supplying these items in reference to this tender.

10. **Production-Capacity assessment certificate:** The manufacturing firm should enclose the certificate issued by the Chartered Accountant/ concerned State Drug Controller indicating actual production detail of a particular molecule batch wise for the items quoted and at least one analysis batch report per year for any two of the last three years for each molecule

quoted (i.e. minimum of two reports of at least **2-different years** of the last three financial years (**2022-23, 2023-24 and 2024-25**) in the enclosed Performa at **Section-XIX.**

11. Tender shall be rejected if the Copy of GST Registration Certificate is not furnished. Firm shall furnish a certificate on their letter head stating that up-to-date returns have been filed and there are no dues with the concerned department.

12. **Turnover Clause:**

(a) The manufacturing firm quoting for the items should have a following minimum average annual turnover from similar jobs, in the last three consecutive years (**FY 2022-23, 2023-24 and 2024-25)**

Schedule Name	Details	Average Annual Turnover
Schedule 1(1.001 to 1……..)	**SUPPLY OF DRUGS (INJECTIONS, PATCH, RESPULES, VACCINE, MDI, SUPPOSITORY, SACHET, IV FLUIDS, ANTISEPTIC, DISINFECTANT AND CONTROLLED SUBSTANCES/NARCOTICS DRUGS ETC.)**	35 Crores

(b) The Turnover Certificate should be duly authenticated by a Chartered Accountant.

(c) Participating pharmaceutical Firms will have to submit audited financial statement (Profit & Loss and Balance Sheet) verified by registered Chartered Accountant for last three preceding financial years (i.e. **2022-23, 2023-24 and 2024-25**) in support of the annual turnover.

13. If a firm is the sole manufacturer of the product, the same can be treated as a Proprietary drug, provided the firm submits a certificate to this effect from the competent authority in India.

14. Scanned copy of **Non-Conviction certificate** issued by the Centre/State Drug Controller to the effect that the manufacturer has not been convicted under the Drugs and Cosmetics Act, 1940 and rules there under during the last three years in respect of any of the drugs for which prices have been quoted by the firm. In case the DCGI does not mention the name of the molecules in their certificates, **a relevant undertaking will be provided with list of drug/molecules along with non-conviction certificate, by the vendor in addition to the above mentioned certificate.** Non- Conviction Certificate must have been issued *by the Drug Controller of the concerned State* within preceding one year from the date of the publication of the tender.

15. In case of Imported products the financial turnover of overseas manufacturing firm (Principal firm) will be considered.

16. The contractor should also give a guarantee as follows, in case of biological and other products having a particular life-period to provide safe-guard against loss on account of deterioration within their stated period of potency.

"The seller hereby declares that the goods/store/articles sold to the buyer under this contract shall be of the best quality and shall be strictly in accordance with the specification and particulars mentioned in the description clauses hereof and the seller hereby guarantees that the said goods/stores/articles would continue to confirm to their description and quality for a period of one year from the date of delivery of the said goods/stores/articles or such portion thereof as may be discovered not to conform to the description and quality. Such rejection of the goods/ articles/ stores will be at the seller's risk and all the provisions herein contained relating to rejection of goods etc., or such portion thereof if rejected by the purchaser shall be applicable. Otherwise the contractor/seller shall pay to the purchaser such damages as may arise by reason of the breach of conditions herein contained. Nothing herein contained shall prejudice any other right of the purchase in that behalf under this contract or otherwise".

17. Certificate on self attested non-judicial stamp paper of Rs.10/- stating that there is no vigilance/ CBI case pending against the firm/supplier and the firm has not been blacklisted/debarred on the date of submission of the bid by any Central Govt./State Govt. department/hospital/PSUs etc. Bidder should also provide information regarding blacklisting/debarring of the firm in last three years (**2022-23, 2023-24 and 2024-25**) by any Government or Private organization/Hospital. In case of any false information provided or concealed the information by any bidder, the bidder shall be debarred for two years and EMD/Bid Security/Performance Security submitted by the firm shall be forfeited.

18. The firms should give an undertaking to the effect that they will be legally bound to supply the medicines/drugs, for which they have quoted the rates in the tender during the validity of the contract. In case, they fail to execute any supply-order placed to them within 45 days from the date of placement of purchase order, they will be liable for action against them as per tender terms.

19. Scanned copy of Information as per the format enclosed **(Section-XVII)** should be submitted with the tender. Furnishing of false information will make the bidder ineligible and the firm will stand blacklisted**.**

20. Scanned copy of List of Items quoted as per **Section- XVI.**

a) Participating Pharmaceutical firm should submit a notarized undertaking on an affidavit of Rs. 100/- (Rupees One Hundred only) stating that:

i. They will comply with all the statues & legislation regarding manufacturing, import, sale and supply of drugs in India and in particular the following Acts/Enactments viz., the Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended), The Legal Metrology Act, 2009, The Drugs (Control) Act, 1950, The Indian Statistical Institute Act, 1959, GST Act.

ii. To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 (as amended). The bidder shall also undertake not to supply items / drugs "not of standard", "Grossly sub- standard" and "Spurious and adulterated drugs" as per the guidelines issued by the Drug Controller of India from time to time.

b) The participating pharmaceutical firm should submit an affidavit of Rs. 100/- (Rupees One Hundred only) duly signed by the Notary as under:-

i. "The pharmaceutical firm hereby declare that the drugs/items sold to the AIIMS under this contract shall be of best quality and workmanship and shall be strictly in accordance with the specifications and particulars contained/mentioned in the description clauses hereof and the pharmaceutical firm/bidder hereby guarantees that the said drugs/items would continue to conforms to their description/ specification and the provisions of law as stated in the contract and that notwithstanding the fact that the purchaser (inspector) may have inspected and/or approved the said drugs/items. If the same be discovered not to conform to the description and quality aforesaid or have deteriorated, the decision of the AIIMS in that behalf will be final and conclusive. AIIMS will be entitled to reject said drugs/items or such portion thereof as may be discovered not to conform to the said description and quality in the manner as prescribed. Such rejection of the drugs/items will be at the seller's risk and all the provisions herein contained relating to rejection of drugs/items etc. or such portion thereof if is rejected by the purchaser. Nothing herein contained shall prejudice any other right of AIIMS in that behalf under this contract or otherwise".

ii. The Bidder submits stating that the drugs, which are being quoted, are not banned under Section 26 (A) of Drugs & Cosmetics Act. Or any other provision of law prevailing in India.

iii. It is declared that the firm / company/ corporation and any of its director / proprietors/ partners/ Authorized signatories are not convicted/ or a criminal case filed against or pending in any court of India by any department of Govt. under prevention of Corruption Act or for cheating/ defrauding Govt/ embezzlement of Govt fund or any criminal conspiracy in the said matter.

iv. The Bidder submits an undertaking that it is not submitting bid for any drug/ combination of drugs which is not approved by DCGI".

v. Company/Authorized Signatory has to submit an affidavit giving address of Manufacturing unit.

21. For the drugs which are being imported, the Participating Pharmaceutical firm will submit valid import license issued by Drug Controller General of India and valid marketing license issued by concerned Licensing Authority (Form 10 & Form 41). That Firm will be eligible if one batch of new drug has been imported at the time of bidding.

22. In case of patented drugs, Participating Pharmaceutical firm will submit valid certificate to this effect from the Licensing Authority else bidder's claim will not be considered.

23. The firm / company/ corporation should not be convicted/ or a criminal case filed against or pending in any court of India by any department of Govt. under prevention of Corruption Act or for cheating/ defrauding Govt./ embezzlement of Govt. fund or any criminal conspiracy in the said matter.

24. For the drugs quoted in the tender enquiry, Participating Pharmaceutical firm will have to submit the samples on demand. If bidder fails to submit the samples within the period specified, the tender will be rejected, if applicable.

Section – IX
TENDER ACCEPTANCE FORM

To

The Executive Director,
All India Institute of Medical Sciences Bilaspur
HP. India.

Ref. Your ATE No. _____due for opening on

_____*insert date*

We, the undersigned have examined the above mentioned Tender Enquiry Document, including amendment/corrigendum (*if any*), the receipt of which is hereby confirmed. We now offer to supply and deliver in conformity with your above referred document for the sum as shown in the Price Schedules (BoQ) uploaded herewith and made part of this bid. If our bid is accepted, we undertake to supply the items for which Rate Contract has been concluded, in accordance with the delivery schedule specified in the Schedule of Requirements.

We further confirm that, if our bid is accepted, we shall provide you with a Performance Security of required amount in an acceptable form in terms of "General Conditions Contract", Section - IV read with modification, if any "Special Conditions of Contract", in Section - V, for due performance of the Rate Contract/Purchase Orders.

We agree to keep our bid valid for acceptance as required in the "General Instruction to Bidders", read with modification, if any in "Special Instructions to Bidders", Section – III or for subsequently extended period, if any, agreed to by us. We also accordingly confirm to abide by this bid up to the aforesaid period and this bid may be accepted any time before the expiry of the aforesaid period. We further confirm that, until a formal Rate Contract is executed, this bid read with your written acceptance thereof within the aforesaid period shall constitute a binding contract between us.

We further understand that you are not bound to accept the lowest or any bid you may receive against your above-referred advertised tender enquiry.

We confirm that we do not stand deregistered/banned/blacklisted by Central Govt./State Govt. Ministries/AIIMS Bilaspur.

We confirm that we fully agree to the terms and conditions specified in above mentioned Tender Enquiry Document, including amendment/ corrigendum if any**.**

We hereby certify that if at any time, information furnished by us is proved to be false or incorrect, we are liable for any action as deemed fit by the purchaser in addition to forfeiture of the Bid Security/Performance Security."

Name: _____
Business Address_____

_____

Place: _____

Date: _____

SECTION – X
PRICE SCHEDULE

BoQ may be uploaded as per instructions given in Tender Enquiry Document.

SECTION – XI
BANK GUARANTEE FORM FOR BID SECURITY

Whereas _____(Name and address of the Bidder)
(*hereinafter called the "Bidders"*)

has submitted its Bid dated _____for the supply of _____
(hereinafter called the "Bid")

against the purchaser's ATE No. _____

Know all persons by these presents that we _____

having our registered office at _____
(Hereinafter called the "Bank")
are bound to AIIMS Bilaspur HP
(hereinafter called the "Purchaser)

in the sum of _____for which payment will and truly to be made to the said Purchaser, the Bank binds itself, its successors and assigns by these presents. Sealed with the Common Seal of the said Bank this

_____day of _____20_____.

The conditions of this obligation are:

1) If the Bidder withdraws or amends, impairs or derogates from the bid in any respect within the period of validity of this Bid.
2) If the Bidder having been notified of the acceptance of his Bid by the Purchaser during the period of its validity: -

   a. If the bidder fails or refuses to furnish the performance security for the due performance of the Rate Contract/Purchase Orders or
   b. If the bidder fails or refuses to accept/execute the Rate Contract/Purchase Orders or
   c. If it comes to notice at any time, that the information/documents furnished in its Bid are false or incorrect or misleading or forged

We undertake to pay the Purchaser up to the above amount upon receipt of its first written demand, without the Purchaser having to substantiate its demand, provided that in its demand the Purchaser will note that the amount claimed by it is due to it owing to the occurrence of one or more the three conditions, specifying the occurred condition(s).

This guarantee will remain in force up to _____*(insert date of additional forty-five days after Bid validity)* and any demand in respect thereof should reach the Bank not later than the above date.

……
(Signature with date of the authorized officer of the Bank)

……
(Name and designation of the Officer)

……..

…….. (Seal,
name & address of the Bank and address of the Branch

SECTION – XII
BANK GUARANTEE FORM FOR PERFORMANCE SECURITY

WHEREAS _____ (Name and address of the Supplier) (Hereinafter called "the Supplier")

has undertaken, in pursuance of Rate Contract No._____

dated _____ valid from _____ to _____ for supply

_____ (*insert description of goods*)
(Hereinafter called "the Contract"),

to AIIMS Bilaspur HP
(Hereinafter called "the Purchaser")

AND WHEREAS it has been stipulated by you in the said contract that the supplier shall furnish you with a bank guarantee by a scheduled commercial bank recognized by you for the sum specified therein as security for compliance with its obligations in accordance with the contract;

AND WHEREAS we have agreed to give the supplier such a bank guarantee;

NOW THEREFORE we hereby affirm that we are guarantors and responsible to you, on behalf of the supplier, up to a total of

_____ (insert *Amount of the Performance Security in words and figures)*, and we undertake to pay you, upon your first written demand declaring the supplier to be in default under the contract and without cavil or argument, any sum or sums within the limits of (amount of guarantee) as aforesaid, without your needing to prove or to show grounds or reasons for your demand or the sum specified therein.

We hereby waive the necessity of your demanding the said debt from the supplier before presenting us with the demand.

We further agree that no change or addition to or other modification of the terms of the contract to be performed there under or of any of the contract documents which may be made between you and the supplier shall in any way release us from any liability under this guarantee and we hereby waive notice of any such change, addition or modification.

This guarantee will remain in force up to _____ *(insert last date of currency of Rate Contract plus Warranty Period (if applicable) plus additional Ninety days)* and any demand in respect thereof should reach the Bank not later than the above date.

……
(Signature with date of the authorized officer of the Bank)

…… Name
and designation of the officer

……..

…… Seal,
name & address of the Bank and address of the Branch

SECTION – XIII
RATE CONTRACT FORM FOR GOODS
(To be submitted after notification of awards)
(To be executed on Non-Judicial Stamp Paper worth of Rs.100/-)

ALL INDIA INSTITUTE OF MEDICAL SCIENCES
(Insert Name of Hospital/Department/Section)
Bilaspur HP

Rate Contract No._____dated_____

To
_____
(*insert name of Supplier with address*)

This is in continuation to this office's Notification of Award No.: _____dated _____

1. Name & address of the Supplier: _____
2. Advertised Tender Enquiry No. of Tender Documents: _____ and subsequent Amendment No.:_____, dated:_____ (if any), issued by the Purchaser
3. Supplier's Bid No.:_____ dated: _____and subsequent communication(s) No.:_____dated: _____(if any), exchanged between the supplier and the purchaser in connection with this Tender Document.
4. In addition to this Rate Contract Form, the following documents etc, which are included in the Tender Enquiry Documents mentioned under paragraphs 2 and 3 above, shall also be deemed to form and be read and construed as integral part of this Rate Contract:

   i) General Conditions of Contract;
   ii) Special Conditions of Contract;
   iii) Schedule of Requirements;
   iv) Technical Specifications;
   v) Tender Acceptance Form uploaded by the supplier;
   vi) Price Schedule(s)/BoQ uploaded by the supplier in its Bid;
   vii) Manufacturers' Authorization Form (if applicable);
   viii) Purchaser's Notification of Award

   Note: The words and expressions used in this Rate Contract shall have the same meanings as are respectively assigned to them in the conditions of Rate Contract referred to above. Further, the definitions and abbreviations incorporated under clause 1 of Section II – "General Instructions to Bidders" of the Tender Enquiry Document shall also apply to this Rate Contract.

5. Some terms, conditions, stipulations etc. out of the above-referred documents are reproduced below for ready reference:

   i) Brief particulars of the goods which shall be supplied by the supplier against Rate Contract are as under:

Item No.	Brief Description of Goods	Unit	Unit Price (in INR)	GST Rate (in %age)	Total Unit Price with GST (in INR)

   ii) Terms of Delivery: Free Delivery At Site
   iii) Delivery schedule: 45 Days from the Date of Issue of Purchase Order
   iv) Performance Security of Rs._____ valid upto _____to be furnished by _____

6. Currency of Rate Contract from: _____to: _____
7. Shelf Life:

At the time of supply, For Drugs having shelf life of Two years or less: As on the date of delivery, Drugs should not be older than one fourth (1/4) of its shelf life from the date of manufacture.
For Drugs having shelf life more than Two years: As on the date of delivery, Drugs should not be older than one sixth (1/6) of its shelf life from the date of manufacture.

8. The supplier shall arrange to effect free replacement of any quantity which may deteriorate in potency, strength etc. before the date of expiry marked on the labels.

9. Payment terms: As per General Conditions of Contract

10. The Supplier will supply the goods as per Rate Contract against Purchase Orders issued by various Centers/Hospital/Section/Departments/Store Sections of AIIMS, Bilaspur HP.

_____

Signature, name and designation of the Purchaser authorized official for and on behalf of Executive Director, AIIMS, may be called as First Party

---

Received and accepted this Rate Contract

Signature, name and address of the supplier's executive duly authorized to sign on behalf of the supplier, may be called as Second Party

for and on behalf of _____
(*Insert Name and address of the supplier*)

(Seal of the Supplier)

Date: _____

Place: _____

SECTION – XIV CONSIGNEE
RECEIPT CERTIFICATE
(To be given by consignee's authorized representative)

The following store(s) has/have been received in good condition:

1) Rate Contract No. & date :_____

2) Purchase Order No. &date : _____

3) Supplier's Name :_____

4) Consignee's Name & Address: _____

5) Name of the item supplied : _____

6) Quantity Supplied :_____

7) Date of Receipt by the Consignee :_____

Signature of Consignee with date:_____

Name and designation of Consignee:_____

Seal of the Consignee: _____

SECTION – XV
FINAL CONSIGNEE ACCEPTANCE CERTIFICATE
(To be given by consignee's authorized representative)

1 This is to certify that the goods as detailed below have been received in good conditions along with all the standard and special accessories in accordance with the Rate Contract/Purchase Order and the same has been installed and accepted.

1) Rate Contract No. &date :_____
2) Purchase Order No. &date : _____
3) Supplier's Name:_____
4) Consignee's Name & Address: _____
5) Name of the item Supplied :_____
6) Quantity Supplied :_____
7) Date of Receipt by the Consignee :_____
8) Quantity Accepted :_____
9) Date of Acceptance by the Consignee :_____
10) The supplier has fulfilled its contractual obligations including installation (if applicable) satisfactorily

OR

The supplier has failed to fulfill its contractual obligations with regard to the following:
i)
ii) iii)
iv)

11) The amount of recovery on account of failure of the supplier to meet his contractual obligations is_____(here indicate the amount).

Signature of Consignee with date: _____
Name and designation of Consignee: _____
Seal of the Consignee: _____

SECTION – XVI

LIST OF ITEMS QUOTED
FORMAT OF SUBMISSION OF VALID REVISED SCHEDULE –M/ WHO- GMP/IMPORT LICENSE/ COPP/ MANUFACTURING LICENSE (STRICT COMPLIANCE).

Sr. No.	Item' serial no. as per tender list	Name of Drugs	Page no. Tender where valid WHO-GMP/ Revised Schedule M/ import license/ COPP/Public Sector undertakings enclosed	Page no. Tender where valid Manufacturing License/ Import license enclosed.

Strict Compliance: - All the bidders are directed to mention the page number of the tender document where WHO-GMP/ Revised Schedule 'M' & page number of manufacturing license for indigenous drugs / import license for imported drugs enclosed. Merely mentioning the word **'Enclosed'** may lead to rejection of tender / bid. Submission

a) Participating Pharmaceutical firm should submit a notarized undertaking on an affidavit of Rs. 100/- (Rupees One Hundred only) stating that:
   i) They will comply with all the statues & legislation regarding manufacturing, import, sale and supply of drugs in India and in particular the following Acts/Enactments viz., the Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended), The Legal Metrology Act, 2009, The Drugs (Control) Act, 1950, The Indian Statistical Institute Act, 1959, GST Act.
   ii) To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 (as amended). The bidder shall also undertake not to supply items / drugs "not of standard", "Grossly sub- standard" and "Spurious and adulterated drugs" as per the guidelines issued by the Drug Controller of India from time to time.

b) The participating pharmaceutical firm should submit an affidavit of Rs. 100/- (Rupees One Hundred only) duly signed by the Notary as under:-
   i) "The pharmaceutical firm hereby declare that the drugs/items sold to the AIIMS under this contract shall be of best quality and workmanship and shall be strictly in accordance with the specifications and particulars contained/mentioned in the description clauses hereof and the pharmaceutical firm/bidder hereby guarantees that the said drugs/items would continue to conforms to their description/ specification and the provisions of law as stated in the contract and that notwithstanding the fact that the purchaser (inspector) may have inspected and/or approved the said drugs/items. If the same be discovered not to conform to the description and quality aforesaid or have deteriorated, the decision of the AIIMS in that behalf will be final and conclusive. AIIMS will be entitled to reject said drugs/items or such portion thereof as may be discovered not to conform to the said description and quality in the manner as prescribed. Such rejection of the drugs/items will be at the seller's risk and all the

provisions herein contained relating to rejection of drugs/items etc. or such portion thereof if is rejected by the purchaser. Nothing herein contained shall prejudice any other right of AIIMS in that behalf under this contract or otherwise".

ii) The Bidder submits stating that the drugs, which are being quoted, are not banned under Section 26 (A) of Drugs & Cosmetics Act. Or any other provision of law prevailing in India.

iii) It is declared that the firm / company/ corporation and any of its director / proprietors/ partners/ Authorized signatories are not convicted/ or a criminal case filed against or pending in any court of India by any department of Govt. under prevention of Corruption Act or for cheating/ defrauding Govt/ embezzlement of Govt fund or any criminal conspiracy in the said matter.

iv) The Bidder submits an undertaking that it is not submitting bid for any drug/ combination of drugs which is not approved by DCGI".

v) Company/Authorized Signatory has to submit an affidavit giving address of Manufacturing unit

SIGNATURE AND ADDRESS OF THE BIDDER

SECTION – XVII

PROFORMA TO BE FILLED BY THE TENDERER

I. GENERAL INFORMATION

a) Name of the firm :

b) Address & Telephone No. :

c) Whether the firm is Indian / Multi- national :

d) Whether Small / Medium/Large Scale Co. :

e) Person responsible for conduct of Business :

f) Particulars of Licenses held under Drugs & Cosmetic Act & the details. (If the license is under renewal, certificate from the Drug Controller that the license is under renewal
and deemed to be enforced) :

g) Procurement agency with which registered and the agencies to whom drugs supplied during last one year :

h) Has the firm been convicted ever, if yes, give details:

i) Any case pending in the Court with details:

j) Has the firm ever been debarred / black-listed by any Govt. Hospital for poor quality or late supply of drugs? If yes, give details.

k) Fax No :

l) E- Mail Address :

m) Name & Mobile No of person/ authorized signatory to be contacted for this tender :

II. TECHNICAL

a) Equipments for material handling, manufacturing of drugs and quality- control of drugs :

b) Specialized testing facilities such as microbiological testing and Biological testing :

c) Details of Technical Staff

i) Manufacturing Staff :
ii) Quality Control Staff :

d) Has the firm carried out stability study for drugs quoted :

e) Is the firm basic manufacturer of the drug quoted, if yes, details :

f) Has the firm following

i) WHO GMP Certificate /Schedule-M :
ii) ISO Certificate :
iii) FDA Certificate :
iv) Import License :

g) Installed capacity and actual production details for different forms of drugs :

i) Tablets :
ii) Capsules :
iii) Syrups/ Suspension :
iv) Injections :
v) Powder :
vi) Inhalation :
vii) Topical :

h) Drugs declared and sub-standard / re-called during the last three years. Give details with reasons and the remedial action taken :

III. FINANCIAL

a) Turnover during last three financial years (year wise) of the pharmaceutical products. Firms should furnish copies of audited Balance-sheet / Sales Tax clearance certificate.

b) Name & Address of the Bankers to the Firm and the facilities available from the bank.

c) Income-tax No./ Central Sales-tax No./ State Sales-tax No.

DECLARATION

I, _____ Proprietor/Partner/Director of M/s _____ hereby declare that the information given in this form is true and correct to the best of my knowledge and belief.

(Signature)

(Name & Designation with Stamp)

WARNING: If the information furnished in this form is found to be incorrect at any point of time, the bidder may be debarred.

SECTION – XVIII

MANUFACTURING & MARKETING CERTIFICATE

This is to certify that M/s _____ are holding valid Manufacturing license No. _____ dated _____ of the _____ State and they are manufacturing and marketing, the following products for last three (3) years.

The products are as follows:

S. No.	Name of the Product	Pharmacopoeia Specification	Strength
1.			
2.			
3.			
4.			
5.			
6.			
7.			
8.			
9.			
10.			

Signature and seal of Drug Controller of the Centre/State.

Dated:

Note: This certificate is to be signed by the Drug Controller of **Centre/State.** Certificate issued by Inspector of Drugs will not be accepted unless an authorization by the concerned centre/State Drug Controller to this effect is supported by adequate documentary proof.

SECTION – XIX

PRODUCTION-CAPACITY ASSESSMENT CERTIFICATE

Item no. & name of items:_____

Indicate details of production of the items quoted at least two years from **2022-23 2023-24 and 2024-25** duly certified by the **Chartered Accountant/ Centre/State Drug Controller.**

S. No. of the item as in Tender Enquiry	Name & Specification of the item	Date of issue of Mfg. License for the product	Date of marketing the 1st batch
1.	2.	3.	4.

2022-23		2023-24		2024-25		REMARKS
Batch No.	Size	Batch No.	Size	Batch No.	Size	

Signature of the Manufacturer:

Signature of the Chartered Accountant/
Centre/State Drug Controller along with address & Seal

SECTION – XX

CERTIFICATE OF PRICE JUSTIFICATION

[*Affidavit on Non-Judicial Stamp Paper of Rs. 100*]

NIT No.:

I/We, M/s. _____ certify that the rates provided are our best rates and we have not given these materials to any Government Department/PSU/Institution for lesser than these rates in last financial year. I/We also certify that the discount offered is not lower than those offer to DGS&D and other government departments and shall not offer higher discount than the quoted one during the period of contract to any other government organization.

Section-XXI

FORMAT FOR AFFIDAVIT OF SELF CERTIFICATION REGARDING LOCAL CONTENT

(To be provided on Rs. 50/- Stamp Paper)

(To be given by Authorized signatory duly authorized by the Board of Director) Date:_____
I_____S/o,D/o,W/o_____,Resident of _____do hereby solemnly affirm and declare as under: That I will agree to abide by the terms and conditions of the policy of Government of India issued vide Public Procurement (Preference to Make in India) order no. F.No.31026/36/2016-MD dated 16 Feb, 2021 issued by Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers as amended from time to time and its subsequent orders, notifications issued by concerned Nodal Ministry. That the information furnished hereinafter is correct to best of my knowledge and belief and I undertake to produce relevant records before the procuring entity or any authority so nominated by the Department of Pharmaceuticals, Government of India for the purpose of assessing the local content. That the local content for all inputs which constitute the said medical device has been verified by me and I am responsible for the correctness of the claims made therein. That in the event of the domestic value addition of the product mentioned herein is found to be incorrect and not meeting the prescribed value-addition norms, based on the assessment of an authority so nominated by the Department of Pharmaceuticals, Government of India for the purpose of assessing the local content, action will be taken against me as per Order No. P45021/2/2017-B.E.-II dated 29.05.2019 and Notification No. 31026/36/2016-MD dated 18.05.2018 or any subsequent orders, notifications issued by concerned Nodal Ministry. I agree to maintain the following information in the Company's record for a period of 8 years and shall make this available for verification to any statutory authority:

i) Name and details of the Domestic Manufacturer (Registered Office, Manufacturing unit location, nature of legal entity)
ii) Date on which this certificate is issued
iii) Medical devices for which the certificate is produced
iv) Procuring entity to whom the certificate is furnished
v) Percentage of local content claimed
vi) Name and contact details of the unit of the manufacturer
vii) Sale Price of the product
viii) Ex-Factory Price of the product
ix) Freight, insurance and handling
x) Total Bill of Material
xi) List and total cost value of inputs used for manufacture of the medical device
xii) List and total cost of inputs which are domestically sourced. Value addition certificates from suppliers, if the input is not in-house to be attached.
xiii) List and cost of inputs which are imported, directly or indirectly.

Note: Details for Sr. No. (vii) to (xiii) may not be uploaded with technical bid inadvertently. **For and on behalf of (Name of firm/entity)**

Authorized signatory (To be duly authorized by the Board of Director.

SECTION – XXII

GFR-144 (xi) compliance certificate (To be printed on the Firm's letterhead)

Tender No:

GFR-144(xi) compliance certificate (as per order F.No. 6/18/2019-PPD, Ministry of Finance, GOI) **and subsequent order thereof**

I have read the clauses regarding restrictions under GFR144(xi) on procurement from a bidder of a country which shares a land border with India. I certify that....., the vendor

- is not such a country
- is from a country and has been registered with a competent authority (attached evidence of validregistration).

(Select one of the above and strike off the other)

I hereby certify that we fulfill all requirement in this regard and is eligible to be considered for the procurement on CPP portal.

We also understand, false declarations will be in breach of the Code of Integrity under Rule 175(1)(i)(h) of the General Financial Rule for which a bidder or its successor can be debarred for up two years as per Rule 151 (iii) of the General Financial Rule along with such other actions as may be permissible under law.

Thanking you.

Seal and Signature of Authorized Signatory

SECTION – XXIII
CHECKLIST

Sr. No.	Documents to be submitted along with the techno- commercial bid	Attached at page number
a.	Scanned copy of "EMD/Bid Security" furnished in accordance with GIB alternatively, documentary evidence as per GIT for claiming exemption from payment of EMD/Bid security to be uploaded.	
b.	Scanned copy of "List of Items Quoted" as per SECTION – XVI of Tender Enquiry Document. **(Only technical details such as specifications, make, and model shall be submitted with the Technical Bid of quoted items. If financial information, rates submitted in the Technical Bid will lead to summary rejection of the bid.)**	
c.	Scanned copy of "Tender Acceptance Form" as per **Section IX** to be uploaded	
d.	Scanned Copy of GST Registration Certificate. Tender shall be rejected if the Copy of GST Registration Certificate is not furnished. Firm shall furnish a certificate on their letter head stating that up-to-date returns have been filed and there are no dues with the concerned department.	
e.	Scanned copy of Documents confirming to Sole Proprietorship/ Partnership/Private Limited Firm in the country of origin as the case may be to be uploaded.	
f.	Scanned copy of **Manufacturing & Market standing/ experience certificate** of minimum **"Three Years"** of the molecule quoted by them duly certified by center/ State Drug Controller in the Performa **Section- XVIII**. The certificate should have been issued recently i.e. not more than one year old from the date of the opening of the tender.	
g.	Scanned Copy of **Valid WHO-GMP certificate/ Valid Schedule 'M' certificate** clearly indicating the products (molecule/drug) issued by Centre/ State Drug Controller and should not have been issued more than five years old**.**	
h.	In case of imported drugs (i.e. not manufactured in India), **COPP (Certificate of Pharmaceutical Products)/ import license** and copy of the import registration of that particular molecule quoted in the tender indicating the list of products should be submitted as per WHO norms and '3-years' Marketing experience certificate issued by the Drug Controller. In case of the newly off-patent molecules wherein MMC of 03 years is not cleared/ completed, it will be relaxed in accordance with the time from which the molecule has been declared off- patent. In case, renewal of MMC is pending, the application for renewal will be read in continuation with the last MMC provided there is no break between the two. However, the renewed MMC will have to be provided by the firm before completion of technical evaluation; failing which the bid will summarily be rejected.	

i.	Scanned copy of **valid manufacturing license** issued by Centre/State Drug Controller indicating the list of products should be submitted**.** Public Sector Undertakings with at least "3-years" market standing having manufacturing license issued by Centre/ State Drug Controller.	
j.	In case of **newly introduced** drugs/molecules, the manufacturer can be eligible provided the firm submits a certificate from the DCGI, in this regard. In such cases, the firm has to submit an MMC of the molecule concerned from the date of issue of Certificate by the DCGI of the new drug to that firm. In such case MMC of 03 years is not cleared/ completed, it will be relaxed accordingly.	
k.	Manufacturing firms should submit scanned copy of performance certificate(s) of at least 02 years in last 05 years (**2020-21, 2021-22, 2022-23, 2023-24 and 2024-25**), from other similar two Hospital, out of which one must be from Government/Public Sector from the Competent Authority.	
l.	Production-Capacity assessment certificate as per section-XIX	
m.	Average Turnover Certificate for FY 2022-23 to 2024-25 duly certified by Chartered Accountant:	
n.	Audited financial statement (Profit & Loss Statement and Balance Sheet) verified by registered Chartered Accountant for last three preceding financial years (i.e. 2022-23, 2023-24 and 2024-25) in support of the annual turnover.	
o.	Scanned copy of Non-conviction certificate: **Non-Conviction certificate** issued by the Centre/State Drug Controller to the effect that the manufacturer has not been convicted under the Drugs and Cosmetics Act, 1940 and rules there under during the last three years in respect of any of the drugs for which prices have been quoted by the firm. In case the DCGI does not mention the name of the molecules in their certificates, **a relevant undertaking will be provided with list of drug/molecules along with non-conviction certificate, by the vendor in addition to the above mentioned certificate.** Non- Conviction Certificate must have been issued *by the Drug Controller of the concerned State* within preceding one year from the date of the publication of the tender	
p.	Certificate on self attested non-judicial stamp paper of Rs.10/- stating that there is no vigilance/ CBI case pending against the firm/supplier and the firm has not been blacklisted/debarred on the date of submission of the bid by any Central Govt./State Govt. department/hospital/PSUs etc. Bidder should also provide information regarding blacklisting/debarring of the firm in last three years (2022-23, 2023-24 and 2024-25) by any Government or Private organization/Hospital. In case of any false information provided or concealed the information by any bidder, the bidder shall be debarred for two years and EMD/Bid Security/Performance Security submitted by the firm shall be forfeited.	
q.	The firms should give an undertaking to the effect that they will be legally bound to supply the medicines/drugs, for which they have quoted the rates in the tender during the validity of the contract. In case, they fail to execute any supply-order placed to them within 45 days from the date of placement of purchase order, they will be liable for action against them as per tender terms.	

r.	Scanned copy of Information as per the format enclosed **(Section-XVII)** should be submitted with the tender. Furnishing of false information will make the bidder ineligible and the firm will stand blacklisted**.**	
s.	At least one analysis batch report per year for any two of the last three years for each molecule quoted (i.e. minimum of two reports of at least **2-different years** of the last three financial years (**2022-23, 2023-24 and 2024-25**) in the enclosed Performa at **Section-XIX.**	
t.	Name and address of the authorized distributor for supplying against the subject tender along with the OEM authorization certificate to be uploaded.	
u.	Affidavit of Local Content as per Section-XXI	
v.	Scanned copy of GFR-144 (xi) compliance certificate	
w.	Scanned copy of **Power of Attorney** in favor of signatory of Tender/Bid to be uploaded.	

ANNEXURE-A
List of Drugs/Medicines

Sr. No.	Name of Item	UOM	Estimated Qty
1.001	Inj. Abatacept 250mg/vial	Vial/Amp.	20
1.002	Inj. Abciximab 2mg/ml 5ml	Vial/Amp.	50
1.003	Inj. Acetylcysteine 200 mg/ml (5 ml)	Vial/Amp.	15000
1.004	Inj. ACTH Adrenocorticotropic hormone 60 IU/ml 5ml	Vial/Amp.	50
1.005	Inj. Actinomycin D (Dactinomycin Injection) 0.5 mg/vial	Vial/Amp.	75
1.006	Inj. Acyclovir 500 mg/ vial	Vial/Amp.	1500
1.007	Inj. Adalimumab 20 mg/ 0.4 ml PFS	Vial/Amp.	5
1.008	Inj. Adalimumab 40mg/0.8ml PFS	Vial/Amp.	5
1.009	Inj. Adenosine 6mg/ 2ml (2ml)	Vial/Amp.	2625
1.010	Inj. Ado-trastuzumab emtansine 100 mg per vial	Vial/Amp.	20
1.011	Inj. Adrenaline tartrate (1:1000) 1ml	Vial/Amp.	45000
1.012	Inj. Aflibercept 2 mg/ 0.05 ml	Vial/Amp.	20
1.013	Inj. Alprostadil 500mcg/1ml	Vial/Amp.	50
1.014	Inj. Alteplase 2 mg/ 2 ml	Vial/Amp.	20
1.015	Inj. Alteplase 50 mg/ 50 ml	Vial/Amp.	20
1.016	Inj. Amikacin 500mg/vial	Vial/Amp.	7500
1.017	Inj. Amikacin 1000mg/ vial	Vial/Amp.	15000
1.018	Inj. Amino Acid 10%, Essential & non-essential amino acids with taurine 10%, 500 ml	Bottle	188
1.019	Inj. Amino Acid Solution 7% for Renal patients 7%, 250 ml	Vial/Amp.	188
1.020	Inj. Amino acids (Amino acids + Glucose (± Electrolytes) intravenous) 1000 ML	Bottle	150
1.021	Inj. Amino acids Intravenous Essential & non-essential 42 % BCAA + 2% aromatic amino acids (for liver patients) 500 ml	Bottle	188
1.022	Inj. Amino Acids Solution (Essential & non-essential amino acids 10% along with taurine intravenous) for paediatrics use 10%/ 100 ml	Bottle	225
1.023	Inj. Amino Acids Solution Intravenous 5 %/ 250 ml	Vial/Amp.	225
1.024	Inj. Aminophylline 25mg/ml 10ml	Vial/Amp.	3375
1.025	Inj. Amiodarone 50mg/ml 3ml	Vial/Amp.	3750
1.026	Inj. amoxycillin and potassium clavulanate 1000mg+200mg	Vial/Amp.	18000
1.027	Inj. Amphotericin B conventional 50mg/ml	Vial/Amp.	1500
1.028	Inj. Amphotericin B liposomal 50mg/ml	Vial/Amp.	1500
1.029	Inj. Ampicillin 500 mg/vial	Vial/Amp.	4125
1.030	Inj. Ampicillin + Sulbactum 1gm+500mcg/vial	Vial/Amp.	750
1.031	Inj. Anakinra 100 mg/0.67 ml PFS	Vial/Amp.	50
1.032	Inj. Anidulafungin 100mg/vial	Vial/Amp.	50
1.033	Inj. Anti Rabies vaccine 1 ml	Vial/Amp.	825
1.034	Inj. ANTI-D RH FACTOR 300 MCG/1ml	Vial/Amp.	600
1.035	Inj. Anti-diphtheritic serum 10000 I.U./10ml	Vial/Amp.	180
1.036	Inj. Anti-Human Thymocyte Immunoglobulin 25mg/5 ml vial	Vial/Amp.	20
1.037	Inj. Anti-Human T-Lymphocyte Immunoglobulin 20mg/ml 5ml	Vial/Amp.	20
1.038	Inj. Anti-Rabies Immunoglobulin 300 IU 2ml	Vial/Amp.	50
1.039	Inj. Anti-Snake Venom (Polyvalent) 10ml/ vial	Vial/Amp.	6000
1.040	Inj. Anti-tetanus immunoglobulin 250 IU/ml 1ml	Vial/Amp.	1200
1.041	Inj. Antithymocyte globulin (ATG) 250 mg/5 ml	Vial/Amp.	20
1.042	Inj. Arbekacin Sulphate 200 mg/4ml	Vial/Amp.	100
1.043	sachet Arginine 5 gm	Sachet	75
1.044	Inj. Arsenic Trioxide 1mg/ml 10ml	Vial/Amp.	75
1.045	Inj. Artemether 80mg/ml 1ml	Vial/Amp.	375
1.046	Inj. Artesunate 60mg/vial	Vial/Amp.	375
1.047	Inj. Atosiban Acetate IP 7.5mg/ml 5ml	Vial/Amp.	20
1.048	Inj. Atracurium Besylate 10mg/ml, 5ml	Vial/Amp.	7500
1.049	Inj. Atropine sulphate 1mg/ml 10 ml	Vial/Amp.	3750
1.050	Inj. Atropine sulphate 1mg/ml 100 ml	Vial/Amp.	825
1.051	Inj. Atropine sulphate 0.6mg/ml 1ml	Vial/Amp.	22500
1.052	Inj. Attenuated strain of hepatitis A virus Hav culture in human diploid cells Live attenuated strain of hepatitis A virus vaccine freezed dried, each 0.5 ml dose contains amino acids salts. Equilibrium solutions: 11.7300mg, trehalose 24.000 mg, sorbitol 9.0000 mg, dextran 40	Vial/Amp.	150
1.053	Inj. Azacitidine Lyophillzed 150mg/vial	Vial/Amp.	20
1.054	Inj. Azithromycin 500mg/vial	Vial/Amp.	6000
1.055	Inj. Aztreonam 500mg/vial	Vial/Amp.	750
1.056	Inj. Aztreonam 1.5 gm + Avibactum 0.5 gm 2 gms	Vial/Amp.	120
1.057	Inj. BCG for immunothreapy 40 mg	Vial/Amp.	100

1.058	MDI Beclomethasone dipropionate and levosalbutamol inhaler 50 mcg+ 50 mcg/dose(One Bottle Contains 200 Doses)	Bottle	113
1.059	Inj. Bendamustin 90mg/ml	Vial/Amp.	20
1.060	Inj. Bendamustine 100mg/vial	Vial/Amp.	20
1.061	Inj. Benzathine penicillin 2.4 mIU/vial	Vial/Amp.	500
1.062	Inj. Benzathine penicillin 1.2 mIU/vial	Vial/Amp.	500
1.063	Inj. Beractant intratracheal solution 25mg/ml 4ml	Vial/Amp.	20
1.064	Inj. Betamethasone 4mg/ml	Vial/Amp.	2250
1.065	Inj. Bevacizumab 400mg/vial	Vial/Amp.	20
1.066	Inj. Bevacizumab 300mg/vial	Vial/Amp.	570
1.067	Inj. Bevacizumab 100mg/vial	Vial/Amp.	600
1.068	Suppository Bisacodyl 10mg	Suppository	900
1.069	Inj. Bleomycin 15 IU/vial	Vial/Amp.	570
1.070	Inj. Bortezomib 2 mg	Vial/Amp.	338
1.071	Inj. Botox injection 50 I.U	Vial/Amp.	20
1.072	Inj. Botulinum Toxin Type A 100 units	Vial/Amp.	200
1.073	Inj. Botulinum Toxin Type A 200 units	Vial/Amp.	100
1.074	Inj. Bovine lipid extract surfactant suspension (Sterile suspension for intratracheal administration only) 5 ml	Vial/Amp.	20
1.075	Inj. Brevetiracetam 50 mg	Vial/Amp.	250
1.076	Respules Budesonide 0.5 mg/2 ml	Respules	6750
1.077	inhalation Solution Budesonide respirator solution for inhalation 2 ml	Bottle	750
1.078	Inj. Bupivacaine (preservative free) 0.25% 20ml	Vial/Amp.	1000
1.079	Inj. Bupivacaine (preservative free) 0.5% 20ml	Vial/Amp.	1100
1.080	Inj. Bupivacaine 0.5% + Dextrose 8% (Heavy) 4ml	Vial/Amp.	2700
1.081	Patch Buprenarphine 10mcg/ hr	Patch	300
1.082	Patch Buprenarphine 20 mcg/ hr	Patch	300
1.083	Inj. Buprenorphine 1 mg/ml	Vial/Amp.	150
1.084	Inj. Busulphan 60mg/10ml	Vial/Amp.	500
1.085	Inj. Butorphanol Tartarate 2mg/ml (1ml)	Vial/Amp.	500
1.086	Inj. Cabazitaxel 60mg/1.5ml	Vial/Amp.	20
1.087	Inj. Caffeine citrate 20mg/ml 2ml	Vial/Amp.	600
1.088	Inj. Calcium Chloride 10% (10ml)	Vial/Amp.	450
1.089	Inj. Calcium gluconate 10% (10ml)	Vial/Amp.	6750
1.090	Inj. Calcium Gluconate IP 50 mg & Calcium Lactobionate USP 87.5 mg equivalent to elemental Calcium 9 mg 10 ml	Vial/Amp.	113
1.091	Sachet Calcium Polystyrene Sulphonate 15g(K exchange Resin)	Sachet	1500
1.092	Inj. Cangrelor 50mg/vial	Vial/Amp.	20
1.093	Inj. Capsaicin Patch 5% 0.005	Vial/Amp.	20
1.094	Inj. Carbetocin 100 mcg/ml (1 ml)	Vial/Amp.	300
1.095	Inj. Carbetocin PFS 100 mcg/ml (1 ml)	PFS	225
1.096	Inj. Carboplatin 10mg/ml 45ml	Vial/Amp.	525
1.097	Inj. Carboplatin 10mg/ml 15ml	Vial/Amp.	525
1.098	Inj. Carboprost Tromethamine 250 mcg/ml (1 ml)	Vial/Amp.	300
1.099	Inj. Cardioplegia Solution 20ml	Vial/Amp.	20
1.100	Inj. Carfilzomib 60mg/vial	Vial/Amp.	20
1.101	Inj. Carfilzomib 10mg/vial	Vial/Amp.	20
1.102	Inj. Carmustine 100mg/vial	Vial/Amp.	20
1.103	Inj. Caspofungin 70mg/vial	Vial/Amp.	225
1.104	Inj. Cefazolin Sodium 500mg/vial	Vial/Amp.	500
1.105	Inj. Cefazolin Sodium 1 g/vial	Vial/Amp.	500
1.106	Inj. Cefepime 500mg/vial	Vial/Amp.	150
1.107	Inj. Cefepime 1 g/vial	Vial/Amp.	150
1.108	Inj. Cefepime + Tazobactam 1gm+125mg/vial	Vial/Amp.	150
1.109	Inj. Cefoperazone 2gm/vial	Vial/Amp.	150
1.110	Inj. Cefoperazone 1gm/vial	Vial/Amp.	300
1.111	Inj. Cefoperazone + Sulbactam 1gm+1gm/vial	Vial/Amp.	3375
1.112	Inj. Cefoperazone + Sulbactam 1gm+500mg/vial	Vial/Amp.	5625
1.113	Inj. Cefotaxime sodium 1 g/vial	Vial/Amp.	6375
1.114	Inj. Cefotaxime sodium 125 mg/vial	Vial/Amp.	2625
1.115	Inj. Cefpirome Sulphate 1 gm/vial	Vial/Amp.	75
1.116	Inj. Ceftalazone- tazobactam 3 gm/vial	Vial/Amp.	100
1.117	Inj. Ceftaroline Fosamil 600mg/ vial	Vial/Amp.	100
1.118	Inj. Ceftazidime 1 g/vial	Vial/Amp.	2625
1.119	Inj. Ceftazidime 250mg/vial	Vial/Amp.	1125
1.120	Inj. Ceftazidime + Avibactam 2gm + 0.5 gm/ vial	Vial/Amp.	675
1.121	Inj. Ceftazidime + Sulbactam 1 gm + 500 mg	Vial/Amp.	3000
1.122	Inj. Ceftazidime+ tazobactum 1gm+125mg	Vial/Amp.	1875

1.123	Inj. Ceftriaxone 250mg/vial	Vial/Amp.	3375
1.124	Inj. Ceftriaxone 1 gm/vial	Vial/Amp.	8850
1.125	Inj. Ceftriaxone + sulbactum 1 gm + 500 mg	Vial/Amp.	1875
1.126	Inj. Ceftriaxone + Sulbactum + Disodium Ethylenediaminetetraacetic Acid (EDTA) 1.5 gm	Vial/Amp.	1500
1.127	Inj. Ceftriaxone + Tazobactam 1gm+125mg/vial	Vial/Amp.	1650
1.128	Inj. Cefuroxime 1.5g/vial	Vial/Amp.	1500
1.129	Inj. Cefuroxime sulbactum 2.25gm/vial	Vial/Amp.	1125
1.130	Inj. Centhaquine Citrate 1mg/vial	Vial/Amp.	50
1.131	Inj. Cetuximab 500 mg/ 100 ml	Vial/Amp.	50
1.132	Inj. Cetuximab 100 mg/ 20 ml	Vial/Amp.	50
1.133	Inj. Chloroquine phosphate 40mg /ml 30ml	Vial/Amp.	1125
1.134	Inj. Chlorpheniramine maleate 10mg/ml 1ml	Vial/Amp.	1650
1.135	Inj. Chlorprocaine 1% 50mg/5ml	Vial/Amp.	1125
1.136	Inj. Cholecalciferol/ Vitamin D3 6 L IU	Vial/Amp.	4500
1.137	Inj. Cidofovir 375mg/5ml	Vial/Amp.	20
1.138	Inj. Ciprofloxacin 200mg/100ml	Vial/Amp.	7500
1.139	Inj. Cisatracurium besylate 10mg/5ml	Vial/Amp.	1875
1.140	Inj. Cisplatin 50mg/50ml	Vial/Amp.	1163
1.141	Inj. Cisplatin 10mg/10ml	Vial/Amp.	1163
1.142	Inj. Cladrabine 10mg/10ml	Vial/Amp.	90
1.143	Inj. Clarithromycin 500mg/vial	Vial/Amp.	900
1.144	Inj. Clindamycin 600mg/vial	Vial/Amp.	4500
1.145	Suppository Clindamycin & clotrimazole Suppository	Suppository	375
1.146	Inj. Clofarabine 20 mg/ 20ml	Vial/Amp.	90
1.147	Inj. Clonidine 150 mcg/ml 1ml	Vial/Amp.	900
1.148	Inj. Cloxacillin 500 mg/ vial	Vial/Amp.	1650
1.149	Inj. Cloxacillin 1 g/ vial	Vial/Amp.	1800
1.150	Inj. Colistimethate sodium powder 4.5 MIU/ Vial	Vial/Amp.	3150
1.151	Inj. Colistimethate sodium powder 1 MIU/ Vial	Vial/Amp.	3750
1.152	Inj. Conivaptan 0.2 mg/ml 100ml	Vial/Amp.	200
1.153	Inj. Corticotrophin Carboxymethylcellulose 60 IU/ml (5ml)	Vial/Amp.	200
1.154	Inj. Cotrimoxazole 80 mg + 400mg /5ml	Vial/Amp.	300
1.155	Inj. Cyclophosphamide 500 mg/ vial	Vial/Amp.	1350
1.156	Inj. Cyclophosphamide 200 mg/ vial	Vial/Amp.	1350
1.157	Inj. Cyclophosphamide 1 g/ vial	Vial/Amp.	1650
1.158	Inj. Cyclosporine 50 mg/ 1ml	Vial/Amp.	750
1.159	Inj. Cytarabine(Cytosine Arabinoside) 500mg/5ml	Vial/Amp.	1350
1.160	Inj. Cytarabine(Cytosine Arabinoside) 100mg/vial	Vial/Amp.	1350
1.161	Inj. Cytosinetarabinoside 1000mg/vial	Vial/Amp.	1125
1.162	Inj. Cytranine 500mg/1ml	Vial/Amp.	375
1.163	Inj. Dacarbazine 500mg/vial	Vial/Amp.	1875
1.164	Inj. Dacarbazine 200mg/vial	Vial/Amp.	1875
1.165	Inj. Dalteparin P F Syringe 5000 I.U. /0.2ml	Vial/Amp.	375
1.166	Inj. Dalteparin P F Syringe 10000 I.U. /0.2ml	Vial/Amp.	375
1.167	Inj. Dalteparin Sodium 2500 IU / 0.2 mL	PFS	375
1.168	Inj. Dantrolene sodium 20 mg	Vial/Amp.	100
1.169	Inj. Daptomycin 350mg/vial	Vial/Amp.	75
1.170	Inj. Darbepoietin 25mcg/.42ml	Vial/Amp.	600
1.171	Inj. Darbepoietin 60mcg/.3ml	Vial/Amp.	750
1.172	Inj. Darbepoietin 40mcg/.40ml	Vial/Amp.	1650
1.173	Inj. Daunorubicin Hydrochloride 20mg/vial	Vial/Amp.	675
1.174	Inj. Decitabine 50mg/vial	Vial/Amp.	375
1.175	Inj. Deferoxamine Mesylate 500 mg /vial	Vial/Amp.	375
1.176	Inj. Degarelix 80 mg /vial	Vial/Amp.	20
1.177	Inj. Degarelix 120 mg /vial	Vial/Amp.	10
1.178	Inj. Degludec 300U/ml 3ml	Vial/Amp.	75
1.179	Inj. Denosumab 60mg/ml PFS	Vial/Amp.	10
1.180	Inj. Denosumab 120 mg/1.7ml PFS	Vial/Amp.	10
1.181	Inj. Desmopressin 4 mcg/ml 1ml	Vial/Amp.	375
1.182	Inj. Dexamethasone 8mg/2ml	Vial/Amp.	6000
1.183	Inj. Dexmedetomidine IV 200 mcg /2ml	Vial/Amp.	1350
1.184	Inj. Dexmedetomidine IV 100 mcg/ 1ml	Vial/Amp.	1050
1.185	Inj. Dexrazoxane 500mg/vial	Vial/Amp.	100
1.186	Inj. Dextran-70 6 %, 500ml	Bottle	300
1.187	Inj. Diatriozoate sod 41.7% w/v 100ml	Vial/Amp.	100
1.188	Inj. Diatrizoate Meglumine and Diatrizoate Sodium Injection USP 370mgI/ml or 76%, 50 ml	Vial/Amp.	100

1.189	Inj. Diatrizoate Meglumine and Diatrizoate Sodium Injection USP 370mgI/ml or 76%, 20 ml	Vial/Amp.	100
1.190	Inj. Diatrizoate Meglumine and Diatrizoate Sodium Injection USP 370mgI/ml or 76%, 30 ml	Vial/Amp.	100
1.191	Inj. Diatrizoate Meglumine and Diatrizoate Sodium Injection USP 292mgI/ml or 60%, 50 ml	Vial/Amp.	100
1.192	Inj. Diatrizoate Meglumine and Diatrizoate Sodium Injection USP 292mgI/ml or 60%, 20 ml	Vial/Amp.	100
1.193	Inj. Diazepam 10mg/2ml	Vial/Amp.	1875
1.194	Inj. Diclofenac I.V., I.M. 75 mg/ 1 ml	Vial/Amp.	33750
1.195	Patch Diclofenac Patch 100 mg/ patch	Patch	200
1.196	Suppository Diclofenac Suppository 100 mg	Suppository	188
1.197	Inj. Dicyclomine 10 mg/ 2ml	Vial/Amp.	16500
1.198	Inj. Digoxin 250mcg/ml 2ml	Vial/Amp.	375
1.199	Inj. Diltiazem 5mg/ml 5ml	Vial/Amp.	1050
1.200	Inj. Dimercaprol 100 mg/2ml	Vial/Amp.	188
1.201	Inj. Diphtheria, Tetanus, Pertussis (Acellular Component) 0.5ml Dose PFS	Vial/Amp.	338
1.202	Inj. Diptheria Antitoxin 10000IU/10ml	Vial/Amp.	338
1.203	Inj. Disodium edetate 37.5mg/0.25 ml 20ml	Vial/Amp.	300
1.204	Inj. DMPA (depot medroxyprogesterone acetate) 150mg/ vial	Vial/Amp.	263
1.205	Inj. DMSO (dimethyl sulfoxide) 50ml	Vial/Amp.	263
1.206	Inj. Dobutamine 250mg /5ml	Vial/Amp.	3000
1.207	Inj. Docetaxel 80mg/ Vial	Vial/Amp.	600
1.208	Inj. Docetaxel 20mg/ Vial	Vial/Amp.	600
1.209	Inj. Docetaxel 120mg/ Vial	Vial/Amp.	600
1.210	Inj. Docetaxel lipid suspension 80 mg	Vial/Amp.	10
1.211	Inj. Dopamine 200mg/5ml	Vial/Amp.	750
1.212	Inj. Doripenem 500mg/vial	Vial/Amp.	90
1.213	Inj. Doxophylline 100mg/10ml	Vial/Amp.	500
1.214	Inj. Doxorubicin 50mg/vial	Vial/Amp.	450
1.215	Inj. Doxorubicin 10mg/vial	Vial/Amp.	450
1.216	Inj. Doxorubicin liposomal 20 mg/vial	Vial/Amp.	20
1.217	Inj. Doxycycline 100mg/vial	Vial/Amp.	3825
1.218	Inj. DPT & Hepatitis B combination 0.5ml/vial	Vial/Amp.	375
1.219	Inj. Drotaverine Hydrochloride 40 mg/ 2ml	Vial/Amp.	3375
1.220	Inj. Dulaglutide 0.75mg/0.5ml	PFS	20
1.221	Inj. Enalaprilat 2.5mg/2ml	Vial/Amp.	500
1.222	Inj. Enoxaparin 20 mg/0.2 ml	PFS	900
1.223	Inj. Enoxaparin 80 mg/ 0.8 ml	PFS	750
1.224	Inj. Enoxaparin 60 mg/0.6 ml	PFS	6750
1.225	Inj. Enoxaparin 40 mg/ 0.4 ml	PFS	6750
1.226	Inj. Ephedrine 30mg/1ml	Vial/Amp.	500
1.227	Inj. Epirubicin 50mg/vial	Vial/Amp.	300
1.228	Inj. Epirubicin 200mg/vial	Vial/Amp.	300
1.229	Inj. Epirubicin 100mg/vial	Vial/Amp.	300
1.230	Inj. Eptifibatide 20 mg/ 10 ml	Vial/Amp.	20
1.231	Inj. Eptifibatide 75 mg/ 100 ml	Vial/Amp.	20
1.232	Inj. Eribulin 0.88mg/ 2ml	Vial/Amp.	50
1.233	Inj. Ertapenem 1gm/vial	Vial/Amp.	20
1.234	Inj. Erythropoietin 3000IU/0.3ml PFS	PFS	600
1.235	Inj. Erythropoietin 4000 IU/1ml PFS	PFS	750
1.236	Inj. Erythropoietin 10000IU/ml PFS	PFS	900
1.237	Inj. Erythropoietin 2000 IU/ml PFS	PFS	600
1.238	Inj. Esmolol 100mg/ 10 ml	Vial/Amp.	375
1.239	Inj. Esomeprazole 40mg/vial	Vial/Amp.	900
1.240	Inj. Etanercept 25mg/ Vial	PFS	100
1.241	Inj. Etanercept 50mg/ Vial	PFS	100
1.242	Inj. Ethamsylate 250mg/2ml	Vial/Amp.	500
1.243	Inj. Ethamsylate 125mg/2ml	Vial/Amp.	500
1.244	Inj. Etomidate 20 mg/ 10 ml	Vial/Amp.	900
1.245	Inj. Etomidate in a 50:50 physical mixture of MCT and LCT with Sodium Oleate as an excipient and presented in a glass ampoule. 20 mg/10 ml	Vial/Amp.	188
1.246	Inj. Etophylline and Theophylline Etophylline 84.7 mg + Theophylline 25.3 mg/ ml (2 ml)	Vial/Amp.	1125
1.247	Inj. Etoposide 100 mg/vial	Vial/Amp.	938
1.248	Inj. Factor IX Recombinant, Fc Fusion Protein-1 600 IU (Human Coagulation factor IX) 600 IU	Vial/Amp.	20
1.249	Inj. Factor Recombinant X a 100	Vial/Amp.	20

1.250	Inj. Factor VII a, recombinant (rFVIIa) 1mg	Vial/Amp.	20
1.251	Inj. Factor XIII concentrate human 1000-1600 IU	Vial/Amp.	20
1.252	Inj. Ferric carboxymaltose 500 mg/10ml	Vial/Amp.	1425
1.253	Inj. Ferrous sulphate + folic acid 80 mg/5 ml	Vial/Amp.	675
1.254	Inj. Ferrous sulphate + Folic acid 20+0.1 mg/ml	Vial/Amp.	675
1.255	Inj. Fibrin glue with synthetic aprotinin 0.5 ml	Vial/Amp.	50
1.256	Inj. Fibrinogen 1gm	Vial/Amp.	938
1.257	Inj. Filgrastim 150 mcg/ml	PFS	1500
1.258	Inj. Filgrastim 300 mcg/ml	PFS	1500
1.259	Inj. Flucloxacillin 1 gm/ vial	Vial/Amp.	90
1.260	Inj. Fluconazole 200 mg/100 ml	Bottle	450
1.261	Inj. Flucytosine 10mg/ml 240ml	Vial/Amp.	20
1.262	Inj. Fludarabine 50mg/vial	Vial/Amp.	20
1.263	Inj. Flumazenil 0.5 mg/ 5 ml	Vial/Amp.	375
1.264	Inj. Flumazenil 0.5 mg/5ml	Vial/Amp.	188
1.265	Inj. Fluorescein sodium 20% 3ml	Vial/Amp.	450
1.266	Inj. Fluorouracil 5-Fluorouracil 500mg/5ml	Vial/Amp.	2100
1.267	Inj. Fluorouracil 5-Fluorouracil 250mg/5ml	Vial/Amp.	1800
1.268	Inj. Flupenthixol 20 mg	Vial/Amp.	500
1.269	Inj. Flupenthixol 40 mg	Vial/Amp.	300
1.270	Inj. Fluphenazine Decanoate 25mg/1ml	Vial/Amp.	100
1.271	Inj. Fluroescein sodium dye 20 %, 3 ml	Vial/Amp.	188
1.272	MDI Fluticasone propionate and formoterol fumarate inhaler 250 mcg+ 6 mcg/ dose (One Bottle Contains 120 Doses)	Bottle	113
1.273	Inj. Folic acid 50 mg/ 10 ml	Vial/Amp.	1125
1.274	Inj. Fomepizole 1.5 g/1.5ml	Vial/Amp.	900
1.275	Inj. Fondaparinux Sod. PFS 7.5mg/ 0.6ml PFS	PFS	50
1.276	Inj. Fondaparinux Sod. PFS 2.5mg/ 0.5ml	PFS	50
1.277	MDI Formoterol fumarate and budesonide inhaler 6 mcg+ 200 mcg/dose(One Bottle Contains 120 Doses)	Bottle	113
1.278	Inj. Fosaprepitant 150mg/ vial	Vial/Amp.	1425
1.279	Inj. Fosfomycine 4gm/vial	Vial/Amp.	173
1.280	Inj. Fosnetupitant + Palonosetron 235 mg + 0.25 mg/ 20ml	Vial/Amp.	200
1.281	Inj. Fosphenytoin 150 mg/ 2 ml	Vial/Amp.	375
1.282	Inj. Frusemide 20 mg/ 2 ml	Vial/Amp.	24000
1.283	Inj. Fulvestrant 250mg/5ml	Vial/Amp.	50
1.284	Inj. Gadobutrol Solution 100 ml	Vial/Amp.	150
1.285	Inj. Gadobutrol Solution 50 ml	Vial/Amp.	150
1.286	Inj. Gadobutrol Solution 20 ml	Vial/Amp.	150
1.287	Inj. Gadobutrol Solution 10 ml	Vial/Amp.	150
1.288	Inj. Ganciclovir 500 mg/ vial	Vial/Amp.	188
1.289	Inj. Gemcitabine 500 mg	Vial/Amp.	1350
1.290	Inj. Gemcitabine 200 mg	Vial/Amp.	1350
1.291	Inj. Gemcitabine 1 g	Vial/Amp.	1125
1.292	Inj. Gentamicin 40mg/ml 2ml	Vial/Amp.	27000
1.293	Inj. Glucagon 1mg/ml	Vial/Amp.	188
1.294	Inj. Glutathione 600 mg	Vial/Amp.	200
1.295	Inj. Glycine 1.5% (Plastic) 3000 ml	Bottle	300
1.296	Inj. Glycopegylated recombinant factor VIII 500 IU	PFS	20
1.297	Inj. Glycopyrolate 0.2mg/ 1 ml	Vial/Amp.	3375
1.298	Inj. Glycopyrolate 0.5 mg + neostigmine methylsulphate 2.5 mg 0.5 mg + 2.5 mg/ 5 ml	Vial/Amp.	4125
1.299	Inj. Golimumab 50 mg/ ml	PFS	15
1.300	Inj. Goserelin 10.8mg/ Injection	PFS	20
1.301	Inj. Granisetron 3mg/3ml	Vial/Amp.	375
1.302	Inj. Haemocoagulase 1cu/ml	Vial/Amp.	50
1.303	Inj. Haloperidol 5 mg/ ml	Vial/Amp.	2625
1.304	Inj. Haloperidol decanoate LA 100 mg/ ml	Vial/Amp.	500
1.305	Inj. Haloperidol decanoate LA 50 mg/ ml	Vial/Amp.	1350
1.306	Inj. Hemophilus Influenza B Conjugated Vaccine 10mcg/1ml	Vial/Amp.	338
1.307	Inj. Heparin 25000 IU/ 5ml	Vial/Amp.	1650
1.308	Inj. Heparin 5000 IU/ 5 ml	Vial/Amp.	1350
1.309	Inj. Hepatitis B Immunoglobin vaccine 100IU/ Vial	Vial/Amp.	1350
1.310	Inj. Hepatitis B Vaccine (rDNA) (20mcg) + Aluminium Hydroxide (0.5mg) + Thiomersal (0.05mg) 10 ml/ vial	Vial/Amp.	2625
1.311	Inj. Heplock (Heparin lock flush solution) 10U/ml (10 ml)	Vial/Amp.	100
1.312	Inj. Herpes zoaster vaccine 0.5 ml	Vial/Amp.	50
1.313	Inj. Highly Purified Chorionic Gonadotrophin 5000 IU	Vial/Amp.	300

1.314	Inj. Highly purified chorionic Gonadotropin 250 IU	Vial/Amp.	300
1.315	Inj. Human Albumin 20% 20 gm/ 100 ml	Vial/Amp.	300
1.316	Inj. Human Albumin 5% 5 gm/ 100ml	Vial/Amp.	1125
1.317	Inj. Human Albumin extra purified 20% 20 gm/ 100ml	Vial/Amp.	1350
1.318	Inj. Human Albumin Low salt 20% 20 gm/ 100 ml	Vial/Amp.	900
1.319	Inj. Human Aspart 100IU/ml	Vial/Amp.	150
1.320	Inj. Human Biphasic Isophane Insulin 50/50 vial 40 IU/ml	Vial/Amp.	150
1.321	Inj. Human Chorionic Gonadotropin (HCG) (Uriniary) highly purified 10000IU 10000 IU	Vial/Amp.	150
1.322	Inj. Human Chorionic Gonadotropin Recombinant HCG 5000 IU	Vial/Amp.	150
1.323	Inj. Human growth Hormone 4-12mg	Vial/Amp.	188
1.324	Sachet Human Milk Fortefier 1g	Sachet	3300
1.325	Inj. human normal immunoglobulin (IVIG) 10 gm (10%) 10 gm/ 100 ml	Vial/Amp.	900
1.326	Inj. Human normal immunoglobulin (IVIG) 5 gm (5%) 5gm/ 100ml	Vial/Amp.	750
1.327	Inj. Human normal immunoglobulin extra purified (IVIG) 5 gm (5%) 5 gm/ 100 ml	Vial/Amp.	600
1.328	Inj. Human Tetnus Immunoglobulins 500 IU/ Vial	Vial/Amp.	1125
1.329	Inj. Hydralazine Hydrochloride 20mg / 1ml	Vial/Amp.	500
1.330	Inj. Hydrocortisone Sodium 100 mg/ Vial	Vial/Amp.	3375
1.331	Inj. Hydroxocobalamin 1 mg/ 1 ml	Vial/Amp.	1875
1.332	Inj. hydroxyethyl starch (HES) 6% solution 6 % w/v ,500 ml	Bottle	1425
1.333	Inj. Hydroxyl Propyl Methylcellulose with PFS 2% W/V 2ml	Vial/Amp.	150
1.334	Inj. Hydroxyprogesteron 500 mg/ 2 ml	Vial/Amp.	1127
1.335	Inj. Hyoscine butyl bromide 20mg/ampule	Vial/Amp.	4125
1.336	Inj. Ibuprofen I.V. Infusion 400mg/ 100ml	Vial/Amp.	1575
1.337	Inj. Idarubicin 5mg/ Vial	Vial/Amp.	20
1.338	Inj. Idarubicin 20 mg/ Vial	Vial/Amp.	20
1.339	Inj. Ifosfamide with Mesna 2gm	Vial/Amp.	200
1.340	Inj. Ifosfamide with Mesna 1gm	Vial/Amp.	200
1.341	Inj. Imipenem + Cilastatin 500 mg + 500 mg	Vial/Amp.	900
1.342	Inj. Indocyanine green 25mg/ Vial	Vial/Amp.	1125
1.343	Inj. Indomethacin 1mg/ vial	Vial/Amp.	750
1.344	Inj. Infliximab 100 mg/ Vial	Vial/Amp.	20
1.345	Inj. Influenza vaccine 0.5 ml	PFS	413
1.346	Inj. Injection Implant for the treatment of Vesicoureteral reflux(VUR) }, suspension of dextranomer microparticles and cross- linked hyaluronic acid of non-animal origin NA	Vial/Amp.	20
1.347	Inj. Insulin asprart 100IU/ml	Vial/Amp.	750
1.348	Inj. Insulin glargine 100 IU/ml (3 ml)	Vial/Amp.	1125
1.349	Inj. Insulin isophane/NPH 70% + Human insulin soluble 30% 40IU/ml	Vial/Amp.	1125
1.350	Inj. Insulin NPH 40 IU/ml	Vial/Amp.	1275
1.351	Inj. Insulin soluble Regular 40 IU/ml	Vial/Amp.	1350
1.352	Inj. Interferon alpha 2b 3 MIU	Vial/Amp.	20
1.353	Inj. Interferon Beta 1a 44 mcg/ 0.5 ml	Vial/Amp.	20
1.354	Inj. Intralipid phospholipids 20% Soybean oil + MCT + Olive oil + Fish oil, 500 ml	Bottle	600
1.355	Inj. Intralipid phospholipids 20% Soybean oil + MCT + Olive oil + Fish oil, 250 ml	Bottle	563
1.356	Inj. Intralipid phospholipids 20% Soybean oil + Egg phospholipids + Glycerol, 250 ml	Bottle	563
1.357	Inj. Intralipid phospholipids 20% Soybean oil + MCT + Olive oil + Fish oil, 100 ml	Bottle	525
1.358	Inj. Intralipid phospholipids 20% Soybean oil + Egg phospholipids + Glycerol, 100 ml	Bottle	375
1.359	Inj. Intravenous Glutamine in Dipeptide Base N (2) L-Alanyl-L-Glutamine concentrate 20% solution. Dipeptide of N(2) Alanyl glutamin 100 ml	Vial/Amp.	200
1.360	Inj. Iodixanol Injection USP 755 mg or 350 mgI/ml, 100 ml	Vial/Amp.	150
1.361	Inj. Iohexol Injection USP 755mg or 350mgI/ml, 100 ml	Vial/Amp.	150
1.362	Inj. Iohexol Injection USP 755mg or 350mgI/ml, 50 ml	Vial/Amp.	150
1.363	Inj. Iohexol Injection USP 755mg or 350mgI/ml, 20 ml	Vial/Amp.	150
1.364	Respules Ipratropium 500 mcg/ 2 ml	Respules	3825
1.365	Respules Ipratropium 500 mcg + Levosalbutamol 1.25 mg 500mcg + 1.25mg/ 2.5ml	Respules	3450
1.366	MDI Ipratropium bromide and levosalbutamol inhaler 20 mcg+ 50 mcg/dose(One Bottle Contains 120 Doses)	Bottle	200
1.367	inhalation Solution Ipratropium Respirator solu. For nebulisers 15 ml	Bottle	600
1.368	Inj. Irinotecan 40 mg/ Vial	Vial/Amp.	600
1.369	Inj. Irinotecan 100 mg/ vial	Vial/Amp.	600
1.370	Inj. Iron isomaltoside 1000 mg/ 10 ml	Vial/Amp.	900
1.371	Inj. Iron sucrose 20 mg/ ml 5 ml	Vial/Amp.	750
1.372	Inj. Isoflurane 250 ml	Bottle	450
1.373	Inj. Isoprenaline 2mg/ 1 ml	Vial/Amp.	240
1.374	Inj. Isotonic Balanced Crystalloid Solution (Na+ 140 -150 mmol / lit , K+ 3.5 - 4.5	Vial/Amp.	188

	mmol / lit, Ca2+ 2 - 3 mmol / lit, Mg2+ 1 mmol / lit, Cl- 125 - 130 mmol/ lit, Acetate 20 - 25 mmol / lit , Malate 5 mmol / lit & Osmolarity 290 – 310 mmol / lit) in PVC and DEHP free 500 ml container Isotonic Balanced Crystalloid Solution (Na+ 140 - 150 mmol / lit , K+ 3.5 - 4.5 mmol / lit, Ca2+ 2 - 3 mmol / lit,mg2+ 1 mmol / lit, Cl- 125 - 130 mmol/ lit, Acetate 20 - 25 mmol / lit , Malate 5 mmol / lit & Osmolarity 290 – 310		
1.375	Sachet Ispaghula Granules 5gm	Sachet	1500
1.376	Inj. Ixabepilone 45 mg/ Vial	Vial/Amp.	20
1.377	Inj. Ketamine 500 mg/ 10 ml	Vial/Amp.	1500
1.378	Inj. Ketorolac 60 mg/ 2 ml	Vial/Amp.	188
1.379	Inj. Labetalol 20 mg/ 4 ml	Vial/Amp.	3375
1.380	Inj. Lacosamide (10 mg/ml) 20ml	Vial/Amp.	100
1.381	Inj. Lactate Free CRRT Fluid (Biphozyle) 0.5%, 4ml	Vial/Amp.	100
1.382	Sachet lactic Acid Bacillus Sachet 1g	Sachet	2175
1.383	Inj. L-Alanyl-L-Glutamine 50 ml	Bottle	100
1.384	Inj. L-Alanyl-L-Glutamine (stable glutamine dipeptide) 100 ml	Bottle	100
1.385	Inj. L-Asparaginase 10000 IU	Vial/Amp.	263
1.386	Inj. L-CARNITINE 1 gm/5 ml	Vial/Amp.	200
1.387	Inj. Leucovorin 50mg/ 5ml	Vial/Amp.	450
1.388	Inj. leuprolide 22.5 mg	PFS	20
1.389	Inj. Leuprolide 3.75 mg	PFS	150
1.390	Inj. Leuprolide 11.25 mg	PFS	188
1.391	Inj. Levetiracetam 500 mg/ 5 ml	Vial/Amp.	1650
1.392	Inj. LEVOBUPIVACAINE (hyperbaric), preservative free 0.5%, 4 ml	Vial/Amp.	100
1.393	Inj. LEVOBUPIVACAINE (isobaric) 0.5%, 4 ml	Vial/Amp.	100
1.394	Inj. LEVOBUPIVACAINE (isobaric) 0.25%, 20 ml	Vial/Amp.	100
1.395	Inj. LEVOBUPIVACAINE (isobaric) 0.50%, 20 ml	Vial/Amp.	100
1.396	Inj. Levofloxacin 500 mg/ 100ml	Vial/Amp.	300
1.397	Respules Levosalbutamol 1.25 mg/2.5ml	Respules	4200
1.398	Inj. Levosimendan 12.5 mg/ Vial	Vial/Amp.	1500
1.399	Inj. Levosulpiride 25 mg/ 2ml	Vial/Amp.	200
1.400	Inj. Lignocaine (preservative free) 2% , 20 ml vial	Vial/Amp.	1275
1.401	Inj. Lignocaine 4 % 4%,30 ml	Vial/Amp.	600
1.402	Inj. Lignocaine HCl 2% with Adrenaline (0.005 mg to 0.0125 mg) 30 ml/vial	Vial/Amp.	1275
1.403	Inj. Lignocaine heavy 5% 5%, 2 ml	Vial/Amp.	375
1.404	Inj. Lignocaine Hydrochloride with preservative 2% , 20 ml vial	Vial/Amp.	1463
1.405	Inj. Lignocaine Spray 10%, 50 ml	Bottle	450
1.406	Inj. Linezolid 600 mg/ 300 ml	Vial/Amp.	4500
1.407	Inj. Lipid Emulsion 10% containing Soyabean Oil, Egg Phospholipid 500 ml 500 ML	Bottle	375
1.408	Inj. Lipid emulsion 20% 50 ml	Bottle	300
1.409	Inj. Lipid Emulsion 20% containing Soyabean Oil, Egg Phospholipid 100 ml 100 ml	Bottle	413
1.410	Inj. Lipid Emulsion 20% containing Soyabean Oil, Egg Phospholipid 250 ml 250 ml	Bottle	413
1.411	Inj. Lipid Emulsion 20% containing Soyabean Oil, Egg Phospholipid 500 ml 500 ml	Bottle	450
1.412	Inj. Lipid emulsion containing 10% fish oil with a high percentage of ω-3 fatty acids 50 ml	Bottle	413
1.413	Inj. Liraglutide 18mg/3 ml	Vial/Amp.	20
1.414	Inj. Lorazepam 4mg /amp	Vial/Amp.	4125
1.415	Inj. Magnesium sulphate 50%, 2ml	Vial/Amp.	4800
1.416	Inj. Mannitol 20% w/v, 100ml	Bottle	3000
1.417	Inj. Medroxyprogesterone 150mg/ml 1ml	Vial/Amp.	100
1.418	Inj. Meglumine Gadoterate Injection 0.5mmol/ml 376.9 mg/ml, 20 ml	Vial/Amp.	150
1.419	Inj. Meglumine Gadoterate Injection 0.5mmol/ml 376.9 mg/ml, 10 ml	Vial/Amp.	150
1.420	Inj. Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Quadrivalent ACYW 135 vaccine 0.5ml	Vial/Amp.	450
1.421	Inj. Menotrophin Urinary Gonadotropin FSH and LH 75 IU/vial	Vial/Amp.	188
1.422	Inj. Mephentermine 30 mg/ ml, (10 ml)	Vial/Amp.	3000
1.423	Inj. Meropenem 500 mg/ vial	Vial/Amp.	3000
1.424	Inj. Meropenem 1 g/ vial	Vial/Amp.	4125
1.425	Inj. Meropenem 125 mg/ vial	Vial/Amp.	1875
1.426	Inj. Meropenem+ Sulbactum 1000 mg + 500 mg	Vial/Amp.	2625
1.427	Inj. Mesna 200 mg/ 2 ml	Vial/Amp.	225

1.428	Inj. Methadone 10mg/ml	Vial/Amp.	500
1.429	Inj. Methotrexate 50 mg/ 2 ml	Vial/Amp.	338
1.430	Inj. Methotrexate 15 mg/ 3 ml	Vial/Amp.	338
1.431	Inj. Methotrexate 25 mg/ 3 ml	Vial/Amp.	300
1.432	Inj. Methotrexate 20 mg/ 3 ml	Vial/Amp.	300
1.433	Inj. Methylcobalamine 1000 mcg/ Amp	Vial/Amp.	3375
1.434	Inj. Methylcobalamine 500 mcg/ Amp	Vial/Amp.	1875
1.435	Inj. Methylene blue 10 mg/ml	Vial/Amp.	100
1.436	Inj. Methylergometrine 0.2mg/ml	Vial/Amp.	188
1.437	Inj. Methylprednisolone 500 mg/ Vial	Vial/Amp.	2700
1.438	Inj. Methylprednisolone 40 mg/ Vial	Vial/Amp.	900
1.439	Inj. Metoclopramide 10 mg/ 2 ml	Vial/Amp.	2625
1.440	Inj. Metoprolol tartrate 5 mg/ 5 ml	Vial/Amp.	2625
1.441	Inj. Metronidazole 500 mg/ 100 ml	Vial/Amp.	5100
1.442	Inj. Micafungin 100 mg/ vial	Vial/Amp.	225
1.443	Inj. Micronised Progesterone 100 mg/ 2ml	Vial/Amp.	300
1.444	Inj. Midazolam 10 mg/ 10 ml	Vial/Amp.	1800
1.445	Inj. Milrinone 10 mg/ 10 ml	Vial/Amp.	195
1.446	Inj. Mitomycin 2 mg/ vial	Vial/Amp.	600
1.447	Inj. Mitomycin 10 mg/ vial	Vial/Amp.	563
1.448	Inj. Moxifloxacin HCL 400 mg/ 100 ml	Vial/Amp.	525
1.449	Inj. Multivitamin injection 10 ml	Vial/Amp.	6750
1.450	Inj. Nab- Paclitaxel (Albumin bound paclitaxel) 100 mg/ Vial	Vial/Amp.	600
1.451	Inj. Nalbuphine hydrochloride 10 mg/ 1 ml	Vial/Amp.	200
1.452	Inj. Naloxone HCl 400 mcg/ 1 ml	Vial/Amp.	495
1.453	Inj. Nanopaclitaxel 300 mg/ Vial	Vial/Amp.	20
1.454	Inj. Neostigmine 2.5 mg/ 5 ml	Vial/Amp.	20
1.455	Inj. Netilmicin 300 mg/ 3 ml	Vial/Amp.	100
1.456	Inj. Nicardipine 10 mg/ 10 ml	Vial/Amp.	195
1.457	Inj. Nicorandil 48 mg/ vial	Vial/Amp.	300
1.458	patch nicotine patch 21 mg	patch	188
1.459	patch nicotine patch 14 mg	patch	188
1.460	patch nicotine patch 7 mg	patch	188
1.461	Inj. Nimodipine 10 mg/ 50 ml	Vial/Amp.	1500
1.462	Inj. Nitroglycerine/Glyceryl Trinitrate 25 mg/ 5 ml	Vial/Amp.	1125
1.463	Inj. Nivolumab 40 mg	Vial/Amp.	20
1.464	Inj. Noradrenaline bitartrate 4mg/ 2 ml	Vial/Amp.	8250
1.465	Inj. Octreotide 50 mcg/ 1 ml	Vial/Amp.	200
1.466	Inj. Octreotide 100 mcg/ 1ml	Vial/Amp.	200
1.467	Inj. Octreotide LAR 30mg/vial	Vial/Amp.	50
1.468	Inj. Ofloxacin 200 mg/ 100 ml	Vial/Amp.	420
1.469	Inj. Olanzapine 10 mg/ vial	Vial/Amp.	300
1.470	Inj. Olanzapine long acting 210 mg/ vial	Vial/Amp.	300
1.471	Inj. Olanzapine long acting 300 mg/ vial	Vial/Amp.	300
1.472	Inj. Olanzapine long acting 405 mg/ vial	Vial/Amp.	300
1.473	Inj. Omalizumab 150 mg/ vial	PFS	53
1.474	Inj. Omega 3 fatty acid, fish oil fat emulsion (EPA, DHA) 50 ml/ bottle	Bottle	100
1.475	Inj. Ondansetron 8 mg/ 4ml	Vial/Amp.	6750
1.476	Sachet Oral Rehydration Salts 21.8g	Sachet	3750
1.477	Inj. Ornidazole + Ofloxacin 500 mg + 200 mg/ 100ml	Vial/Amp.	900
1.478	Inj. Ornithine L Aspartate (L-Ornithine aspartate) 10 ml amp or 5gm/10ml	Vial/Amp.	188
1.479	Inj. Oxaliplatin 100 mg/ vial	Vial/Amp.	1275
1.480	Inj. Oxaliplatin 50 mg/ vial	Vial/Amp.	1275
1.481	Inj. Oxytocin 5 IU/ 1 ml	Vial/Amp.	4125
1.482	Inj. Paclitaxel 260 mg/ vial	Vial/Amp.	525
1.483	Inj. Paclitaxel 100 mg/ vial	Vial/Amp.	675
1.484	Inj. Palliperidone 150 mg	Vial/Amp.	20
1.485	Inj. Palliperidone 100 mg	Vial/Amp.	20
1.486	Inj. Palliperidone 75 mg	Vial/Amp.	20
1.487	Inj. Palonosetron 0.25 mg/ 5 ml	Vial/Amp.	200
1.488	Inj. Pamidronate 60 mg/ vial	Vial/Amp.	200
1.489	Inj. Pantoprazole 40 mg/ vial	Vial/Amp.	17250
1.490	Inj. Papaverine 60 mg/ 2ml	Vial/Amp.	200
1.491	Inj. Paracetamol 150 mg/ ml (2 ml)	Vial/Amp.	825
1.492	Suppository Paracetamol 80 mg	Suppository	225
1.493	Suppository Paracetamol 250 mg	Suppository	225
1.494	Suppository Paracetamol 500 mg	Suppository	225
1.495	Inj. Paracetamol 1 gm/ 100 ml	Bottle	8700

1.496	Inj. Pertuzumab and trastuzumab 1200/600 mg	SC Vial/ Amp	5
1.497	Inj. Pertuzumab and trastuzumab 600/600 mg	SC Vial/ Amp	5
1.498	Inj. PEG L -ASPARGINASE 1500 IU 1500 IU/2ml	PFS	300
1.499	Inj. PEG L ASPARGINASE 3750 IU 3750 IU/5ml	PFS	300
1.500	Inj. Pegfilgrastim 6mg/0.6ml	PFS	338
1.501	Inj. Peginterferon alfa 2b 80 mcg/0.5ml	PFS	188
1.502	Inj. Pegylated- Asparaginase (Peg L Asparaginase) 750 Iu/ ml 5ml	PFS	563
1.503	Inj. Pemetrexed 500 mg/ vial	Vial/Amp.	300
1.504	Inj. Pemetrexed 100 mg/ vial	Vial/Amp.	300
1.505	Inj. Penicillin G 5 Lac IU/vial	Vial/Amp.	420
1.506	Inj. Pentazocine 30 mg/ 1 ml	Vial/Amp.	450
1.507	Inj. Pheniramine 45.5 mg/ 2ml	Vial/Amp.	600
1.508	Inj. Phenoxybenzamine 100 mg/ 2ml	Vial/Amp.	600
1.509	Inj. Phentolamine 10 mg/ 1 ml	Vial/Amp.	600
1.510	Inj. Phenylephrine 500 mcg/ 10 ml	Vial/Amp.	100
1.511	Inj. Phenytoin 100 mg/ 2 ml	Vial/Amp.	3600
1.512	Inj. Physostigmine 2 mg/ 2 ml	Vial/Amp.	210
1.513	Inj. Piperacillin 1 g +Tazobactam 125 mg 1 g + 125 mg/vial	Vial/Amp.	3000
1.514	Inj. Piperacillin 4 g +Tazobactam 500 mg 4 g + 500 mg/vial	Vial/Amp.	6750
1.515	Inj. Piroxicam 40 mg/ 2 ml	Vial/Amp.	200
1.516	Inj. Plasma-derived High Purity Coagulation factor IX 500 IU/ml	Bottle	20
1.517	Inj. Plerixafor 24 mg/ Vial	Vial/Amp.	20
1.518	Inj. Pneumococcal Polysaccharide Conjugate Vaccine (adsorbed) I.P, 13-valent 0.5 mL	PFS	100
1.519	Inj. Pneumococcal Polysaccharide conjugate Vaccine (adsorbed) I.P., 20-valent 0.5 mL	PFS	100
1.520	Inj. Polidocanol 60 mg/ 2 ml (3 %)	Vial/Amp.	20
1.521	Poly ethlene glycol 3350 powder 119 gm	Bottle	20
1.522	Inj. Polymyxine –B Sulphate 500000 IU	Vial/Amp.	200
1.523	Inj. Polysaccharide Typhoid 0.5 ml	Vial/Amp.	420
1.524	Inj. Poractant alpha (intratracheal solution) 3 ml	Vial/Amp.	20
1.525	Inj. Poractant alpha (intratracheal solution) 1.5 ml	Vial/Amp.	20
1.526	Inj. Posaconazole 300 mg/ 16.7 ml	Vial/Amp.	100
1.527	Inj. Potassium chloride 20 mEq/ 10 ml	Vial/Amp.	3188
1.528	Inj. Potassium phosphate 15 ml	Vial/Amp.	500
1.529	Inj. Pralidoxime chloride 500 mg/ vial	Vial/Amp.	338
1.530	Inj. Prednisolone 20 mg/ 2 ml	Vial/Amp.	188
1.531	Inj. Procainamide 1 gm/ 10 ml	Vial/Amp.	375
1.532	Inj. Procaine penicillin 6 lac U 6 lac IU	Vial/Amp.	375
1.533	Inj. Prochlorperazine 12.5 mg 12.5 mg/ 1 ml	Vial/Amp.	2175
1.534	Inj. Promethazine Hydrochloride 50 mg/ 2 ml	Vial/Amp.	1650
1.535	Inj. Propofol 1% (100 mg/10 ml) in a 50:50 physical mixture of MCT and LCT with Sodium Oleate as an excipient and presented in a 10 ml glass ampoule. 10ml	Vial/Amp.	1350
1.536	Inj. Propofol 1% (200 mg/20 ml) in a 50:50 physical mixture of MCT and LCT with Sodium Oleate as an excipient and presented in a 20 ml glass ampoule. 20ml	Vial/Amp.	1125
1.537	Inj. Propofol 1% (500 mg/50 ml) in a 50:50 physical mixture of MCT and LCT with Sodium Oleate as an excipient and presented in a 50 ml glass vial. 50ml	Vial/Amp.	20
1.538	Inj. Propranolol 1mg/ 1 ml	Bottle	500
1.539	Inj. Prostaglandin E1 500 mcg/1ml	PFS	135
1.540	Inj. Protamine Insulin 70%:30%, 100iu/ml	Vial/Amp.	20
1.541	Inj. Protamine sulphate 50 mg/ 5 ml	Vial/Amp.	263
1.542	Inj. Prothrombin Complex Factor 500 IU	Vial/Amp.	20
1.543	Inj. Pyridoxine 200 mg/ 2 ml	Vial/Amp.	150
1.544	Inj. Quinine 600 mg/ 2 ml	Vial/Amp.	188
1.545	Inj. Quinupristin and Dalfopristin 150 mg+350 mg/vial	Vial/Amp.	20
1.546	Inj. Rabies Human Monoclonal Antibodies(rDna) 100 IU 2.5 ml	Vial/Amp.	200
1.547	Inj. Rabies Human Monoclonal Antibodies(rDna) 50 IU 1.25 ml	Vial/Amp.	20
1.548	Inj. Ranibizumab 10 mg/ ml	Vial/Amp.	20
1.549	Inj. Ranitidine 50 mg/ 2ml	Vial/Amp.	375
1.550	Inj. Rec. Haemophilic factor-IX 1000 IU	Vial/Amp.	20
1.551	Inj. Rec. Haemophilic factor-VIII 250 IU	Vial/Amp.	20
1.552	Inj. Recombinant Coagulation factor – IX 1000 IU	Vial/Amp.	20
1.553	Inj. Recombinant Coagulation factor – IX 500 IU	Vial/Amp.	20
1.554	Inj. Recombinant Coagulation factor – IX 250 IU	Vial/Amp.	20
1.555	Inj. Recombinant Factor VII 2mg	Vial/Amp.	20
1.556	Inj. Recombinant Factor VII 1mg	Vial/Amp.	20
1.557	Inj. RECOMBINANT FACTOR VII (ACTIVATED) 2mg	Vial/Amp.	200
1.558	Inj. Recombinant FSH (Follitropin a b) Multidose vials 75 IU	Vial/Amp.	200

1.559	Inj. Recombinant FSH (Follitropin a b) Multidose vials 150 IU	Vial/Amp.	20
1.560	Inj. RECOMBINANT HUMAN ANTI-HEMOPHILIC FACTOR IX CONCENTRATE 600iu	Vial/Amp.	20
1.561	Inj. RECOMBINANT HUMAN ANTI-HEMOPHILIC FACTOR VIII CONCENTRATE 250 iu	Vial/Amp.	100
1.562	Inj. Recombinant Human Growth Hormone (rHGH) 4IU/ Vial	Vial/Amp.	50
1.563	Inj. Remdesivir 100 mg/ vial	Vial/Amp.	500
1.564	Inj. Reteplase 18 mg/ vial	Vial/Amp.	20
1.565	Inj. Ribavirin 100 mg/ 1 ml	Vial/Amp.	150
1.566	Inj. Rifampicin 600 mg/ vial	Vial/Amp.	338
1.567	Inj. Risperidone 50 mg	Vial/Amp.	360
1.568	Inj. Risperidone 25 mg	Vial/Amp.	360
1.569	Inj. Risperidone Long Acting 50 mg	Vial/Amp.	300
1.570	Inj. Risperidone Long Acting 25 mg	Vial/Amp.	300
1.571	Inj. Ritodrine hydrochloride 50 mg/ 5ml	Vial/Amp.	135
1.572	Inj. Rituximab 100 mg/ 10ml	Vial/Amp.	600
1.573	Inj. Rituximab 500 mg/ 50ml	Vial/Amp.	750
1.574	Patch Rivastigmine 9.5mg/24 H	Patch	300
1.575	Patch Rivastigmine 4.6mg/24 H	Patch	300
1.576	Inj. Rocuronium Bromide 50 mg/ 5 ml	Vial/Amp.	1388
1.577	Inj. Romiplostim 250 mcg/ Vial	Vial/Amp.	20
1.578	Inj. Ropivacaine 0.2% 2 mg/ ml, 20 ml	Vial/Amp.	128
1.579	Inj. Ropivacaine 0.2% 2 mg/ml, 20 ml	Vial/Amp.	210
1.580	Inj. Ropivacaine 0.5% 5 mg/ml, 20 ml	Vial/Amp.	188
1.581	Inj. Ropivacaine 0.75% 7.5 mg/ml, 20 ml	Vial/Amp.	188
1.582	inhalation Solution Salbutamol 50 ml	Bottle	375
1.583	inhalation Solution Salbutamol 15 ml	Bottle	375
1.584	MDI Salbutamol MDI 100 mcg/dose(One Bottle Contains 200 Doses)	Bottle	500
1.585	MDI Salmeterol and fluticasone propionate IP 25 mcg+ 125 mcg/dose(One Bottle Contains 120 Doses)	Bottle	135
1.586	Inj. Sargramostim 250 mcg	Vial/Amp.	20
1.587	Inj. Serplulimab 100 mg	Vial/Amp.	20
1.588	Inj. Sevoflurane 250 ml	Bottle	165
1.589	Inj. Sildenafil 10 mg/ 12.5 ml	Vial/Amp.	500
1.590	Granules Soda Lime Granules 5KG	Can	900
1.591	Granules Sodium benzoate 500 gm	Can	500
1.592	Granules Sodium acid phosphate 3.2 g	Sachet	500
1.593	Inj. Sodium bicarbonate 8.4 %/ 25 ml	Vial/Amp.	1050
1.594	Inj. Sodium bicarbonate 7.5 %/ 10 ml	Vial/Amp.	1650
1.595	Inj. Sodium hyaluronate 1.5% w/v	PFS	20
1.596	Inj. Sodium Nitrite 300 mg/ 10 ml	Vial/Amp.	500
1.597	Inj. Sodium nitroprusside 50 mg/ vial	Vial/Amp.	1650
1.598	Inj. Sodium phenyl acetate 10% 50ml	Vial/Amp.	750
1.599	Inj. Sodium Thiosulphate 250 mg/ ml (50ml)	Vial/Amp.	750
1.600	Inj. Sodium valproate 500 mg/ 5 ml	Vial/Amp.	413
1.601	Inj. Somatrogon 60 mg/ 1.2 mL	PFS	20
1.602	Inj. Somatrogon 24 mg/ 1.2 mL	PFS	20
1.603	Inj. Streptokinase 15,00,000 IU/vial 5ml	Vial/Amp.	413
1.604	Inj. Streptomycin 1 gm/ vial	Vial/Amp.	1425
1.605	Inj. Succinyl choline 500 mg/ 10 ml	Vial/Amp.	900
1.606	Inj. SUGAMADEX 100 mg/ ml, 2ml	Vial/Amp.	150
1.607	Inj. Sulbactam 2gm	Vial/Amp.	210
1.608	Inj. Sulbactum 1gm	Vial/Amp.	210
1.609	Inj. Sulfamethoxazole And Trimethoprim 80 + 400 mg/ 5ml	Vial/Amp.	338
1.610	Inj. Tedizolid 200 mg/ vial	Vial/Amp.	113
1.611	Inj. Teicoplanin 400mg/vial	Vial/Amp.	20
1.612	Inj. TEMSIROLIMUS 25 mg/ ml	Vial/Amp.	135
1.613	Inj. Tenecteplase 40 mg/ vial	Vial/Amp.	150
1.614	Inj. Tenecteplase 20 mg/ vial	Vial/Amp.	143
1.615	Inj. Terbutaline 0.5 mg/ ml	Vial/Amp.	188
1.616	Inj. Teriparatide 750 mcg/ 3 ml	Vial/Amp.	200
1.617	Inj. Terlipressin 1 mg/ 10 ml	Vial/Amp.	300
1.618	Inj. testosterone enanthate 250 mg/ 1 ml	Vial/Amp.	200
1.619	Inj. testosterone enanthate 1000 mg/ 4 ml	Vial/Amp.	200
1.620	Inj. Tetanus Immunoglobulin (Human) vial. 500 IU/vial	Vial/Amp.	338
1.621	Inj. Tetnus toxoid 0.5 ml/ Amp	Vial/Amp.	1650
1.622	Inj. Tetracosatide 250 mcg/ ml	Vial/Amp.	50
1.623	Inj. Thiamine Hydrochloride I.V./ I.M. 200 mg/ 2ml	Vial/Amp.	1125
1.624	Inj. Thiocolchicoside 4 mg/ 2ml	Vial/Amp.	20

1.625	Inj. Thiopentone 500 mg/ vial	Vial/Amp.	20
1.626	Inj. Thiotepa 15 mg/ vial	Vial/Amp.	50
1.627	Inj. Thiotepa 100 mg/ vial	Vial/Amp.	50
1.628	Inj. Thymosin Alpha 1 1.6 mg	Vial/Amp.	50
1.629	Inj. Ticarcillin and Clavulanic acid 3 gm + 100 mg	Vial/Amp.	300
1.630	Inj. Tigecycline 50 mg/ vial	Vial/Amp.	338
1.631	MDI Tiotropium bromide inhaler 9 mcg (One Bottle Contains 200 Doses)	Bottle	500
1.632	Inj. Tirofiban 5 mg/ 100ml	Vial/Amp.	20
1.633	Inj. Tobramycin 80 mg/ 2ml	Vial/Amp.	500
1.634	Inj. Topotecan 2.5 mg/ 2.5 ml	Vial/Amp.	500
1.635	Inj. Torsemide 20 mg/ 2 ml	Vial/Amp.	338
1.636	Inj. TPN 3 Chambered Bag containing Amino Acid 10% with Taurine, 4 oil combined lipid emulsion soyabean oil, MCT, Olive Oil and Fish oil, Glucose, Vitamine E, Zinc, Electrolytes and Nitrogen ratio for central infusion 1400-1500 ml	Bag	188
1.637	Inj. TPN 3 Chambered Bag containing Amino Acid 10% with Taurine, 4 oil combined lipid emulsion soyabean oil, MCT, Olive Oil and Fish oil, Glucose, Vitamine E, Zinc, Electrolytes and Nitrogen ratio for central infusion 900 – 1000 ml	Bag	188
1.638	Inj. TPN 3 Chambered Bag containing Amino Acid 10% with Taurine, 4 oil combined lipid emulsion soyabean oil, MCT, Olive Oil and Fish oil, Glucose, Vitamine E, Zinc, Electrolytes and Nitrogen ratio for Peripheral infusion 1000-1250 ml	Bag	188
1.639	Inj. TPN 3 Chambered Bag containing Amino Acid 10% with Taurine, 4 oil combined lipid emulsion soyabean oil, MCT, Olive Oil and Fish oil, Glucose, Vitamine E, Zinc, Electrolytes and Nitrogen ratio for Peripheral infusion 1400-1500 ml	Bag	188
1.640	Inj. Trabectidin 1 mg/ vial	Vial/Amp.	50
1.641	Inj. Trace elements 3ml/ vial	Vial/Amp.	500
1.642	Inj. Tramadol 100 mg/2ml	Vial/Amp.	20
1.643	Inj. Tranexamic acid 500 mg/ 5ml	Vial/Amp.	2925
1.644	Inj. Trastuzumab 150 mg/ vial	Vial/Amp.	150
1.645	Inj. Trastuzumab 440 mg/ vial	Vial/Amp.	360
1.646	Inj. Treosulfan 5 gm/ vial	Vial/Amp.	20
1.647	Inj. Triamcinolone acetonide 40 mg/1ml	Vial/Amp.	2925
1.648	Inj. Triptorelin 11.25 mg	Vial/Amp.	50
1.649	Inj. Triptorelin 3.75 mg	Vial/Amp.	50
1.650	Inj. Trypan Blue Dye 0.4%, 100ml	Vial/Amp.	180
1.651	Inj. Tuberculin purified protein derivative 5IU/0.1ml 5ml	Vial/Amp.	500
1.652	Inj. Ulinastatin 200000 IU/ Vial	Vial/Amp.	20
1.653	Inj. Ulinastatin 100000 IU/ Vial	Vial/Amp.	20
1.654	Inj. Urofillitropin 75 IU	Vial/Amp.	300
1.655	Inj. Urokinase 5000 IU/ Vial	Vial/Amp.	500
1.656	Inj. Urokinase 5,00,000 IU/ Vial	Vial/Amp.	500
1.657	Inj. Vaccine typhoid, Purified vi_capsular polysaccharide of salmonella typhi:25 mcg and conjugated to tetnus toxoid canier protein 16-50 mcg Purified vi_capsular polysaccharide of salmonella typhi:25 mcg and conjugated to tetnus toxoid canier protein 16-50 mcg	PFS	4650
1.658	Inj. Valethamate Bromide 8 mg/ vial	Vial/Amp.	11250
1.659	Inj. Valganciclovir 450 mg	Vial/Amp.	100
1.660	Inj. Vancomycin 500 mg/ vial	Vial/Amp.	750
1.661	Inj. Vancomycin 1000 mg/ vial	Vial/Amp.	750
1.662	Inj. Varicella Zoster Immunoglobulin vaccine 250 IU/vial	Vial/Amp.	100
1.663	Inj. Vasopressin IV/IM/SC 20 units/ 1ml	Vial/Amp.	3300
1.664	Inj. Vecuronium 10 mg	Vial/Amp.	1350
1.665	Inj. Vecuronium 4mg	Vial/Amp.	1125
1.666	Inj. Verapamil 5 mg/ 2 ml	Vial/Amp.	240
1.667	Inj. Vinblastin 10 mg/ 10ml	Vial/Amp.	270
1.668	Inj. Vincristine Sulphate 1 mg/ 1 ml	Vial/Amp.	345
1.669	Inj. Vinorelbine 50 mg/ 5 ml	Vial/Amp.	187.5
1.670	Inj. Vitamin A 600000 IU/ injection	Vial/Amp.	420
1.671	Inj. Vitamin B 12 2 ml	Vial/Amp.	375
1.672	Inj. Vitamin B complex 2 ml	Vial/Amp.	510
1.673	Inj. Vitamin C 1000 mg	Vial/Amp.	600
1.674	Inj. Vitamin D 6 L IU/ 1 ml	Vial/Amp.	1575
1.675	Inj. Vitamin K (Phytomenadione) 10 mg/ 1 ml	Vial/Amp.	2625
1.676	Inj. Vitamin K (Phytomenadione) 1 mg/ 0.5 ml	Vial/Amp.	3075
1.677	Inj. Voriconazole 200 mg/ vial	Vial/Amp.	150
1.678	Inj. Water for injection 10 ml	Vial/Amp.	1687.5
1.679	Inj. Zidovudine 200 mg/ 20 ml	Vial/Amp.	187.5
1.680	Inj. Zinc chloride 10 mg/ 10 ml	Vial/Amp.	172.5
1.681	Inj. Zoledronic acid 5 mg/100 ml	Vial/Amp.	500

1.682	Inj. Zoledronic acid 4 mg/ vial	Vial/Amp.	450
1.683	Inj. Zuclopenthixol acetate 50 mg/ 1 ml	Vial/Amp.	500
1.684	Inj. Zuclopenthixol Decanoate 200mg/vial	Vial/Amp.	200
1.685	IVF Balance Salt Solution 500 ML	Bottle	2000
1.686	Benzalkonium chloride 0.5% 500ml	Bottle	70
1.687	Boric acid + Chlorine 5 L	Can	100
1.688	Boric acid + Chlorine 400ML	Bottle	5000
1.689	Cetrimide IP 15% w/v + Isopropyl alcohol 6-8% v/v + Chlorhexidine gluconate solution 7.5% v/v 1 Litre	Bottle	8000
1.690	Chlorhexidine (2.5%)+ Ethyl Alcohol Handrub 5 Liter	Can	1500
1.691	Chlorhexidine (2.5%)+ Ethyl Alcohol Handrub with pump 500 ml	Bottle	12000
1.692	Chlorhexidine gluconate (4% w/v) surgical scrub 500 ml	Bottle	6000
1.693	Chloroxylenol 4.8% w/v 500 ml	Bottle	100
1.694	Citric Acid Solution 21 % Composition Citric Acid 21 % , Malic Acid & Lactic Acid as adjuvants Purified water, Disinfectant Liquid, 5 Litre	Can	50
1.695	IVF Dextran 40 in Normal saline (FFS) 500 ml	pcs	600
1.696	IVF Dextrose 10 % FFS , Single Port 500ml	Bottle	30000
1.697	IVF Dextrose 10 % , FFS, Twin Port 500ml	Bottle	5000
1.698	IVF Dextrose 10 % ,Glass Bottle, Double Port 500ml	Bottle	2000
1.699	IVF Dextrose 10 % ,Glass Bottle, Single Port 500ml	Bottle	2000
1.700	IVF Dextrose 25% FFS 100ml	Bottle	30000
1.701	IVF Dextrose 25% Glass 100ml	Bottle	2000
1.702	IVF Dextrose 5 % FFS , Single Port 500ml	Bottle	30000
1.703	IVF Dextrose 5 % , FFS, Twin Port 500ml	Bottle	2000
1.704	IVF Dextrose 5 % ,Glass Bottle, Double Port 500ml	Bottle	2000
1.705	IVF Dextrose 5 % ,Glass Bottle, Single Port 500ml	Bottle	2000
1.706	IVF Dextrose 50% FFS 100 ml	Bottle	800
1.707	IVF Dextrose 50% Glass 100 ml	Bottle	200
1.708	IVF Dextrose and Sodium Chloride DNS FFS, Single Port 500 ml, 5% +0.90 %	Bottle	30000
1.709	IVF Dextrose and Sodium Chloride DNS Glass, Single Port 500 ml, 5% +0.90 %	Bottle	2000
1.710	IVF Dextrose Saline N/2 (Dex.+Sod. Chloride) (FFS) 5gm + 0.45gm/100ml (500 ml) 500ml	Bottle	10000
1.711	IVF Dextrose Saline N/2 (Dex.+Sod.Chloride) 5gm+0.45gm/100ml (500 ml), Glass Bottle 500ml	Bottle	2000
1.712	IVF Dextrose Saline N/3 (Dex.+Sod. Chloride) 5gm+0.33gm/100ml (500 ml), Glass Bottle 500ml	Bottle	4000
1.713	IVF Dextrose Saline N/3 (Dex.+Sod. Chloride)(FFS) 5gm+0.33gm/100ml (500 ml) 500ml	Bottle	2000
1.714	IVF Dextrose Saline N/5 (Dex.+Sod. Chloride) 5gm+0.20gm/100ml (500 ml) FFS 500ml	Bottle	2000
1.715	IVF Dextrose Saline N/5 (Dex.+Sod. Chloride) 5gm+0.20gm/100ml (500 ml), Glass Bottle 500ml	Bottle	2000
1.716	IVF Distilled water, Glass Bottle 100 ml	Bottle	3000
1.717	IVF Distilled water, Glass Bottle 500ml	Bottle	3000
1.718	IVF Distilled water, Glass Bottle 3 L	Bottle	3000
1.719	IVF Distilled water, Plastic Container 100 ml	Bottle	3000
1.720	IVF Distilled water, Plastic Container 500ml	Bottle	8000
1.721	IVF Distilled water, Plastic Container 3 L	Bottle	3000
1.722	IVF Distilled water,Plastic Can 5L	CAN	500
1.723	Ethanol 70% w/v 500 ml	Bottle	3700
1.724	Ethanol 95% Ethanol 95% 1L	Bottle	700
1.725	Ethanol, 2-propanol (isopropanol), and 1-propanol 5 litre	Can	800
1.726	Ethanol, 2-propanol (isopropanol), and 1-propanol 250ml with spray	Bottle	1500
1.727	Fogger Solution 1litre	Bottle	2500
1.728	Formaldehyde 37-41% (5 Litre Can)	Bottle	1500
1.729	Formaldehyde Aqueous 10% 1 litre	Bottle	1500
1.730	Glacial acetic acid IP 400 ml	Bottle	1000
1.731	Glutaraldehyde solution 2.45% w/v 5 litres	Can	1800
1.732	Glycerin 100% w/v 400gm	Bottle	500
1.733	Glycine Irrigation Solution (FFS) 1.5% w/v 3000 ml	Bottle	1600
1.734	Hydrogen Peroxide 6% 400ML	Bottle	2500
1.735	Iodine Tincture 100 ml	Bottle	1200
1.736	Isopropyl alcohol based handsanitizer 70% w/v 5Litre	Can	2000
1.737	Isopropyl alcohol based handsanitizer with pump 70% w/v 500 ml	Bottle	800
1.738	Enema Lactulose enema 20% w/v 250 ml	Bottle	4000
1.739	Lugol‟s iodine IP 200 ml	Bottle	300
1.740	Lysol (50% cresol with soap solution) IP 10 Litres	Bottle	40
1.741	IVF Mannitol 20% Glass Bottle 100 ml	Bottle	1500

1.742	IVF Mannitol 20% Glass Bottle 350 ml	Bottle	1500
1.743	IVF Mannitol 20% Glass Bottle 500 ml	Bottle	1500
1.744	IVF Mannitol (FFS) 20% 100 ml	Bottle	12000
1.745	IVF Mannitol (FFS) 20% 350 ml	Bottle	6000
1.746	IVF Mannitol (FFS) 20% 500 ml	Bottle	2000
1.747	IVF Multielectrolyte in 5% Dextrose 500ml	Bottle/Bag	3000
1.748	IVF NORMAL SALINE ,FFS, Twin Port 0.9% 100ml	Bottle	1500
1.749	IVF NORMAL SALINE ,FFS, Twin Port 0.9% 500ml	Bottle	1500
1.750	IVF NORMAL SALINE ,FFS, Twin Port 0.9% 3 L	Bottle	500
1.751	IVF NORMAL SALINE Glass Bottle, Single Port 0.9% 100ml	Bottle	2000
1.752	IVF NORMAL SALINE Glass Bottle, Single Port 0.9% 500ml	Bottle	2500
1.753	IVF NORMAL SALINE Glass Bottle, Single Port 0.9% 3 L	Bottle	500
1.754	IVF NORMAL SALINE Glass Bottle, Twin Port 0.9% 100ml	Bottle	500
1.755	IVF NORMAL SALINE Glass Bottle, Twin Port 0.9% 500ml	Bottle	500
1.756	IVF NORMAL SALINE Glass Bottle, Twin Port 0.9% 3 L	Bottle	500
1.757	IVF Normal Saline Sodium Chloride 0.45% FFS 500ml	Bottle	10000
1.758	IVF Normal Saline Sodium Chloride 3 % FFS 100ml	Bottle	15000
1.759	IVF NORMAL SALINE, FFS, Single Port 0.9% 100ml	Bottle	100000
1.760	IVF NORMAL SALINE, FFS, Single Port 0.9% 500ml	Bottle	150000
1.761	IVF NORMAL SALINE, FFS, Single Port 0.9% 3 L	Bottle	15000
1.762	IVF Ortho-Phthaldehyde 0.55% 5 LTR	CAN	600
1.763	IVF Part A (Electrolyte Solution 10 L) Concentrated Acid Solution Composition Sodium Chloride 170G/L, Potassium Chloride 5.25G/L, Calcium Chloride 900G/L, Magnesium 5.50G/L, Acetic Acid 8.50 G/L, Glucose 35 G/L	Can	3000
1.764	Salt Part B (Sodium bicarbonate) Sodium Bicarbonate Part-B contains Sodium Bi-Carbonate 626G, Sodium Chloride 221G	Bag	6000
1.765	PD Solution 1.5 % (2000 ML) Sterile Non-Pyrogenic, Peritoneal Dialysis Solution Filled in Single soft Flexible Medical Grade, PVC Bag, Each 1000 ML contains dextrose equivalent to Dextrose mono Hydrate 15.0 G Sodium Chloride 5.38 Calcium Chloride 0.257 gm , Magnesium Chloride 0.0508 gm, sodium Lactate Solution, 4.48 gm water to injection 2000 ML	Can	1000
1.766	Salt Peritoneal dialysis fluid 2.5% 2 Litres 2.5 % 5 Liters	Pack	500
1.767	Povidone Iodine Scrub 7.5 % 500 ml	Pcs	3000
1.768	Povidone iodine solution 10% 500 ml	Bottle	12000
1.769	Povidone iodine solution 5% 500 ml	Bottle	12000
1.770	IVF Prismasol 5000 ml	Bottle	600
1.771	Enema Proctoglycerine enema 100 ml	Bottle	18000
1.772	IVF Ringer lactate FFS, Single Port 500 ml	Bottle	80000
1.773	IVF Ringer lactate Glass Single Port 500 ml	Bottle	15000
1.774	IVF Ringer Lactate FFS, Twin Port 500 ml	Bottle	5000
1.775	IVF Ringer Lactate Glass, Twin Port 500 ml	Bottle	2500
1.776	Sodium hypochlorite 5-6% 5 LTR	Can	2000
1.777	IVF Succinylated Gelatines 500ml	Bottle	2000
1.778	Surgical spirit IP 5 Litres	Can	800
1.779	Surgical spirit IP 500 ml	Bottle	800
1.780	Tincture benzoin compound 500 ml	Bottle	1000
1.781	Fentanyl 50 mcg/ml 2 ml	Ampoule	20000
1.782	Fentanyl 50 mcg/ml 10 ml	Ampoule	10000
1.783	Fentanyl patch 12.5 mcg/hr	Transdermal Patch	1000
1.784	Fentanyl patch 25 mcg/hr	Transdermal Patch	5000
1.785	Fentanyl patch 50 mcg/hr	Transdermal Patch	5000
1.786	Fentanyl patch 75 mcg/hr	Transdermal Patch	1000
1.787	Fentanyl patch 100 mcg/hr	Transdermal Patch	1000
1.788	Morphine Sulphate 10 mg/ml 1ml Preserverative Free	Amp	1000
1.789	Morphine Sulphate 10 mg	Tab	30000
1.790	Morphine Sulphate 20 mg	Tab	15000
1.791	Morphine Sulphate 30 mg	Tab	15000
1.792	Morphine Sulphate 60 mg	Tab	1000
1.793	Morphine Sulphate 10 mg CR/ SR	Tab	30000
1.794	Morphine Sulphate 20 mg CR/ SR	Tab	15000
1.795	Morphine Sulphate 30 mg CR/ SR	Tab	15000
1.796	Morphine Sulphate 60 mg CR/ SR	Tab	1000

1.797	Remifentanil Hydrochloride 1mg/Vial	Vial/Amp	400
1.798	Remifentanil Hydrochloride 2mg/Vial	Vial/Amp	400
1.799	Pethdine 100mg/2ml	Vial/Amp	200
1.800	Pethidine HCL 50mg/ml 1ml	Vial/Amp	200
1.801	PHENOBARBITONE INJECTION 200mg/ml	Vial/Amp	200